Methods for allogeneic hematopoietic stem cell transplantation

JP2023549114A5Pending Publication Date: 2024-11-12ORCA BIOSYSTEMS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526960
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-04
Filing Date
2021-11-04
Publication Date
2024-11-12
Patent Text Reader

Abstract

Various embodiments of the present invention provide therapeutic compositions and related methods for improving hematopoietic stem cell transplantation, including methods for enhancing protection from graft-versus-host disease while maintaining an effective immune response, such as a graft-versus-tumor immune response. Embodiments of the present invention are particularly useful for treating hematologic cancers (e.g., leukemia, lymphoma, GVHD, and other diseases). In a first aspect, embodiments of the present invention provide multi-component pharmaceutical treatments administered to a human subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH This invention was made with government support under HL114591 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0002] cross reference This application claims the benefit of priority to U.S. Provisional Application No. 63 / 109,811, filed November 4, 2020, and U.S. Provisional Application Nos. 63 / 121,453, 63 / 121,742, and 63 / 121,534, filed December 4, 2020, all of which are incorporated by reference in their entirety and for all purposes. [Background technology]

[0003] background Patients with hematologic malignancies, such as leukemia and lymphoma, who have gone beyond first remission or have refractory relapse are rarely cured with standard chemotherapy. Myeloablative allogeneic hematopoietic cell transplantation (alloHCT) is associated with improved survival in these patients, but morbidity and mortality related to graft-versus-host disease (GVHD) are major factors limiting the success of alloHCT. Summary of the Invention [Means for solving the problem]

[0004] overview In a first aspect, embodiments of the present invention provide a multi-component pharmaceutical treatment administered to a human subject in need thereof. According to one embodiment, the multi-component treatment comprises: (a) a solution comprising a first population of CD45+ cells, including hematopoietic stem progenitor cells (HSPCs) and granulocytes, wherein up to about 10% of the first population of CD45+ cells comprises granulocytes; (b) a solution comprising a population of cells enriched for regulatory T cells (Tregs); (c) a solution comprising a second population of CD45+ cells, wherein the second population of CD45+ cells comprises at least about 20% CD3+ conventional T cells (Tcon), at least about 10% monocytes, and at least about 10% granulocytes; and (d) one or more doses of a graft-versus-host disease (GVHD) prophylactic agent.

[0005] In many embodiments, the GVHD prophylactic agent comprises tacrolimus and / or analogs and derivatives thereof, which, according to various embodiments, may be formulated for oral or intravenous administration to a human subject or other methods of administration or delivery known in the pharmaceutical arts, including, for example, intramuscular, transdermal, nasal, buccal, and intravaginal administration.

[0006] In various embodiments, tacrolimus can be administered in an amount to maintain a target blood level of at least about 3 ng per ml of blood in a human subject for at least about 20 days after administration of the second population of CD45+ cells, to maintain a target blood level of about 4 ng / ml or more for at least about 40 days after administration of the second population of CD45+ cells, and / or to maintain a target blood level of about 4 ng / ml or more for at least about 40 days after administration of the second population of CD45+ cells. In some cases, tacrolimus is administered in an amount to maintain a target blood level of up to about 10 ng / ml for at least 30 days after administration of the second population of CD45+ cells.

[0007] In some embodiments, tacrolimus is administered for at least about 60 days after administration of the second population of CD45+ cells, at least about 90 days after administration of the second population of CD45+ cells, up to about 150 days after administration of the second population of CD45+ cells, or up to about 120 days after administration of the second population of CD45+ cells.

[0008] In some embodiments, the first population of CD45+ cells comprises at least about 0.5% granulocytes, at least about 1% granulocytes, up to about 5% granulocytes, up to about 3% granulocytes, up to about 3% monocytes, up to about 2% monocytes, up to about 0.5% lymphocytes, up to about 2% lymphocytes, at least about 15% granulocytes, at least about 20% granulocytes, up to about 35% granulocytes, up to about 30% granulocytes, up to about 25% granulocytes, at least about 15% monocytes, at least about 20% monocytes, up to about 35% monocytes, up to about 30% monocytes, up to about 25% monocytes, at least about 0.5% NK cells, and or at least about 2% NK cells.

[0009] In some embodiments, the second population of CD45+ cells comprises at least about 0.1% CD34+ cells or about 0.2% to about 20% CD34+ cells and / or at least about 0.1% Tregs.

[0010] In various embodiments, the multi-component pharmaceutical treatment further comprises a conditioning regimen, which is administered prior to any of the above-listed components (a)-(d), e.g., the conditioning regimen is administered about 2 to about 10 days prior to any of (a)-(d). In some embodiments, the conditioning regimen is a myeloablative conditioning regimen. In some cases, the conditioning regimen comprises at least three conditioning reagents, and at least one conditioning reagent is thiotepa. In embodiments, the myeloablative conditioning regimen comprises at least one dose of thiotepa, e.g., at least about 5 milligrams of thiotepa per kilogram of actual or ideal body weight of the human subject, or at least about 10 milligrams of thiotepa per kilogram of actual or ideal body weight of the human subject. In various embodiments, the conditioning regimen comprises one or more doses of busulfan, fludarabine, and thiotepa. In some embodiments, one or more doses each comprise about 5 to about 12 mg of thiotepa per kg of actual or ideal body weight of a human subject, about 7 to about 11 mg of busulfan per kg of actual or ideal body weight of a human subject, and about 100 to about 200 mg of fludarabine per square meter of body surface area.

[0011] In some embodiments, the first population of CD45+ cells comprises less than about 5 EU of endotoxin per ml of solution, less than about 1 EU of endotoxin per ml of solution, and / or less than about 0.5 EU of endotoxin per ml of solution. In some cases, the population of cells enriched for Tregs comprises less than about 5 EU of endotoxin per ml of solution, less than about 1 EU of endotoxin per ml of solution, and / or less than about 0.5 EU of endotoxin per ml of solution. In various embodiments, the second population of CD45+ cells comprises less than about 5 EU of endotoxin per ml of solution, less than about 1 EU of endotoxin per ml of solution, and / or less than about 0.5 EU of endotoxin per ml of solution.

[0012] In some embodiments, the HSPCs are CD34+.

[0013] In some embodiments, the Tregs are CD4+ CD25+ CD127dim or CD4+ FOXP3+. In some cases, the population of cells enriched for Tregs comprises CD45+ cells, e.g., greater than about 90% of the CD45+ cells are Tregs. In various embodiments, the population of cells enriched for Tregs comprises about 1 x 10 per kilogram of the human subject's actual or ideal body weight. 5 ~Approx. 1×10 7 Tregs or about 5 x 10 per kilogram of the human subject's actual or ideal body weight 5 ~Approx. 4×10 6 Contains Tregs.

[0014] In some embodiments, the first population of CD45+ cells comprising HSPCs is about 5×10 per kilogram of ideal body mass of said human subject. 5 ~Approx. 2×10 7 In some cases, the second population of CD45+ cells comprises about 1 x 10 HSPCs per kilogram of the human subject's actual or ideal body weight. 5 ~Approx. 1×10 7 or about 5 x 10 per kilogram of the human subject's actual or ideal body weight 5 ~Approx. 5×10 6 Includes Tcon.

[0015] In some embodiments, the first population of CD45+ cells and the population of cells enriched for Tregs are administered before the second population of CD45+ cells.

[0016] In various embodiments, the first of the one or more doses of GVHD prophylactic agent is administered after administration of the second population of CD45+ cells.

[0017] Another aspect provides a method of treating a human subject diagnosed with a hematological malignancy. According to one embodiment, the method comprises administering to the human subject a solution comprising a first population of CD45+ cells, a solution comprising a population of cells enriched for regulatory Tregs, a solution comprising a second population of CD45+ cells, and one or more doses of a GVHD prophylactic agent. In this aspect, the solution comprising the first population of CD45+ cells, the solution comprising the population of cells enriched for regulatory Tregs, the solution comprising the second population of CD45+ cells, and the one or more doses of a GVHD prophylactic agent are as defined according to any of the multi-component pharmaceutical treatments disclosed herein.

[0018] The hematological malignancy may correspond to one or more of acute lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, multiple myeloma, lymphoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

[0019] In some embodiments, the administering step comprises infusing said first population of CD45+ cells, said population of cells enriched for Tregs, and said second population of CD45+ cells into a human subject.

[0020] In some embodiments, the second population of CD45+ cells may be administered at least about 12 hours after the first population of CD45+ cells; the second population of CD45+ cells is administered about 24 to about 96 hours after the first population of CD45+ cells; the second population of CD45+ cells is administered about 36 to about 60 hours after the first population of CD45+ cells; the second population of CD45+ cells is administered at least about 12 hours after the population of cells enriched for Tregs; the second population of CD45+ cells is administered about 24 to about 96 hours after the population of cells enriched for Tregs; and / or the second population of CD45+ cells is administered about 36 to about 60 hours after the population of cells enriched for Tregs.

[0021] In various embodiments, the human subject does not develop greater than stage 2 GVHD within about 100 days of said administration of said second population of CD45+ cells, the human subject does not develop greater than stage 2 GVHD within about 180 days or about 200 days of said administration of said second population of CD45+ cells, and the human subject does not develop greater than stage 2 GVHD within about 1 year of said administration of said second population of CD45+ cells.

[0022] In some embodiments, the human subject has been previously treated or is concurrently treated for a hematological malignancy.

[0023] In some embodiments, the GVHD prophylactic agent is tacrolimus (and / or its analogs and derivatives) and is initially administered to the human subject at about 0.03 mg per kg of the human subject's actual or ideal body weight per day, or tacrolimus is initially administered about 12 hours to about 24 hours after said administration of said second population of CD45+ cells.

[0024] In various embodiments, the dose of tacrolimus may be tapered starting about 90 days after the first dose is administered to the human subject, or the dose of tacrolimus is tapered starting about 45 days after the first dose is administered to the human subject.

[0025] In some embodiments, the first population of CD45+ cells, the population of cells enriched for Tregs, and the second population of CD45+ cells are obtained from a single donor in one day or over multiple days.

[0026] In some embodiments, at least one mobilized peripheral blood donation is collected from the donor, or up to two mobilized peripheral blood donations are collected from the donor.

[0027] In various embodiments, at least one of the mobilized peripheral blood donations is processed and sorted to enrich for CD34+ cells and Tregs. In some embodiments, the processing and sorting time for one or more of the mobilized peripheral blood donations is less than about 35 hours, the processing and sorting time for one or more of the mobilized peripheral blood donations is less than about 30 hours, the processing and sorting time for one or more of the mobilized peripheral blood donations is less than about 25 hours, the processing and sorting time for one or more of the mobilized peripheral blood donations is up to about 35 hours, and / or the processing and sorting time for one or more of the mobilized peripheral blood donations is up to about 25 hours.

[0028] In various embodiments, one or more of the mobilized peripheral blood donations are processed and sorted using one or more immunoseparation particles (ISPs), e.g., the ISPs comprise affinity reagents such as immunomagnetic separation particles, which may each be an antibody conjugated to an iron-containing particle. In some embodiments, the affinity reagents comprise a plurality of CD34 reagents (e.g., anti-CD34 antibodies) that bind to one or more CD34 receptors of HSPCs. In some cases, the average number of ISPs per HSPC in the HSPC cell population is less than about 20,000, the average number of ISPs per HSPC in the HSPC cell population is equal to or less than about 10,000, and / or the average number of ISPs per HSPC in the HSPC cell population is between about 1500 and about 20,000. In embodiments, the affinity reagents comprise a plurality of CD25 reagents (e.g., anti-CD25 antibodies) that bind to one or more CD25 receptors of Tregs. In some cases, the average number of ISPs per T-reg cell in the Treg population is equal to or less than about 4000, or the average number of ISPs per T-reg cell in the Treg population is between about 1500 and about 2500.

[0029] In various embodiments, the cells of the mobilized peripheral blood donation are sorted so that the first population of CD45+ cells comprises up to about 10% granulocytes. In some cases, the cells of the mobilized peripheral blood donation are sorted so that the first population of CD45+ cells comprises up to about 7% granulocytes.

[0030] In some embodiments, the cells of the mobilized donor peripheral blood donation are sorted so that the first population of CD45+ cells comprises up to about 4% monocytes. In some cases, the cells of the mobilized donor peripheral blood donation are sorted so that the first population of CD45+ cells comprises at least about 0.1% monocytes.

[0031] In embodiments, cells from a mobilized donor peripheral blood donation are sorted so that the population enriched for Tregs contains up to about 10% CD25 cells.

[0032] In various embodiments, the first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are allogeneic to said human subject.

[0033] In some embodiments, the first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are obtained from a donor that is HLA-matched to said human subject.

[0034] In embodiments, the first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are obtained from a donor that is HLA-mismatched to said human subject.

[0035] In various embodiments, the first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are obtained from a donor that is haploidentical to said human subject.

[0036] In some embodiments, the second population of CD45+ cells comprises invariant natural killer T cells (iNKT), eg, a population of iNKT that are CD3+ Vα24Jα18+.

[0037] In embodiments, the population of iNKT is about 5×10 per kilogram of actual or ideal body weight of said human subject. 2 Includes more than iNKT.

[0038] In various embodiments, the population of iNKT is about 5×10 per kilogram of actual or ideal body weight of said human subject. 2 ~Approx. 1×10 7 Includes iNKT.

[0039] In some embodiments, the second population of CD45+ cells comprises memory T cells (Tmem), eg, a population of Tmem that are CD3+ CD45RA- CD45RO+.

[0040] In embodiments, the population of Tmems is about 3 x 10 per kilogram of actual or ideal body weight of said human subject. 5 Contains more than one Tmem.

[0041] In various embodiments, the population of Tmems is about 3 x 10 per kilogram of actual or ideal body weight of said human subject. 5 ~Approx. 1×10 9 Contains Tmem.

[0042] Yet another embodiment provides a multi-component pharmaceutical treatment in which the risk and / or severity of adverse events associated with the multi-component pharmaceutical treatment is reduced compared to a similar pharmaceutical treatment in which a human subject receives Tcon but not Tregs, or a method in which the risk and / or severity of adverse events associated with any of the methods disclosed herein is reduced compared to a similar method in which a human subject receives Tcon but not Tregs.

[0043] In some embodiments, the adverse event is acute GVHD (aGVHD), which may include stage 2 or greater aGVHD.

[0044] In various embodiments, the adverse event is chronic GVHD (cGVHD), which can be moderate to severe cGVHD.

[0045] In some embodiments, the human subject is free of cGVHD about one year after being administered the cell population.

[0046] In various embodiments, the adverse event is a recurrence of a malignant tumor in a human subject.

[0047] In some embodiments, the human subject does not have a recurrence of their malignancy after about one year of being administered the pharmaceutical dosing regimen.

[0048] In embodiments, the human subject has undergone a myeloablative conditioning regimen prior to administration of either cell population, and the adverse event is associated with the myeloablative conditioning.

[0049] In various embodiments, the method further includes providing an instruction for use (IFU), the IFU including instructions for administering the cell population to a patient. In some cases, the IFU also includes instructions for administering one or more pharmaceutical agents or compositions to the patient.

[0050] A further embodiment provides a method for transplanting a population of conventional T cells (Tcon) as part of a treatment regimen for a hematological malignancy, the method reducing the risk and / or severity of adverse events associated with the treatment regimen. The method comprises administering to a patient a population of regulatory T cells (Tregs) comprising Tregs and a liquid suspending the Tregs; and administering to the patient a heterogeneous cell population comprising lymphocytes, granulocytes, monocytes, and a liquid suspending the cells. In this embodiment, at least about 30% of the lymphocytes comprise Tcon, and after administration of the cell population, the patient has a reduced risk and / or severity of adverse events compared to a patient with a hematological malignancy who received Tcon but not Tregs.

[0051] A still further embodiment provides a method for transplanting a cell population into a human patient as part of a treatment regimen for a hematological malignancy, the method reducing the risk and / or severity of adverse events associated with the treatment regimen. The method includes the steps of: providing a population of hematopoietic stem progenitor cells (HSPCs) for administration to the patient, wherein the population of HSPCs comprises HSPCs and a liquid suspending the HSPCs; providing a population of regulatory T cells (Tregs) for administration to the patient, wherein the population of Tregs comprises Tregs and a liquid suspending the Tregs; and providing a heterogeneous cell population for administration to the patient, wherein the heterogeneous cell population comprises lymphocytes, granulocytes, monocytes, and a liquid suspending the cells. In this embodiment, at least about 30% of the lymphocytes comprise conventional T cells (Tcon), and following administration of the cell population, the patient has a reduced risk and / or severity of adverse events compared to a patient with a hematological malignancy who received the Tcon cell population but not the T-reg cell population.

[0052] In some embodiments, the cell population is administered to the patient by intravenous infusion.

[0053] In embodiments, each cell population is provided as a separate cell population and is derived from a single human blood donor.

[0054] In various embodiments, the adverse event is acute graft-versus-host disease (aGVHD), e.g., aGVHD at or above Stage 2. In some cases, the patient does not have aGVHD at or above Stage 2 about 180 days after being administered the cell population.

[0055] In some embodiments, the adverse event is chronic graft-versus-host disease (cGVHD). In some cases, the patient is free of cGVHD about one year after receiving the cell population.

[0056] In embodiments, the adverse event is moderate to severe cGVHD. In some cases, the patient does not have moderate to severe cGVHD about one year after receiving the cell population.

[0057] In various embodiments, the adverse event is a recurrence of the malignancy in the patient. In some cases, the patient does not have a recurrence of the malignancy about one year after being administered the cell population.

[0058] In some embodiments, the adverse events include graft-versus-host disease (GVHD) and recurrence of the patient's malignancy. In some cases, the patient has no GVHD or no recurrence of the malignancy one year after receiving the cell population.

[0059] In embodiments, at least one of the cell populations contains less than about 5 EU of endotoxin per ml of each suspension.

[0060] In various embodiments, the patient has undergone a myeloablative conditioning regimen prior to administration of the cell population, and the adverse event is associated with the myeloablative conditioning. In some cases, the adverse event comprises a recurrence of the patient's malignancy or infection.

[0061] In some embodiments, the heterogeneous cell population comprises about 0.2 to about 2.0 percent hematopoietic stem progenitor cells.

[0062] In embodiments, the hematological malignancy is acute lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, multiple myeloma, lymphoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

[0063] In various embodiments, the gene expression levels of T-reg cells correlate to cells harvested from a donor within about 60 hours prior to administration to a patient.

[0064] In some embodiments, the number of T-reg cells in the T-reg population is approximately equal to the number of T-con cells in the heterogeneous cell population. In some cases, the T-reg cells in the T-reg population inhibit activation of conventional T cells in the heterogeneous cell population by up to about 20 percent, depending on the patient's healthy tissue.

[0065] In embodiments, the peripheral blood of the patient exhibits an elevated ratio of Tregs to CD4+ T cells up to about 100 days after administration of the cell population, compared to a healthy human subject who has not received the cell population.

[0066] In various embodiments, at least about 50% of the cells in the HSPC cell population are colony forming units.

[0067] In some embodiments, at least one of the cell populations has an elevated amount of granulocyte colony-stimulating factor compared to unmobilized blood. In some cases, at least one cell population is a heterogeneous cell population.

[0068] In embodiments, at least one of the cell populations has a plurality of immunoseparation particles (ISPs) bound to receptors on cells of the cell population. In some cases, the plurality of ISPs are immunomagnetic separation particles. In various embodiments, the plurality of ISPs comprises antibodies conjugated to iron-containing particles.

[0069] In some embodiments, the population of Tcon is administered at least about 12 hours after the population of HSPCs, e.g., the population of Tcon is administered about 24 to about 96 hours after the population of HSPCs, or the population of Tcon is administered about 36 to about 60 hours after the population of HSPCs.

[0070] In some embodiments, the population of Tcon is administered at least about 12 hours after the population of cells comprising Tregs, e.g., the population of Tcon is administered about 24 to about 96 hours after the population of cells comprising Tregs, or the population of Tcon is administered about 36 to about 60 hours after the population of cells comprising Tregs.

[0071] In various embodiments, the methods disclosed herein further include administering to the patient a single graft-versus-host disease (GVHD) prophylaxis (GVHDPA) comprising tacrolimus (tacrolimus GHVDPA) for a period of up to about 180 days, wherein the tacrolimus GHVDPA is administered to maintain the patient's blood tacrolimus concentration above a threshold level during the period; and the risk and / or severity of GHVD is significantly reduced.

[0072] In some embodiments, the threshold level is greater than about 4 ng of tacrolimus per ml of the patient's blood, or the threshold level is greater than about 5 ng of tacrolimus per ml of the patient's blood.

[0073] In embodiments, tacrolimus GHVDPA is administered to maintain a concentration of tacrolimus in the patient's blood below an upper threshold level for a period of time, in some cases, the upper threshold level is less than about 10 ng of tacrolimus per ml of the patient's blood.

[0074] In various embodiments, the patient has a reduced risk of at least one of malignant tumor recurrence, infection, or renal failure.

[0075] In some embodiments, the patient does not develop GVHD within about 30 days of administration of Tcon, does not develop GVHD within about 100 days of administration of Tcon, does not develop GVHD within about 180 days of administration of Tcon, and / or does not develop GVHD within about 1 year of administration of Tcon.

[0076] In various embodiments, tacrolimus graft-versus-host disease (GVHD) prophylaxis (GVHDPA) may be administered intravenously or orally to a patient. In various embodiments, administration of tacrolimus graft-versus-host disease (GVHD) prophylaxis (GVHDPA) is initiated about 12 to about 24 hours after administration of T-con. In some cases, tacrolimus GHVDPA is administered for a period of up to about 90 days, and for a period of up to about 60 days. In some embodiments, tacrolimus GHVDPA is initially administered to a patient at about 0.03 mg / kg of the patient's actual or ideal body weight per day. In some cases, the dose of tacrolimus GVHDPA administered to a patient is tapered beginning about 90 days after the first dose is administered to the patient, or is tapered beginning about 45 days after the first dose is administered to the patient.

[0077] In some embodiments, the method further comprises administering a myeloablative conditioning regimen to the patient prior to administration of either cell population, wherein the conditioning regimen comprises administering at least one conditioning agent to the patient.

[0078] In embodiments, the patient does not receive any radiation therapy as part of the myeloablative conditioning regimen.

[0079] In various embodiments, the at least one conditioning agent is administered about 2 to about 10 days prior to administration of any of the cell populations, hi some instances, the at least one conditioning agent is administered about 5 days prior to administration of any of the cell populations.

[0080] In some embodiments, the at least one conditioning agent comprises thiotepa. In some cases, the dose of thiotepa administered to a patient is in the range of about 5 to about 10 mg per kilogram of actual or ideal body weight.

[0081] In embodiments, the at least one conditioning agent comprises busulfan and fludarabine. In some cases, the doses of thiotepa, busulfan, and fludarabine administered to the patient comprise about 10 mg per kilogram of the patient's actual or ideal body weight, about 9.6 mg per kilogram of the patient's actual or ideal body weight, and about 150 mg per square meter of body surface area, respectively.

[0082] In various embodiments, the method further includes providing an instruction for use (IFU), the IFU including instructions for administering the cell population to a patient. In some cases, the IFU also includes instructions for administering one or more pharmaceutical agents or compositions to the patient.

[0083]

[0010] Yet another aspect provides a method for transplanting a cell population into a human patient as part of a treatment regimen for a hematological malignancy, the method comprising the steps of: administering to the patient a population of hematopoietic stem progenitor cells (HSPCs), the population of HSPCs comprising the HSPCs and a liquid suspending the HSPCs; administering to the patient a population of regulatory T cells (Tregs), the population of Tregs comprising the Tregs and a liquid suspending the Tregs, administered to the patient; and administering to the patient a heterogeneous cell population, the heterogeneous cell population comprising lymphocytes, granulocytes, monocytes and a liquid suspending the cells, administered to the patient, wherein at least about 3% of the lymphocytes are erythrocytes. 0% comprise conventional T cells (Tcon); and administering to the patient a single graft-versus-host disease (GVHD) prophylaxis (GVHDPA) comprising tacrolimus (tacrolimus GHVDPA) for a period of up to about 180 days, wherein the tacrolimus GHVDPA is administered to maintain a tacrolimus concentration in the patient's blood above a threshold level during the period, thereby significantly reducing the risk and / or severity of GHVD associated with a treatment regimen for a hematologic malignancy.

[0084] Another aspect is

[0085] A kit is provided that includes a solution comprising a first container containing a first population of CD45+ cells, a second container containing a solution containing a second population of CD45+ cells, and a third container containing a solution containing a population of cells enriched for regulatory T cells (Tregs). In this aspect, the solution containing the first population of CD45+ cells, the solution containing the second population of CD45+ cells, and the solution containing the population of cells enriched for Tregs are as defined according to any of the multi-component pharmaceutical treatments or methods disclosed herein. In some embodiments, the kit further includes a fourth container containing a GVHD prophylactic agent. In some cases, the kit further includes instructions for practicing any of the methods disclosed herein.

[0086] Another aspect provides a kit comprising: (a) one or more reagents for selecting CD34+ cells from a mobilized peripheral blood composition, (b) one or more reagents for selecting regulatory T cells (Tregs) from the mobilized peripheral blood composition, (c) one or more reagents for detecting the number of CD3+ conventional T cells in the mobilized peripheral blood, and (d) one or more doses of a solution comprising a graft-versus-host disease (GVHD) prophylactic agent. In embodiments, the kit further comprises instructions for practicing any of the methods disclosed herein.

[0087] An embodiment provides a method for transplanting a population of conventional T cells (Tcon) into a human subject without inducing a stage 2 or higher graft-versus-host disease (GVHD) response up to about 100 days after transplantation. The method includes the steps of: (i) administering a heterologous cell population comprising lymphocytes, granulocytes, and monocytes, wherein at least about 30% of the lymphocytes comprise conventional T cells (Tcon); and (ii) administering a population of regulatory T cells (Treg). In this method, the heterologous cell component and / or the population of Tregs contains less than about 5 EU / ml of endotoxin.

[0088] Another aspect provides a method of treating a human subject, comprising: (a) administering a plurality of cell populations, the plurality of cell populations comprising: (i) a population of hematopoietic stem progenitor cells (HSPCs); (ii) a population of cells comprising regulatory T cells (Tregs); and (iii) a population of conventional T cells (Tcons); and (b) administering only one graft-versus-host disease (GVHD) prophylactic agent for less than about 120 days, wherein the population of HSPCs comprises less than about 2% CD3+ cells.

[0089] A further aspect provides a method of treating a human subject in need thereof, comprising administering to the human subject at least two pharmaceutical compositions, the pharmaceutical compositions selected from (a) a pharmaceutical composition comprising a population of hematopoietic stem progenitor cells (HSPCs); (b) a pharmaceutical composition comprising a population of regulatory T cells (Tregs); and (c) a pharmaceutical composition comprising a population of conventional T cells (Tcons). In this method, pharmaceutical compositions (a), (b), and (c) each contain less than about 5 EU / ml of endotoxin; and fewer than 15 human subjects in a group of 100 human subjects administered two or more pharmaceutical compositions develop a stage 2 or higher graft-versus-host disease (GVHD) response within about 30 days after receiving the pharmaceutical composition comprising the Tcon population.

[0090] An additional embodiment provides a method for transplanting a population of conventional T cells (Tcon) into a human subject without inducing a stage 2 or higher graft-versus-host disease (GVHD) response up to about 100 days after transplantation. The method includes: (i) administering a solution comprising a population of conventional T cells (Tcon); and (ii) administering a solution comprising a population of regulatory T cells (Treg). In this method, the population of Tcon has been cryopreserved for at least about 4 hours, and the solution comprising the population of Tcon and the solution comprising the population of Treg contain less than about 5 EU of endotoxin per ml of solution.

[0091] An embodiment provides a method of treating a hematological malignancy in a human subject in need thereof, the method comprising administering to the human subject: (a) a population of hematopoietic stem progenitor cells (HSPCs); (b) a population of regulatory T cells (Tregs); and (c) a population of conventional T cells (Tcon). In the method, the population of HSPCs and the population of Tregs are administered before the population of Tcon; and the peripheral blood of the human subject exhibits elevated numbers of Tregs by about 100 days after administration of the three cell populations, compared to a healthy human subject who did not receive the three cell populations.

[0092] A further aspect provides a method for transplanting a population of conventional T cells (Tcon) into a human subject without inducing a stage 2 or higher graft-versus-host disease (GVHD) response up to about 100 days after transplantation. The method includes the steps of (i) administering a population of conventional T cells (Tcon); and (ii) administering a population of regulatory T cells (Treg). In this method, the population of Tcon is administered at least about 12 hours after the population of Treg is administered; and the population of Tcon and the population of Treg contain less than about 5 EU / ml of endotoxin.

[0093] It will be understood that the various aspects and / or embodiments of the present invention can be considered individually, collectively, or in combination with each other. Any description herein of a particular composition, multi-component pharmaceutical treatment, cell population, solution, formulation, kit, and / or method may also apply to and be used for any other particular composition, multi-component pharmaceutical treatment, cell population, solution, formulation, kit, and / or method. In other words, any aspect or embodiment described herein may be combined with any other aspect or embodiment disclosed herein. Incorporation by Reference

[0094] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0095] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings, in which: [Brief explanation of the drawings]

[0096] [Figure 1A-B]Figure 1A-B illustrates a schematic of transplantation according to the method described herein (identified as high-precision Orca-T or OrcaT) and the differences compared to the standard of care (SOC) cohort (identified as conventional transplantation or SOC).

[0097] [Figure 1C] FIG. 1C illustrates a schematic of graft production and administration.

[0098] [Figure 2A] FIG. 2A illustrates the weights of patients enrolled in the study disclosed in the Examples.

[0099] [Figure 2B-C] Figures 2B-C illustrate the HSPC and Treg cell doses administered to patients enrolled in the studies disclosed in the Examples.

[0100] [Figure 2D] FIG. 2D illustrates the purity of Treg cells administered to patients enrolled in the study disclosed in the Examples.

[0101] [Figure 3A] Figure 3A shows the time to platelet engraftment in the test group (identified as Orca-T) and standard of care (SOC) cohorts.

[0102] [Figure 3B-C]Figures 3B-3L illustrate the engraftment of various cell populations in patients from the study groups disclosed in the Examples. These figures also illustrate the levels of each cell type in the donors prior to sample collection. Boxplots are shown: boxes indicate the 75th, 50th, and 25th percentiles; whiskers indicate the 90th and 10th percentiles. X-axis nomenclature: leading numbers (e.g., 01, 02, 025, ...) are used for ordering; following the underline: Dscrn = healthy donor blood before G-CSF mobilization; Rscrn = recipient blood within one month prior to conditioning; apher = healthy donor blood collected at the time of apheresis; d028 = recipient day 28 post-transplant; d056-d365 = recipient days post-transplant. The indicated N indicates the sample size per time point. Symbols indicate the values ​​of individual measurements. 10-3 cells per uL of blood equals 1000 cells per uL of blood. [Figure 3D-E] Figures 3B-3L illustrate the engraftment of various cell populations in patients from the study groups disclosed in the Examples. These figures also illustrate the levels of each cell type in the donors prior to sample collection. Boxplots are shown: boxes indicate the 75th, 50th, and 25th percentiles; whiskers indicate the 90th and 10th percentiles. X-axis nomenclature: leading numbers (e.g., 01, 02, 025, ...) are used for ordering; following the underline: Dscrn = healthy donor blood before G-CSF mobilization; Rscrn = recipient blood within one month prior to conditioning; apher = healthy donor blood collected at the time of apheresis; d028 = recipient day 28 post-transplant; d056-d365 = recipient days post-transplant. The indicated N indicates the sample size per time point. Symbols indicate the values ​​of individual measurements. 10-3 cells per uL of blood equals 1000 cells per uL of blood. [Figure 3F-G]Figures 3B-3L illustrate the engraftment of various cell populations in patients from the study groups disclosed in the Examples. These figures also illustrate the levels of each cell type in the donors prior to sample collection. Boxplots are shown: boxes indicate the 75th, 50th, and 25th percentiles; whiskers indicate the 90th and 10th percentiles. X-axis nomenclature: leading numbers (e.g., 01, 02, 025, ...) are used for ordering; following the underline: Dscrn = healthy donor blood before G-CSF mobilization; Rscrn = recipient blood within one month prior to conditioning; apher = healthy donor blood collected at the time of apheresis; d028 = recipient day 28 post-transplant; d056-d365 = recipient days post-transplant. The indicated N indicates the sample size per time point. Symbols indicate the values ​​of individual measurements. 10-3 cells per uL of blood equals 1000 cells per uL of blood. [Figure 3H-I] Figures 3B-3L illustrate the engraftment of various cell populations in patients from the study groups disclosed in the Examples. These figures also illustrate the levels of each cell type in the donors prior to sample collection. Boxplots are shown: boxes indicate the 75th, 50th, and 25th percentiles; whiskers indicate the 90th and 10th percentiles. X-axis nomenclature: leading numbers (e.g., 01, 02, 025, ...) are used for ordering; following the underline: Dscrn = healthy donor blood before G-CSF mobilization; Rscrn = recipient blood within one month prior to conditioning; apher = healthy donor blood collected at the time of apheresis; d028 = recipient day 28 post-transplant; d056-d365 = recipient days post-transplant. The indicated N indicates the sample size per time point. Symbols indicate the values ​​of individual measurements. 10-3 cells per uL of blood equals 1000 cells per uL of blood. [Figure 3J-K]Figures 3B-3L illustrate the engraftment of various cell populations in patients from the study groups disclosed in the Examples. These figures also illustrate the levels of each cell type in the donors prior to sample collection. Boxplots are shown: boxes indicate the 75th, 50th, and 25th percentiles; whiskers indicate the 90th and 10th percentiles. X-axis nomenclature: leading numbers (e.g., 01, 02, 025, ...) are used for ordering; following the underline: Dscrn = healthy donor blood before G-CSF mobilization; Rscrn = recipient blood within one month prior to conditioning; apher = healthy donor blood collected at the time of apheresis; d028 = recipient day 28 post-transplant; d056-d365 = recipient days post-transplant. The indicated N indicates the sample size per time point. Symbols indicate the values ​​of individual measurements. 10-3 cells per uL of blood equals 1000 cells per uL of blood. [Figure 3L] Figures 3B-3L illustrate the engraftment of various cell populations in patients from the study groups disclosed in the Examples. These figures also illustrate the levels of each cell type in the donors prior to sample collection. Boxplots are shown: boxes indicate the 75th, 50th, and 25th percentiles; whiskers indicate the 90th and 10th percentiles. X-axis nomenclature: leading numbers (e.g., 01, 02, 025, ...) are used for ordering; following the underline: Dscrn = healthy donor blood before G-CSF mobilization; Rscrn = recipient blood within one month prior to conditioning; apher = healthy donor blood collected at the time of apheresis; d028 = recipient day 28 post-transplant; d056-d365 = recipient days post-transplant. The indicated N indicates the sample size per time point. Symbols indicate the values ​​of individual measurements. 10-3 cells per uL of blood equals 1000 cells per uL of blood.

[0103] [Figure 3M-N] Figure 3M-N shows the timeline of lymphocyte and monocyte engraftment in a subset of the test group (Orca-T) and standard of care cohort.

[0104] [Figure 3O] Figure 3O shows representative flow cytometry data for the frequency of CD3+CD4+ T cells that were Tregs in two subjects compared with healthy controls. In healthy controls, 3.72% of circulating CD3+CD4+ T cells were Tregs (CD25+CD127dim). In two transplant recipients, 28.1% and 23.7% of CD3+CD4+ T cells were Tregs at day +28, 32.3% and 17.8% at day +56, and 19.2% and 20.7% at day +100 after transplantation.

[0105] [Figure 3P-1] Figure 3P shows flow cytometry data for B cell markers from samples derived from recipients of compositions of the present disclosure compared to healthy controls. In all cases, the Y-axis refers to CD19+ staining. The left panel shows lymphocyte gating to identify B cells (CD19+) and T cells (CD3+). 13.4% of lymphocytes in graft recipients were B cells, compared to 9.84% in healthy controls. The second panel from the left shows that 98.3-100% of cells gated as CD19+ were also CD20+. The second panel from the right shows the fraction of B cells that are IgD+, which can be used to identify mature B cells. 92.1% of B cells in graft recipients were IgD+, compared to 89.5% in healthy controls. The rightmost panel shows staining for CD27, which can be used to identify, for example, memory B cells, late plasmablasts, and plasma cells. 43.6% of B cells in graft recipients were CD27+, compared with 67.1% in healthy controls. [Figure 3P-2]Figure 3P shows flow cytometry data for B cell markers from samples derived from recipients of compositions of the present disclosure compared to healthy controls. In all cases, the Y-axis refers to CD19+ staining. The left panel shows lymphocyte gating to identify B cells (CD19+) and T cells (CD3+). 13.4% of lymphocytes in graft recipients were B cells, compared to 9.84% in healthy controls. The second panel from the left shows that 98.3-100% of cells gated as CD19+ were also CD20+. The second panel from the right shows the fraction of B cells that are IgD+, which can be used to identify mature B cells. 92.1% of B cells in graft recipients were IgD+, compared to 89.5% in healthy controls. The rightmost panel shows staining for CD27, which can be used to identify, for example, memory B cells, late plasmablasts, and plasma cells. 43.6% of B cells in graft recipients were CD27+, compared with 67.1% in healthy controls.

[0106] [Figure 4A] Figure 4A shows the onset of grade >2 aGVHD in the experimental group (Orca-T) and standard of care cohorts by day +120 post-transplant. At nearly all time points, the Orca-T data is below the standard of care data.

[0107] [Figure 4B] Figure 4B shows the onset of grade >3 aGVHD in the experimental group (Orca T) and standard of care cohorts by day +120 post-transplant. At nearly all time points, the Orca-T data is below the standard of care data.

[0108] [Figure 4C] Figure 4C shows the onset of moderate-to-severe cGVHD in the experimental (Orca-T) and standard of care (SOC) cohorts by day +365 post-transplant. At nearly all time points, the Orca-T data are below the standard of care data.

[0109] [Figure 4D] Figure 4D shows non-relapse-related mortality in the experimental (Orca-T) and standard of care (SOC) cohorts up to day +365 post-transplant. At nearly all time points, the Orca-T data is below the standard of care data.

[0110] [Figure 4E] Figure 4E shows the relapse rates in the experimental group (Orca-T) and standard of care cohorts up to day +365 post-transplant. At the final time point, the Orca-T relapse rate is 16% and the standard of care relapse rate is 19%.

[0111] [Figure 4F] Figure 4F shows GVHD-free and relapse-free survival in the experimental (Orca-T) and standard of care cohorts up to day +365 post-transplant. At nearly all time points, the Orca-T data outperform the standard of care data.

[0112] [Figure 4G] Figure 4G shows cGVHD-free survival in the experimental and standard of care cohorts up to day +365 post-transplant. At nearly all time points, the Orca-T data outperform the standard of care data.

[0113] [Figure 4H] Figure 4H shows overall survival in the experimental and standard of care cohorts up to day +365 post-transplant. At the final time point, the Orca-T overall survival rate is 90% and the standard of care overall survival rate is 78%. [Figure 4I] Figure 4I shows the number of hospital days in the study group and a subset of the standard of care (SOC) cohort through day +365 post-transplant.

[0114] [Figure 5] Figure 5 summarizes the disease status of a small subset of subjects in the study group before transplant and at +90, +180, and +356 days after transplant. CR denotes complete response and MRD denotes minimal residual disease.

[0115] [Figure 6A-D] Figures 6A-F compare aGVHD, cGVHD, relapse, relapse-free survival, GVHD- and relapse-free survival (GRFS), and overall survival in subsets of patients in the study arms who received different conditioning regimens. [Figure 6E-F] Figures 6A-F compare aGVHD, cGVHD, relapse, relapse-free survival, GVHD- and relapse-free survival (GRFS), and overall survival in subsets of patients in the study arms who received different conditioning regimens.

[0116] [Figure 7A-B] Figures 7A-H compare aGVHD, cGVHD, non-relapse-related mortality, relapse, relapse-free survival, GVHD-free and relapse-free survival (GRFS), and overall survival in subsets of patients in the study groups who received different GVHD prophylaxis. [Figure 7C-F] Figures 7A-H compare aGVHD, cGVHD, non-relapse-related mortality, relapse, relapse-free survival, GVHD-free and relapse-free survival (GRFS), and overall survival in subsets of patients in the study groups who received different GVHD prophylaxis. [Figure 7G-H] Figures 7A-H compare aGVHD, cGVHD, non-relapse-related mortality, relapse, relapse-free survival, GVHD-free and relapse-free survival (GRFS), and overall survival in subsets of patients in the study groups who received different GVHD prophylaxis.

[0117] [Figure 8A] Figures 8A-C illustrate aGVHD and cGVHD rates in patients with different serum tacrolimus trough levels. [Figure 8B-C] Figures 8A-C illustrate aGVHD and cGVHD rates in patients with different serum tacrolimus trough levels.

[0118] [Figure 9A-B]Figures 9A-B compare aGVHD and cGVHD levels in patients with different serum tacrolimus levels.

[0119] [Figure 9C-D] Figure 9C-D compare aGVHD and cGVHD levels in patients who had different serum tacrolimus levels but received the same conditioning regimen of busulfan and cyclophosphamide (Bu / Cy).

[0120] [Figure 9E-F] Figure 9E-G compares aGVHD and cGVHD levels in patients who had different serum tacrolimus levels but were given the same conditioning regimen of total body irradiation (TBI) / busulfan, fludarabine, thiotepa (TBI / BFT). [Figure 9G] Figure 9E-G compares aGVHD and cGVHD levels in patients who had different serum tacrolimus levels but were given the same conditioning regimen of total body irradiation (TBI) / busulfan, fludarabine, thiotepa (TBI / BFT).

[0121] [Figure 9H] Figure 9H shows mean tracheacrolimus levels up to day +30 post-transplant plotted against the percentage of donor-derived CD3+ cells at day +30 (except chimerism data are from day 90, indicated by "D90"). DETAILED DESCRIPTION OF THE INVENTION

[0122] Detailed Description introduction Various embodiments of the present invention provide compositions, multi-component pharmaceutical treatments, cell populations, solutions, formulations, kits, and / or methods related to improving allogeneic hematopoietic stem cell transplantation (alloHCT).

[0123] AlloHCT is the transplantation of multipotent hematopoietic stem and progenitor cells (HSPCs), usually derived from the donor's bone marrow, peripheral blood, or umbilical cord blood, into a recipient. The recipient may be subjected to myeloablative conditioning, which kills hematopoietic cells, including tumor cells and host immune cells. The HSPCs transplanted into the recipient then reconstitute the hematopoietic compartment. HCT can be useful as a treatment for cancer due to the ability of donor T cells to exert an antitumor effect, termed the graft-versus-tumor response (GVT). In patients with hematologic malignancies refractory to chemotherapy, HCT is associated with improved survival.

[0124] Surprisingly, alloHCT recipients who received single-agent tacrolimus-based graft-versus-host disease (GVHD) prophylaxis had significantly better clinical outcomes than those receiving existing alloHCT regimens and standard therapies. These recipients experienced improved clinical outcomes, including increased overall survival, increased relapse-free survival, increased GVHD-free and relapse-free survival (GRFS), more rapid and / or complete engraftment of various hematopoietic components (e.g., neutrophils, platelets, T cells, B cells), improved donor chimerism (e.g., T cell chimerism), reduced relapse, reduced primary graft failure, reduced secondary graft failure, reduced treatment-related mortality, reduced acute and / or chronic GVHD, and reduced time to hospital discharge after single-agent tacrolimus-based GVHD prophylaxis.

[0125] Although alloHCT is associated with improved survival for patients with hematologic malignancies refractory to chemotherapy, some subjects treated with existing alloHCT regimens experience cancer recurrence, and several complications may limit the effectiveness of alloHCT. The efficacy of alloHCT may be limited, for example, by primary graft failure, secondary graft failure, limited or delayed engraftment of various hematopoietic components (e.g., neutrophils, platelets, T cells, or B cells), and limited donor chimerism (e.g., T cell chimerism). Furthermore, alloHCT may result in treatment-related ethics or toxicity. However, donor T cells may also attack non-tumor host cells, resulting in graft-versus-host disease (GVHD). GVHD is a major cause of post-HCT complications and can be fatal. Managing GVHD may require immunosuppressive therapy or cytotoxic mediators, which can lead to toxicity, increased susceptibility to infection, and / or blunted antitumor immunity. Early morbidity and mortality associated with acute graft-versus-host disease (aGVHD; occurring within the first 100 days after transplantation) are major factors limiting the success of HCT, as is the long-term morbidity associated with chronic GVHD (cGVHD). GVHD is a risk for both HLA-matched and HLA-mismatched transplants. GVHD can occur even when the donor and recipient are HLA-matched because the immune system can still recognize other differences between the donor tissues.

[0126] Both GVHD and GVHD are largely mediated by conventional T cells (Tcon), which initiate immune responses upon recognition of alloantigens by T cell receptors. Depleting T cells from hematopoietic stem cell transplant (HCT) grafts can reduce GVHD but also reduce GVHD and increase the likelihood of cancer recurrence. In addition to Tcon, Tregs are a further subset of T cells that negatively regulate inflammation and promote immune tolerance. Tregs can prevent or reduce GVHD by negatively regulating inflammation, including inflammation induced by donor Tcon upon recognition of recipient antigens.

[0127] Provided herein are methods for improving alloHCT, comprising administering to a subject certain cell populations, including populations of cells comprising a first population of CD45+ cells comprising at least HSPCs, a population of cells enriched for at least Tregs, and a second population of CD45+ cells comprising at least Tcon. Without wishing to be bound by theory, administering the population of cells enriched for Tregs reduces the incidence and / or severity of GVHD, while administering the second population of CD45+ cells comprising Tcon enhances GVT. Embodiments of the present invention provide compositions, multi-component pharmaceutical treatments, cell populations, solutions, formulations, kits, and / or methods for administering at least both populations of T cells to enhance GVT while minimizing GVHD. Thus, the compositions, multi-component pharmaceutical treatments, cell populations, solutions, formulations, kits, and / or methods disclosed herein preserve the graft-versus-tumor (GVT) effect of alloHCT administered to a subject with cancer (e.g., a hematological cancer), while preventing or reducing graft-versus-host disease (GVHD) in the subject. In some embodiments, the two or more cell populations are administered at different times, e.g., a first population of CD45+ cells comprising at least HSPCs and a cell population enriched for Tregs can be administered before a second population of CD45+ cells comprising at least Tcon. I. Cell Populations

[0128] Embodiments of the present invention provide a multi-component pharmaceutical treatment administered to a human subject in need thereof. The multi-component treatment includes: (a) a solution comprising a first population of CD45+ cells, including hematopoietic stem progenitor cells (HSPCs) and granulocytes, wherein up to about 10% of the first population of CD45+ cells comprises granulocytes; (b) a solution comprising a population of cells enriched for regulatory T cells (Tregs); (c) a solution comprising a second population of CD45+ cells, wherein the second population of CD45+ cells comprises at least about 20% CD3+ conventional T cells (Tcon), at least about 10% monocytes, and at least about 10% granulocytes; and (d) one or more doses of a graft-versus-host disease (GVHD) prophylactic agent, such as tacrolimus. In various embodiments, the HSPCs are CD34+.

[0129] In some embodiments, the first population of CD45+ cells comprising HSPCs is about 5×10 per kilogram of ideal body mass of said human subject. 5 ~Approx. 2×10 7In embodiments, the first population of CD45+ cells comprises at least about 0.5% granulocytes, at least about 1% granulocytes, up to about 5% granulocytes, up to about 3% granulocytes, up to about 3% monocytes, up to about 2% monocytes, up to about 0.5% lymphocytes, up to about 2% lymphocytes, at least about 15% granulocytes, at least about 20% granulocytes, up to about 35% granulocytes, up to about 30% granulocytes, up to about 25% granulocytes, at least about 15% monocytes, at least about 20% monocytes, up to about 35% monocytes, up to about 30% monocytes, up to about 25% monocytes, at least about 0.5% NK cells, and or at least about 2% NK cells. In various embodiments, the first population of CD45+ cells, the population of cells enriched for Tregs, and the second population of CD45+ cells are obtained from a single donor. In some embodiments, the first population of CD45+ cells, the population of cells enriched for Tregs, and / or the second population of CD45+ cells are allogeneic to the human subject. In embodiments, the first population of CD45+ cells, the population of cells enriched for Tregs, and / or the second population of CD45+ cells are obtained from a donor that is HLA-matched to the human subject. In various embodiments, the first population of CD45+ cells, the population of cells enriched for Tregs, and / or the second population of CD45+ cells are obtained from a donor that is HLA-mismatched to the human subject. In some embodiments, the first population of CD45+ cells, the population of cells enriched for Tregs, and / or the second population of CD45+ cells are obtained from a donor that is haplomatched to the human subject.

[0130] In embodiments, Tregs are CD4+ CD25+ CD127dim or CD4+ FOXP3+. In some cases, the population of cells enriched for Tregs includes CD45+ cells, e.g., greater than about 90% of the CD45+ cells are Tregs. In various embodiments, the population of cells enriched for Tregs is about 1 x 10 per kilogram of the human subject's actual or ideal body weight. 5 ~Approx. 1×10 7Tregs or about 5 x 10 per kilogram of the human subject's actual or ideal body weight 5 ~Approx. 4×10 6 Contains Tregs.

[0131] In some embodiments, the second population of CD45+ cells is about 1 x 10 per kilogram of actual or ideal body weight of the human subject. 5 ~Approx. 1×10 7 or about 5 x 10 per kilogram of the human subject's actual or ideal body weight 5 ~Approx. 5×10 6 In some embodiments, the second population of CD45+ cells comprises at least about 0.1% CD34+ cells or about 0.2% to about 20% CD34+ cells and / or at least about 0.1% Tregs. In various embodiments, the second population of CD45+ cells comprises a population of memory T cells (Tmem), e.g., Tmem that are CD3+ CD45RA- CD45RO+. In some embodiments, the population of Tmem is about 3 x 10 per kilogram of actual or ideal body weight of said human subject. 5 In embodiments, the population of Tmems comprises more than about 3 x 10 per kilogram of actual or ideal body weight of said human subject. 5 ~Approx. 1×10 9 In various embodiments, the second population of CD45+ cells comprises invariant natural killer T cells (iNKT), e.g., a population of iNKT that are CD3+ Vα24Jα18+. In some embodiments, the population of iNKT comprises about 5×10 per kilogram of actual or ideal body weight of said human subject. 2 In embodiments, the population of iNKTs comprises more than about 5 x 10 iNKTs per kilogram of actual or ideal body weight of said human subject. 2 ~Approx. 1×10 7 Includes iNKT.

[0132] Provided herein are compositions, multi-component pharmaceutical treatments, cell populations, solutions, formulations, kits, and / or methods for improving hematopoietic stem cell transplantation (HCT), e.g., allogeneic hematopoietic stem cell transplantation (alloHCT). The compositions, multi-component pharmaceutical treatments, cell populations, solutions, formulations, kits, and / or methods disclosed herein may include one or more cell populations that can be administered in combination with a GVHD prophylactic agent to achieve positive clinical results. The cell populations may include one or more cell types, e.g., hematopoietic stem progenitor cells (HSPCs), conventional T cells (Tcon), regulatory T cells (Treg), invariant natural killer T cells (iNKT), memory T cells (Tmem), and combinations thereof.

[0133] The present disclosure provides parameters for cell populations and methods for administering cell populations, which can contribute to successful clinical outcomes in HCT recipient subjects. Without wishing to be bound by theory, parameters that can contribute to successful clinical outcomes in HCT recipient subjects include, for example, the co-administration of GVHD prophylactic agents (e.g., tacrolimus) described herein, the populations administered, the order and timing of administration of different populations, purity standards for the populations, methods for obtaining the populations, methods for handling or selecting the populations, dosages of the populations administered, methods for obtaining the populations, and combinations thereof.

[0134] In various embodiments, the administering step comprises infusing the first population of CD45+ cells, the population of cells enriched for Tregs, and the second population of CD45+ cells into the human subject.

[0135] In some embodiments, the second population of CD45+ cells (disclosed herein) is administered at least about 12 hours after the first population of CD45+ cells (disclosed herein), the second population of CD45+ cells is administered about 24 to about 96 hours after the first population of CD45+ cells, the second population of CD45+ cells is administered about 36 to about 60 hours after the first population of CD45+ cells, the second population of CD45+ cells is administered at least about 12 hours after the population of cells enriched for Tregs (disclosed herein), the second population of CD45+ cells is administered about 24 to about 96 hours after the population of cells enriched for Tregs, and / or the second population of CD45+ cells is administered about 36 to about 60 hours after the population of cells enriched for Tregs.

[0136] HSPCs have extensive self-renewal capabilities and the ability to differentiate into specialized cell types, such as the ability to reconstitute all hematopoietic cell lineages. HSPCs can undergo asynchronous replication, generating two daughter cells with distinct phenotypes. HSPCs can exist in a mitotically quiescent state. HSPCs can be derived from bone marrow, peripheral blood, and / or umbilical cord blood.

[0137] Subsets of immune cells, such as conventional T cells (Tcon), regulatory T cells (Treg), invariant natural killer T cells (iNKT), and memory T cells (Tmem), may contribute to aspects of GVHD after HCT, including the GVHD immune response, immune reconstitution, susceptibility to infection, and patient survival.

[0138] GVHD can be mediated primarily by donor T cells, which can induce an inflammatory response upon recognition of recipient antigens. T cell depletion (TCD) of a cell population intended for transplant into a subject can reduce the likelihood of acute and / or chronic GVHD. T cells can be depleted using methods including, but not limited to, physical adsorption of T cells to protein ligands such as lectins, immunodepletion with T cell-specific antibodies, and immunoaffinity techniques (e.g., the use of T cell- or lymphocyte-specific antibodies in immunoadsorption columns, magnetic-activated cell sorting (MACS), or fluorescence-activated cell sorting (FACS)). Application of TCD techniques to donor grafts can result in, for example, the depletion of 10 to 10% of T cells. 5 TCD can result in a 1:1 reduction in T cell depletion and a reduced incidence of GVHD. However, TCD can also result in an increased rate of cancer recurrence because the lack of T cells can reduce the immune response in graft-versus-tumor (GVT). Furthermore, TCD can result in impaired immune recovery and increased susceptibility to infection.

[0139] Both GVT and GVHD are largely mediated by conventional T cells (Tcon), which may initiate an immune response upon recognition of alloantigens (tumor antigens for GVT and non-tumor recipient antigens for GVHD) by T cell receptors. Tcon may, for example, cause GVT, GVHD, or a combination thereof. In some embodiments, administration of Tcon after Treg administration may enhance GVT immunity and / or reduce susceptibility to infection.

[0140] Tcon may broadly refer to all CD3+ T cells, cells expressing CD3 and CD4, or cells expressing CD3 and CD8, cells expressing medium to high levels of CD127, cells expressing CD3 and medium to high levels of CD127, cells expressing CD3, cells expressing medium to high levels of CD127, and cells expressing CD4 or CD8. In some embodiments, Tcon does not express Vα24Jα18 TCR. Tcon and regulatory T cells ("Treg") may be cell populations that are not mutually exclusive. In some embodiments, Tcon and Treg are mutually exclusive cell populations.

[0141] Regulatory T cells ("Tregs") are a specialized subpopulation of T cells that negatively regulate (e.g., suppress) immune system activation, thereby promoting immune tolerance. Without wishing to be bound by theory, the cell population of the present disclosure enriched for Tregs contributes to a positive clinical outcome, for example, by reducing the incidence and / or severity of GVHD in transplant recipient subjects and / or improving immune reconstitution in transplant recipients. Administration of a cell population enriched for Tregs together with a population of CD45+ cells comprising at least HSPCs can, for example, promote preservation of graft-versus-tumor response (GVT) and a reduction in the incidence and / or severity of GVHD. Without wishing to be bound by theory, for example, administration of a population of cells enriched for Tregs can prevent GVHD and administration of a second population of CD45+ cells comprising at least Tcon can promote the GVT effect compared to alternative hematopoietic stem cell transplant (HCT) methods, i.e., methods separate from the compositions, multi-component pharmaceutical treatments, cell populations, solutions, formulations, kits, and / or methods disclosed and / or claimed herein. In some embodiments, administration of a population of cells enriched for Tregs reduces the risk of developing GVHD and administration of a second population of CD45+ cells comprising at least Tcon promotes the GVT effect compared to alternative HCT methods, i.e., methods separate from the compositions, multi-component pharmaceutical treatments, cell populations, solutions, formulations, kits, and / or methods disclosed and / or claimed herein.

[0142] As used herein, an alternative composition lacks one or more cell populations and / or prophylactic agents disclosed and / or claimed herein. For example, the alternative composition lacks one or more of a cell population comprising HSPC, a cell population comprising Treg, a cell population comprising Tcon, and a prophylactic agent. In some embodiments, the alternative composition or treatment regimen comprises an additional cell population or agent, such as an additional or different GVHD prophylactic agent, compared to the composition or treatment regimen of the present disclosure.

[0143] Several Treg subsets exist, such as TCRαβ+ CD4+ regulatory T cells, including natural regulatory T cells (nTregs) and inducible regulatory T cells (iTregs). nTregs may be T cells generated in the thymus and delivered to the periphery as a long-lived lineage of autoantigen-specific lymphocytes. iTregs are mobilized from circulating lymphocytes and can acquire regulatory properties under specific peripheral stimulation conditions. nTregs and iTregs are CD4+CD25+, and both can inhibit the proliferation of CD4+CD25- T cells in a dose-dependent manner. In some embodiments, Tregs are anergic and do not proliferate even upon TCR stimulation. In addition to being positive for CD4 and CD25, Tregs may be positive for an intracellular marker called the transcription factor FOXP3. Tregs can be identified or selected based on various marker expression profiles. Non-limiting examples of marker expression profiles that can be used to select Tregs include: (1) CD4+CD25+CD127dim, (2) CD4+FOXP3+, (3) CD3+CD4+CD25+, (5) CD3+CD4+CD25+CD127dim, (6) CD3+CD4+CD25+CD127dimFOXP3+, (7) CD3+FOXP3+, (8) CD3+CD4+FOXP3+, (9) CD3+ These include CD4+CD25+FOXP3+, (10)CD3+CD25+FOXP3+, (11)CD3+CD25+CD127dim, (12)CD4+CD25+, (13)CD4+CD25+CD127dimFOXP3+, (14)FOXP3+, CD4+FOXP3+, (15)CD4+CD25+FOXP3+, (16)CD25+FOXP3+, and (17)CD25+CD127dim.

[0144] Selection based on a particular expression profile, for example, selection based on CD4+CD25+CD127dim, can be achieved based on extracellular markers and without the need for cell permeabilization.

[0145] Cell populations comprising Tregs can, for example, reduce the incidence of transplant rejection, reduce the incidence and / or severity of GVHD, promote hematopoietic reconstitution, promote immune reconstitution, promote mixed chimerism, or a combination thereof.

[0146] The cell populations of the present disclosure may include invariant natural killer T cells (iNKT). iNKT is a subclass of CD1d-restricted natural killer T (NKT) cells that express a highly conserved αβ-T cell receptor, including that of the Vα24Jα18 TCR α chain in humans (referred to herein as "Vα24Jα18+"). iNKT cells can be identified by binding to CD1d multimers, such as those loaded with α-galactosylceramide (GalCer), PBS-57, PBS-44, or other natural or synthetic glycolipids. Another identification method is an antibody or combination of antibodies that specifically recognize the Vα24Jα18 region. Examples include a Vα24 antibody, a Jα18 antibody, or the monoclonal antibody clone 6B11, which specifically bind to a unique region of the Vα24Jα18 TCR and can be used to identify iNKT cells. iNKT may be CD3+Vα24Jα18+.

[0147] In some embodiments, iNKT can promote engraftment, promote GVT, reduce the incidence and / or severity of GVHD, reduce susceptibility to cancer recurrence, reduce susceptibility to infection, or a combination thereof. In some embodiments, iNKT promotes the activity of Tregs. In some embodiments, iNKT promotes the activity of HSPCs.

[0148] The cell populations of the present disclosure may include memory T cells (Tmems). Tmems may refer to antigen-experienced T cells that express, for example, the phenotypic markers CD45RO, TCRα, TCRβ, CD3, CD4, CD95, and IL-2Rβ, or the phenotypic markers CD45RO, TCRα, TCRβ, CD3, CD8, CD95, and IL-2Rβ. Tmems confer immunity and can persist in an inactive state for long periods. Tmems can rapidly acquire effector function upon antigen reloading. The Tmem population may include any combination of the subclasses of central memory T cells and effector memory T cells. In some embodiments, Tmems are CD3+CD45RA-CD45RO+. In various methods, Tmems administered to a subject undergoing HCT can, for example, promote GVT, reduce GVHD, reduce susceptibility to cancer recurrence, reduce susceptibility to infection, or a combination thereof. A. Cell Acquisition and Treatment

[0149] In some embodiments, at least one mobilized peripheral blood donation is collected from the donor, or up to two mobilized peripheral blood donations are collected from the donor.

[0150] In embodiments, at least one of the mobilized peripheral blood donations is processed and sorted to enrich for CD34+ cells and Tregs. In some embodiments, the processing and sorting time for one or more of the mobilized peripheral blood donations is less than about 35 hours, the processing and sorting time for one or more of the mobilized peripheral blood donations is less than about 30 hours, the processing and sorting time for one or more of the mobilized peripheral blood donations is less than about 25 hours, the processing and sorting time for one or more of the mobilized peripheral blood donations is up to about 35 hours, and / or the processing and sorting time for one or more of the mobilized peripheral blood donations is up to about 25 hours.

[0151] In various embodiments, one or more of the mobilized peripheral blood donations are processed and sorted using one or more immunoseparation particles (ISPs), e.g., the ISPs include affinity reagents such as immunomagnetic separation particles, which may each be an antibody conjugated to an iron-containing particle. In some embodiments, the affinity reagents include multiple CD34 reagents (e.g., anti-CD34 antibodies) that bind to one or more CD34 receptors on HSPCs.

[0152] In some cases, at least some of the plurality of ISPs bind to CD34+ receptors of HSPCs in the HSPC cell population; optionally, the average number of ISPs per HSPC in the HSPC cell population is less than about 20,000, the average number of ISPs per HSPC in the HSPC cell population is equal to or less than about 10,000, and / or the average number of ISPs per HSPC in the HSPC cell population is between about 1,000 and about 20,000.

[0153] In some embodiments, the average number of ISPs per HSPC in the HSPC cell population may be about 1,500 to about 20,000. In some embodiments, the average number of ISPs per HSPC in the HSPC cell population may be at least about 1,500. In some embodiments, the average number of ISPs per HSPC in the HSPC cell population may be up to about 20,000. In some embodiments, the average number of ISPs per HSPC in the HSPC cell population is about 1,500 to about 2,000, about 1,500 to about 5,000, about 1,500 to about 6,000, about 1,500 to about 10,000, about 1,500 to about 12,000, about 1,500 to about 15,000, about 1,500 to about 20,000, about 2,000 to about 5,000, about 2,000 to about 6,000, about 2,000 to about 10,000, about 2,000 to about 12,000, about 2,000 to about 15,000, about 2,000 to about 20,000, or about 5,000. It may be 0 to about 6,000, about 5,000 to about 10,000, about 5,000 to about 12,000, about 5,000 to about 15,000, about 5,000 to about 20,000, about 6,000 to about 10,000, about 6,000 to about 12,000, about 6,000 to about 15,000, about 6,000 to about 20,000, about 10,000 to about 12,000, about 10,000 to about 15,000, about 10,000 to about 20,000, about 12,000 to about 15,000, about 12,000 to about 20,000, or about 15,000 to about 20,000. In some embodiments, the average number of ISPs per HSPC in the HSPC cell population may be about 1,500, about 2,000, about 5,000, about 6,000, about 10,000, about 12,000, about 15,000, or about 20,000. In some embodiments, the average number of ISPs per HSPC in the HSPC cell population may be at least 1,500, 2,000, 5,000, 6,000, 10,000, 12,000, 15,000, or 20,000. In some embodiments, the average number of ISPs per HSPC in the HSPC cell population may be up to 1,500, 2,000, 5,000, 6,000, 10,000, 12,000, 15,000, or 20,000.

[0154] In some cases, at least a portion of the plurality of ISPs bind to CD25+ receptors on cells of the Treg cell population; optionally, the average number of ISPs per T-reg cell in the Treg population is equal to or less than about 4000, or the average number of ISPs per T-reg cell in the Treg population is between about 1500 and about 2500. In some cases, at least a portion of the plurality of ISPs bind to CD3+ receptors on cells of the heterogeneous cell population; optionally, the average number of ISPs per cell in the heterogeneous population is less than about 4,000.

[0155] In some embodiments, the average number of ISPs per Treg cell in a Treg cell population may be about 500 to about 4,000. In some embodiments, the average number of ISPs per Treg cell in a Treg cell population may be at least about 500. In some embodiments, the average number of ISPs per Treg cell in a Treg cell population may be up to about 4,000. In some embodiments, the average number of ISPs per Treg cell in a Treg cell population is about 500 to about 1,000, about 500 to about 1,500, about 500 to about 2,000, about 500 to about 2,500, about 500 to about 3,000, about 500 to about 4,000, about 1,000 to about 1,500, about 1,000 to about 2,000, about 1,000 to about 2,500, about 1,000 to about 3,000, or about 4,000. In some embodiments, the average number of ISPs per Treg cell in the Treg cell population may be about 500, about 1,000, about 1,500, about 2,000, about 2,500, about 3,000, about 4,000, about 1,000 to about 4,000, about 1,500 to about 2,000, about 1,500 to about 2,500, about 1,500 to about 3,000, about 1,500 to about 4,000, about 2,000 to about 2,500, about 2,000 to about 3,000, about 2,000 to about 4,000, about 2,500 to about 3,000, about 2,500 to about 4,000, or about 3,000 to about 4,000. In some embodiments, the average number of ISPs per Treg cell in the Treg cell population may be at least 500, 1,000, 1,500, 2,000, 2,500, 3,000, or 4,000. In some embodiments, the average number of ISPs per Treg cell in the Treg cell population may be up to 500, 1,000, 1,500, 2,000, 2,500, 3,000, or 4,000.

[0156] In some embodiments, the average number of ISPs per Tcon cell in the Tcon cell population may be about 100 to about 1,000. In some embodiments, the average number of ISPs per Tcon cell in the Tcon cell population may be at least about 100. In some embodiments, the average number of ISPs per Tcon cell in the Tcon cell population may be up to about 1,000. In some embodiments, the average number of ISPs per Tcon cell in the Tcon cell population may be about 100 to about 200, about 100 to about 500, about 100 to about 1,000, about 200 to about 500, about 200 to about 1,000, or about 500 to about 1,000. In some embodiments, the average number of ISPs per Tcon cell in the Tcon cell population may be about 100, about 200, about 500, or about 1,000. In some embodiments, the average number of ISPs per Tcon cell in the Tcon cell population may be at least 100, 200, 500, or 1,000. In some embodiments, the average number of ISPs per Tcon cell in a Tcon cell population may be up to 100, 200, 500, or 1,000.

[0157] In various embodiments, the cells of the mobilized peripheral blood donation are sorted so that the first population of CD45+ cells comprises up to about 10% granulocytes. In some cases, the cells of the mobilized peripheral blood donation are sorted so that the first population of CD45+ cells comprises up to about 7% granulocytes.

[0158] In some embodiments, the cells of the mobilized donor peripheral blood donation are sorted so that the first population of CD45+ cells comprises up to about 4% monocytes. In some cases, the cells of the mobilized donor peripheral blood donation are sorted so that the first population of CD45+ cells comprises at least about 0.1% monocytes.

[0159] In embodiments, cells from a mobilized donor peripheral blood donation are sorted so that the population enriched for Tregs contains up to about 10% CD25 cells.

[0160] In some embodiments, the cell populations of the present disclosure are obtained from whole blood. The cell populations of the present disclosure can be obtained from peripheral blood apheresis products, such as mobilized peripheral blood apheresis products mobilized by administering GCSF, GM-CSF, Mozobil, and combinations thereof to a donor. The cell populations of the present disclosure can be obtained from at least one apheresis product, two apheresis products, three apheresis products, four apheresis products, five apheresis products, six apheresis products, or more apheresis products. In some embodiments, the cell populations of the present disclosure are obtained from one apheresis product. In some embodiments, the cell populations of the present disclosure are obtained from two apheresis products. In some embodiments, the cell populations of the present disclosure are obtained from apheresis products from one donor and apheresis products from at least a second donor.

[0161] In some embodiments, the cell populations of the present disclosure are obtained from bone marrow.

[0162] In some embodiments, the cell populations of the present disclosure are obtained from umbilical cord blood.

[0163] The cell populations of the present disclosure can be purified by selection from a population of cells, such as peripheral blood or peripheral blood apheresis products. Cell population selection methods can include methods involving positive or negative selection of the desired cell population. Cell population selection methods can include affinity reagents, including, but not limited to, antibodies, full-length antibodies, antibody fragments, naturally occurring antibodies, synthetic antibodies, engineered antibodies, full-length affibodies, affibody fragments, full-length affilins, affilin fragments, full-length anticalins, anticalin fragments, full-length avimers, avimer fragments, full-length DARPins, DARPin fragments, full-length finomers, finomer fragments, full-length kunitz domain peptides, kunitz domain peptide fragments, full-length monobodies, monobody fragments, peptides, or polyamino acids. In some embodiments, the affinity reagent is directly conjugated to the detection reagent and / or purification reagent. In some cases, the detection reagent and the purification reagent are the same. In some cases, the detection reagent and the purification reagent are different. For example, the detection and / or purification reagents are fluorescent, magnetic, etc. In some cases, the detection and / or purification reagents are magnetic particles for column purification. For example, magnetic column purification can be performed using the columns, antibodies, buffers, preparation materials and reagents of the Miltenyi system (CliniMAC).

[0164] In various embodiments, at least one of the cell populations has a plurality of immunoseparation particles (ISPs) bound to receptors on cells of the cell population. In some cases, the plurality of ISPs are immunomagnetic separation particles. In some embodiments, the plurality of ISPs comprises antibodies conjugated to iron-containing particles. In some cases, at least some of the plurality of ISPs are bound to CD34+ receptors on HSPCs in the HSPC cell population; optionally, the average number of ISPs per HSPC in the HSPC cell population is less than about 6,000, the average number of ISPs per HSPC in the HSPC cell population is equal to or less than about 3,000, and / or the average number of ISPs per HSPC in the HSPC cell population is between about 1700 and about 3,000. In some cases, at least a portion of the plurality of ISPs bind to CD25+ receptors on cells of the Treg cell population; optionally, the average number of ISPs per T-reg cell in the Treg population is equal to or less than about 1700, or the average number of ISPs per T-reg cell in the Treg population is between about 1400 and about 1700. In some cases, at least a portion of the plurality of ISPs bind to CD3+ receptors on cells of the heterogeneous cell population; optionally, the average number of ISPs per cell in the heterogeneous population is less than about 1,000.

[0165] Affinity reagents include immunoaffinity reagents that utilize the binding specificity of antibodies or their fragments or derivatives to positively or negatively select a cell population of interest. Selection methods for cell populations, such as magnetic-activated cell sorting (MACS), which involves specific antibodies and microbeads, may include affinity agents and columns. Selection methods for cell populations may also include fluorescence-activated cell sorting (FACS), in which a cell population is sorted based on its staining profile with one or more fluorescently conjugated antibodies. Selection methods for cell populations may include physical adsorption, for example, to a protein ligand such as a T cell lectin.

[0166] HSPCs can be obtained by collection from bone marrow or peripheral blood. Bone marrow can be aspirated from the posterior or anterior iliac crest while the donor is under local or general anesthesia. HSPCs can also be obtained by collection from peripheral blood, for example, by peripheral blood apheresis. The number of collected stem cells can be increased by treating the donor with a mobilization agent, i.e., an agent that mobilizes stem cells from bone marrow to peripheral blood. Non-limiting examples of mobilization agents include granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), mozobil, and combinations thereof. Techniques for mobilizing stem cells into peripheral blood can include administering a mobilization agent to the donor, for example, at 10 to 40 μg / kg / day. The mobilization agent can be administered to the donor in, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses. The apheresis product can be isolated from the donor, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, or 30 hours after administration of the mobilizing agent.

[0167] The population of CD45+ cells of the present disclosure can include HSPCs. HSPCs can be selected based on CD34 expression. For example, HSPCs of the present disclosure can be selected using anti-CD34 antibodies as part of a magnetic activated cell sorting (MACS) or fluorescence activated cell sorting (FACS) system.

[0168] The number of HSPCs in a population of CD45+ cells can be determined by, for example, quantifying CD34+ cells by flow cytometry.In some embodiments, dosage calculation is adjusted based on the measurement of cell viability, for example, the viability determined by flow cytometry using propidium iodide or 7-AAD or by trypan blue exclusion.

[0169] The cell populations of the present disclosure can be enriched for Tregs. Tregs can be selected based on the expression of markers including CD3, CD4, CD25, CD127, FOXP3, and combinations thereof.

[0170] Tregs can be selected using magnetic-activated cell sorting (MACS). Tregs can be selected using fluorescence-activated cell sorting (FACS). Tregs can be selected using multiple procedures, such as multiple MACS selections, multiple FACS selections, or a combination of MACS and FACS selections. For example, the first selection can be performed for CD25 expression, for example, by MACS to isolate CD25+ cells from a hematopoietic cell sample. The second selection can be performed by contacting CD25+ cells with antibodies specific for CD4 and CD127, where FACS is used to isolate CD4+CD127dim cells.

[0171] Tregs can be isolated from whole blood. Tregs can be isolated from peripheral blood apheresis products. Tregs can be isolated from a cell population that has been previously enriched and / or depleted from one or more other cell types, for example, from a cell population that has been depleted of CD34+ cells. In some embodiments, Tregs are isolated from the flow-through fraction of CD34+ MACS selection.

[0172] The number of Treg in cell population can be determined by, for example, flow cytometry, where Treg can be identified as, for example, CD4+CD25+CD127dim or CD4+FOXP3+.Dose calculation can be adjusted based on the measurement of cell viability, for example, the viability determined by flow cytometry using propidium iodide or 7-AAD, or by trypan blue exclusion.

[0173] The second population of CD45+ cells may include a population of Tcon. The second population of CD45+ cells containing at least Tcon may originate from peripheral blood. The second population of CD45+ cells may be sourced from a peripheral blood apheresis product.

[0174] In some embodiments, no selection step is performed, and the second population of CD45+ cells containing at least Tcon is directly sourced from an aliquot of peripheral blood or apheresis product. In some embodiments, the population of cells can be enriched for Tcon by sorting based on the expression of various markers, for example, using MACS, FACS, or a combination thereof. The second population of CD45+ cells can be enriched by sorting for CD3+ cells. The second population of CD45+ cells can be enriched by sorting for CD4+ cells and CD8+ cells. The second population of CD45+ cells can be enriched by negative selection, where non-Tcon cells are removed, for example, by depleting cells expressing CD34, CD19, CD25, or a combination thereof, by MACS.

[0175] The number of Tcon present in the second population of CD45+ cells can be quantified, for example, by quantifying CD3+ cells by flow cytometry.The number of CD3+ cells in an aliquot can be determined, and the volume containing the appropriate dose of CD3 cells can be administered to the recipient.Dose calculation can be adjusted based on the measure of cell viability, for example, the viability determined by flow cytometry using propidium iodide or 7-AAD, or by trypan blue exclusion.

[0176] The apheresis product of the present disclosure can be divided into two parts: one part used to provide a second population of CD45+ cells containing at least Tcon, and the other part for isolating and purifying a population of CD45+ cells containing at least HSPCs and a cell population enriched for Tregs. In an alternative embodiment, CD34+ cells are isolated and purified from the apheresis product to create a CD34-negative cell fraction from which Treg cells are then isolated, helping to provide a cell population enriched for Tregs.

[0177] The cell populations of the present disclosure can include a population of iNKT. The population of iNKT can be sourced from peripheral blood. The population of iNKT can be sourced from a peripheral blood apheresis product.

[0178] A population of cells can be enriched for iNKT by sorting based on the expression of various markers, for example, using MACS, FACS, or a combination thereof. A population of iNKT can be enriched, for example, by sorting for CD3+Vα24Jα18+ cells.

[0179] The number of iNKT present in a population can be quantified, for example, by quantifying CD3+Vα24Jα18+ cells by flow cytometry.The number of CD3+Vα24Jα18+ cells in an aliquot can be determined, and the volume containing the appropriate dose of iNKT can be administered to the recipient.In some embodiments, the dose calculation is adjusted based on a measure of cell viability, for example, viability determined by flow cytometry using propidium iodide or 7-AAD, or by trypan blue exclusion.

[0180] The cell populations of the present disclosure can include a population of Tmem. The population of Tmem can be sourced from peripheral blood. The population of Tmem can be sourced from a peripheral blood apheresis product.

[0181] A population of cells can be enriched for Tmem by sorting based on the expression of various markers, e.g., using MACS, FACS, or a combination thereof. A population of Tmem can be enriched, e.g., by sorting for CD3+CD45RA-CD45RO+ cells.

[0182] The number of Tmem present in a population can be quantified, for example, by quantifying CD3+CD45RA-CD45RO+ cells by flow cytometry.The number of CD3+CD45RA-CD45RO+ cells in an aliquot can be determined, and the volume containing the appropriate dose of Tmem can be administered to the recipient.Dose calculation can be adjusted based on cell viability measurements, for example, viability determined by flow cytometry using propidium iodide or 7-AAD, or by trypan blue exclusion.

[0183] The cell populations of the present disclosure or cell populations of the present disclosure may be administered fresh after isolation or after cryopreservation and subsequent thawing.

[0184] Freshly isolated cells from a donor ("fresh cells") can be administered to a recipient subject. Fresh cells can be stored in a buffer, such as CliniMACS PBS-EDTA buffer containing 0.5% human serum albumin, or Plasma-Lyte-A at pH 7.4 supplemented with 2% human serum albumin. Fresh cells can be stored cryopreserved / unfrozen at low temperatures (e.g., 2-8°C).

[0185] After obtaining a fresh population of cells from a donor, the fresh cells may be incubated for at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 7 hours, at least about 8 hours, at least about 9 hours, at least about 10 hours, at least about 11 hours, at least about 12 hours, at least about 13 hours, at least about 14 hours, at least about 15 hours, at least about 16 hours, at least about 17 hours, at least about 18 hours, at least about 19 hours, at least about 20 hours, at least about 21 hours, at least about 22 hours, at least about 23 hours, at least about 24 hours, at least about 25 hours, at least about 26 hours, at least about 27 hours, at least about 28 hours, or at least about 30 hours prior to administration to a subject. and may be stored for at least about 29 hours, at least about 30 hours, at least about 31 hours, at least about 32 hours, at least about 33 hours, at least about 34 hours, at least about 35 hours, at least about 36 hours, at least about 37 hours, at least about 38 hours, at least about 39 hours, at least about 40 hours, at least about 44 hours, at least about 48 hours, at least about 50 hours, at least about 55 hours, at least about 60 hours, at least about 61 hours, at least about 62 hours, at least about 65 hours, at least about 70 hours, at least about 72 hours, at least about 80 hours, at least about 90 hours, at least about 96 hours, at least about 120 hours, at least about 150 hours, at least about 200 hours, at least about 300 hours, or longer.

[0186] After obtaining a fresh population of cells from a donor, the fresh cells may be stored for up to about 1 hour, up to about 2 hours, up to about 3 hours, up to about 4 hours, up to about 5 hours, up to about 6 hours, up to about 7 hours, up to about 8 hours, up to about 9 hours, up to about 10 hours, up to about 12 hours, up to about 14 hours, up to about 16 hours, up to about 18 hours, up to about 20, up to about 22 hours, up to about 24 hours, up to about 30 hours, up to about 36 hours, up to about 40 hours, up to about 48 hours, up to about 60 hours, up to about 70 hours, up to about 72 hours, up to about 80 hours, up to about 90 hours, up to about 96 hours, up to about 120 hours, up to about 150 hours, up to about 200 hours, or up to about 300 hours before administration to a subject.

[0187] The cell of the present disclosure can be cryopreserved.In some embodiments, cryopreservation can be beneficial for the method disclosed herein.For example, by cryopreserving the second group of CD45+ cells that comprises at least Tcon before subsequent thawing and administration to subject, GVHD can be reduced.

[0188] An additional embodiment provides a method for transplanting a population of conventional T cells (Tcon) into a human subject without inducing a stage 2 or higher graft-versus-host disease (GVHD) response up to about 100 days after transplantation. The method includes: (i) administering a solution comprising a population of conventional T cells (Tcon); and (ii) administering a solution comprising a population of regulatory T cells (Treg). In this method, the population of Tcon has been cryopreserved for at least about 4 hours, and the solution comprising the population of Tcon and the solution comprising the population of Treg contain less than about 5 EU of endotoxin per ml of solution.

[0189] Cryopreservation can involve adding a preservative (e.g., DMSO) and slowly cooling the cells in a controlled-rate freezer to prevent cell damage from the osmotic pressure resulting from ice crystal formation. Cryopreservation can involve commercially available cryopreservation reagents and materials, such as Cryobags and CryoStor® CS10.

[0190] Cryopreserved cells can be stored at low temperatures for periods ranging from a few hours to several years. Cryopreserved cells can be stored at ultra-low temperatures, such as -50°C, -60°C, -70°C, -80°C, -90°C, -100°C, -110°C, -120°C, -130°C, -140°C, -150°C, -160°C, -170°C, -180°C, -190°C, -196°C, or lower. Cryopreserved cells can be stored in a storage device containing liquid nitrogen.

[0191] Cells may be cryopreserved before or after certain steps in the methods of the present disclosure, for example, before or after a sorting step, or before or after a characterization step such as determining cell viability or concentration of a particular cell type.

[0192] In some embodiments, whole blood may be cryopreserved. Whole blood may be cryopreserved without sorting or characterization. Whole blood may be cryopreserved after sorting but without characterization. Whole blood may be cryopreserved after characterization but without sorting. Whole blood may be cryopreserved after characterization and sorting. Whole blood may be cryopreserved after quantifying the cell types of the present disclosure. Whole blood may be cryopreserved after quantifying conventional T cells (Tcon, e.g., CD3+ cells). Whole blood may be cryopreserved after quantifying the viability of whole cells or cell populations (e.g., conventional T cells) of the present disclosure.

[0193] The peripheral blood apheresis product of the present disclosure may be cryopreserved. The peripheral blood apheresis product may be cryopreserved without sorting or characterization. The peripheral blood apheresis product may be cryopreserved after sorting but without characterization. The peripheral blood apheresis product may be cryopreserved after characterization but without sorting. The peripheral blood apheresis product may be cryopreserved after characterization and sorting. The peripheral blood apheresis product may be cryopreserved after quantifying the cell types of the present disclosure. The peripheral blood apheresis product may be cryopreserved after quantifying conventional T cells (Tcon, e.g., CD3+ cells). The peripheral blood apheresis product may be cryopreserved after quantifying the viability of the total cells or cell populations (e.g., conventional T cells) of the present disclosure.

[0194] A cell population that has been sorted or selected from another cell population may be cryopreserved, for example, a population of CD45+ cells, HSPCs, Tregs, Tcon, iNKT, or Tmem may be cryopreserved.

[0195] The cell populations of the present disclosure may be cryopreserved for any length of time. The cells of the disclosure may be cryopreserved for at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 7 hours, at least about 8 hours, at least about 9 hours, at least about 10 hours, at least about 11 hours, at least about 12 hours, at least about 14 hours, at least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, at least about 24 hours, at least about 30 hours, at least about 36 hours, at least about 48 hours, at least about 50 hours, at least about 55 hours, at least about 60 hours, at least about 61 hours, at least about 62 hours, at least about 65 hours, at least about 70 hours, at least about 72 hours, at least about 80 hours, at least about 90 hours, at least about 96 hours, at least about 120 hours, at least about 150 hours, at least about 200 hours, at least about 300 hours, or longer, prior to thawing and administration to a subject.

[0196] In some embodiments, the cell populations of the disclosure are cryopreserved for up to about 1 hour, up to about 2 hours, up to about 3 hours, up to about 4 hours, up to about 5 hours, up to about 6 hours, up to about 7 hours, up to about 8 hours, up to about 9 hours, up to about 10 hours, up to about 11 hours, up to about 12 hours, up to about 14 hours, up to about 16 hours, up to about 18 hours, up to about 20 hours, up to about 22 hours, up to about 24 hours, up to about 30 hours, up to about 36 hours, up to about 48 hours, up to about 50 hours, up to about 55 hours, up to about 60 hours, up to about 61 hours, up to about 62 hours, up to about 65 hours, up to about 70 hours, up to about 72 hours, up to about 80 hours, up to about 90 hours, up to about 96 hours, up to about 120 hours, up to about 150 hours, up to about 200 hours, or up to about 300 hours prior to thawing and administration to a subject.

[0197] In some embodiments, the cell populations of the present disclosure are cryopreserved for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 10 days, at least about 14 days, at least about 21 days, at least about 28 days, at least about 50 days, at least about 60 days, or at least about 96 days or more prior to thawing and administration to a subject.

[0198] In some embodiments, the cell populations of the present disclosure are cryopreserved for up to about 1 day, up to about 2 days, up to about 3 days, up to about 4 days, up to about 5 days, up to about 6 days, up to about 7 days, up to about 10 days, up to about 14 days, up to about 21 days, up to about 28 days, up to about 50 days, up to about 60 days, or up to about 96 days prior to thawing and administration to a subject. B. Donor

[0199] In embodiments, each cell population is provided as a separate cell population and is derived from a single human blood donor.

[0200] The cell population can include cells from one or more donors, each HLA-typed to determine, for example, the degree of HLA compatibility with the subject who will receive the cell population.

[0201] Human leukocyte antigens (HLA), also broadly referred to as major histocompatibility complex (MHC) antigens, can be protein molecules expressed on the cell surface that can confer antigen specificity to that cell. HLA / MHC antigens are target molecules that can be recognized by T cells and natural killer (NK) cells, whether they are derived from the same source as hematopoietic stem cells as immune effector cells ("self") or from a separate source from hematopoietic cells ("non-self"). HLA class I antigens (A, B, and C in humans) are expressed by the majority of cells, while HLA class II antigens (DR, DP, and DQ in humans) are primarily expressed by professional antigen-presenting cells. Both HLA classes can be involved in GVHD.

[0202] HLA antigens are encoded by highly polymorphic genes, with a range of alleles present for each HLA class I and II gene. Allele products may differ by one or more amino acids in the α and / or β domains. A panel of specific antibodies or nucleic acid reagents can be used to determine an individual's HLA haplotype, for example, using leukocytes expressing class I and class II molecules. HLA alleles can be described with varying levels of detail. Most designations begin with the HLA- and locus name, followed by an * and several (even-numbered) digits to identify the allele. The first two digits may identify a group of alleles. The third and fourth digits, if present, may identify synonymous alleles. The fifth and sixth digits, if present, may indicate any synonymous mutations within the coding frame of the gene. The seventh and eighth digits, if present, may distinguish mutations outside the coding region. A letter, such as L, N, Q, or S, may follow the allele designation and identify its known expression level or other non-genomic data. Thus, a fully described allele may be up to 9 numbers, excluding the HLA- prefix and locus designation.

[0203] A set of HLA alleles inherited from one parent forms a haplotype. HLA haplotype matching can refer to a donor-recipient pair in which one chromosome is at least matched between donor and recipient in HLA-A, HLA-B, and HLA-DR. A haplotype-matched pair may be matched or mismatched in other alleles, such as other HLA genes on the other chromosome, or additional histocompatibility loci on either chromosome. Such donors may frequently exist within families; for example, parents may be matched with children, and siblings may be matched with each other in haplotype.

[0204] Cell population can be derived from donor that is divided by HLA type in any number of HLA alleles.Donor and subject can be HLA compatible, for example, can be HLA compatible in all HLA alleles of type.Donor and subject can be HLA incompatible, for example, at least one HLA antigen can be incompatible between donor and recipient.

[0205] In some embodiments, donor and subject can be divided by HLA type in six alleles consisting of HLA-A, HLA-B and HLA-DR alleles.Donor and subject can be matched, for example, in 3 / 6, 4 / 6, 5 / 6 or 6 / 6 alleles.In some embodiments, donor and subject are matched in at least 5 / 6 alleles.In some embodiments, donor and subject are matched in 6 / 6 alleles.

[0206] In some embodiments, the donor and the subject may be HLA-typed at eight alleles, consisting of HLA-A, HLA-B, HLA-C, and HLA-DR alleles (e.g., HLA-DRB1 alleles). The donor and the subject may be matched, for example, at 4 / 8, 5 / 8, 6 / 8, 7 / 8, or 8 / 8 alleles. In some embodiments, the donor and the subject are matched at least at 6 / 8 alleles. In some embodiments, the donor and the subject are matched at least at 7 / 8 alleles. In some embodiments, the donor and the subject are matched at 8 / 8 alleles.

[0207] In some embodiments, the donor and the subject can be HLA-typed at 10 alleles consisting of HLA-A, HLA-B, HLA-C, and HLA-DR alleles (e.g., HLA-DRB1 allele). The donor and the subject may be matched, for example, at 5 / 10, 6 / 10, 7 / 10, 8 / 10, 9 / 10, or 10 / 10 alleles. In some embodiments, the donor and the subject are matched at least at 7 / 10 alleles. In some embodiments, the donor and the subject are matched at least at 8 / 10 alleles. In some embodiments, the donor and the subject are matched at least at 9 / 10 alleles. In some embodiments, the donor and the subject are matched at 10 / 10 alleles.

[0208] The cell population can be generated from a matched sibling donor that is an 8 / 8 match for HLA-A, -B, -C, and -DRB1, i.e., all typed using DNA-based high-resolution methods. The cell population can be generated from a matched sibling donor that is a 7 / 8 match for HLA-A, -B, -C, and -DRB1, i.e., all typed using DNA-based high-resolution methods. The cell population can be generated from a matched sibling donor that is a 6 / 8 match for HLA-A, -B, -C, and -DRB1, i.e., all typed using DNA-based high-resolution methods. The cell population can be generated from a matched sibling donor that is a 10 / 10 match for HLA-A, -B, -C, -DQB1, and -DRB1, i.e., all typed using DNA-based high-resolution methods. The cell population can be generated from a matched sibling donor that is a 9 / 10 match for HLA-A, -B, -C, -DQB1, and -DRB1, i.e., all typed using high-resolution DNA-based methods. The cell population can be generated from a matched sibling donor that is an 8 / 10 match for HLA-A, -B, -C, -DQB1, and -DRB1, i.e., all typed using high-resolution DNA-based methods. The cell population can be generated from a matched sibling donor that is a 7 / 10 match for HLA-A, -B, -C, -DQB1, and -DRB1, i.e., all typed using high-resolution DNA-based methods.

[0209] The cell population can be generated from a matched unrelated donor that is an 8 / 8 match for HLA-A, -B, -C, and -DRB1, i.e., all typed using DNA-based high-resolution methods. The cell population can be generated from a matched unrelated donor that is a 7 / 8 match for HLA-A, -B, -C, and -DRB1, i.e., all typed using DNA-based high-resolution methods. The cell population can be generated from a matched unrelated donor that is a 6 / 8 match for HLA-A, -B, -C, and -DRB1, i.e., all typed using DNA-based high-resolution methods. The cell population can be generated from a matched unrelated donor that is a 10 / 10 match for HLA-A, -B, -C, -DQB1, and -DRB1, i.e., all typed using DNA-based high-resolution methods. The cell population can be generated from a matched unrelated donor that is a 9 / 10 match for HLA-A, -B, -C, -DQB1 and -DRB1, i.e., all typed using high resolution DNA-based methods. The cell population can be generated from a matched unrelated donor that is an 8 / 10 match for HLA-A, -B, -C, -DQB1 and -DRB1, i.e., all typed using high resolution DNA-based methods.

[0210] In various embodiments, the first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are allogeneic to said human subject.

[0211] In some embodiments, the first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are obtained from a donor that is HLA-matched to said human subject.

[0212] In embodiments, the first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are obtained from a donor that is HLA-mismatched to said human subject.

[0213] In various embodiments, the first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are obtained from a donor that is haploidentical to said human subject.

[0214] The cell population can be derived from an allogeneic donor. The cell population can be generated from a donor who is a first-degree relative of the subject. The cell population can be generated from a donor who is a second-degree relative of the subject. The cell population can be generated from a donor who is unrelated to the subject. The cell population can be generated from a donor who is HLA-matched to the recipient subject. The cell population can be generated from a donor who is HLA-mismatched to the recipient subject. The cell population can be generated from a donor who is haplotype-matched to the recipient subject. The cell population can be generated from a donor who is related to the recipient subject, for example, a parent, child, sibling, grandparent, grandchild, aunt, uncle, or cousin. The cell population can be generated from a donor who is at least 16 years of age. The cell population can be generated from a donor who is at least 18 years of age.

[0215] The cell population can be generated from donors who meet the eligibility criteria for donors of viable leukocyte-rich cells or tissue as defined in 21 CFR §1271 2018 and the associated FDA Guidance for Industry. For example, cell populations can be generated from donors who meet the eligibility criteria outlined in any one or more of the following: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, 2007; Use of Donor Screening Tests to Test Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products for Infection with Treponema pallidum (Syphilis), 2015; Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, 2016; Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT / Ps), 2016; and Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products, 2018).The cell population can be generated from donors who meet any criteria for donation as specified by standard NMDP guidelines (NMDP donors).

[0216] The cell population can be generated from donors who show no evidence of active infection. The cell population can be generated from donors who are not seropositive for HIV-1 or -2, HTLV-1 or 2. The cell population can be generated from donors who are not positive for anti-hepatitis C (HCV) antibodies or HCV NATs. The cell population can be generated from donors who test negative for chronic HBV infection. The cell population can be generated from donors who are not at high risk for Zika virus infection, defined as any of the following: (i) a medical diagnosis of Zika virus infection within the past six months; (ii) residence in or travel to an area with active Zika virus transmission within the past six months; or (iii) unprotected intercourse with a person known to have either risk factor (i) or (ii) within the past six months. The cell population can be generated from donors who have no signs or symptoms consistent with active Zika virus infection.

[0217] One or more cell populations of the present disclosure can be obtained from a single donor, for example, from mobilized peripheral blood apheresis of a single donor. HSPCs, Tregs, Tcon, iNKT, Tmem, or any combination thereof can be obtained from a single donor.

[0218] One or more cell populations of the present disclosure can be obtained from one donor, and one or more additional cell populations of the present disclosure can be obtained from a second donor. One cell population of the present disclosure can be obtained from a single donor, and a second cell population of the present disclosure can be obtained from multiple donors. The populations of the present disclosure can be obtained from multiple donors, for example, from mobilized peripheral blood apheresis of multiple donors. HSPCs can be obtained from multiple donors. Tregs can be obtained from multiple donors. Tcon can be obtained from multiple donors. iNKT can be obtained from multiple donors. Tmem can be obtained from multiple donors. C. Cell Population Dose

[0219] The dose of the cell population administered to a subject may be based on the subject's body weight. In some cases, the subject's body weight may be used to determine the dose of one or more cell populations administered to the subject. In some cases, the cell dose may be based on the subject's actual weight, for example, the subject's ideal body weight instead of the actual body weight. The ideal body weight may be a preferred dose calculation method to avoid incorrect cell doses due to excess body fat and / or muscle mass. The subject's ideal body weight can be calculated using the subject's height and sex. Other methods of calculating a subject's ideal body weight may also be used. For example, other methods of determining the subject's body fat percentage. The dose of the cell population may also be based on the subject's adjusted body weight (ABW) if the subject's actual body weight is more than 120% of their ideal body weight (IBW). HSPC

[0220] The first population of CD45+ cells, which comprises at least HSPCs, may be at least about 1 x 10 first population of CD45+ cells and / or HSPCs (e.g., CD34+ cells) per kg actual or ideal body weight of the recipient subject. 4 , at least about 1 x 10 5 , at least about 5 × 10 5 , at least about 6 × 10 5 , at least about 7 × 10 5, at least about 8 × 10 5 , at least about 9 × 10 5 , at least about 1 x 10 6 , at least about 1.1 × 10 6 , at least about 1.2 × 10 6 , at least about 1.3 × 10 6 , at least about 1.4 × 10 6 , at least about 1.5 x 10 6 , at least about 1.6 × 10 6 , at least about 1.7 × 10 6 , at least about 1.8 × 10 6 , at least about 1.9 × 10 6 , at least about 2 × 10 6 , at least about 2.1 x 10 6 , at least about 2.2 × 10 6 , at least about 2.3 × 10 6 , at least about 2.4 × 10 6 , at least about 2.5 x 10 6 , at least about 2.6 × 10 6 , at least about 2.7 × 10 6 , at least about 2.8 × 10 6 , at least about 2.9 × 10 6 , at least about 3 × 10 6 , at least about 3.1 × 10 6 , at least about 3.2 × 10 6 , at least about 3.3 × 10 6 , at least about 3.4 × 10 6 , at least about 3.5 x 10 6 , at least about 3.6 × 10 6 , at least about 3.7 × 10 6 , at least about 3.8 × 10 6 , at least about 3.9 × 10 6 , at least about 4 × 10 6 , at least about 4.1 × 10 6 , at least about 4.2 × 10 6 , at least about 4.3 × 10 6 , at least about 4.4 × 10 6 , at least about 4.5 x 10 6 , at least about 4.6 × 10 6, at least about 4.7 × 10 6 , at least about 4.8 × 10 6 , at least about 4.9 × 10 6 , at least about 5 × 10 6 , at least about 5.1 × 10 6 , at least about 5.2 × 10 6 , at least about 5.3 × 10 6 , at least about 5.4 × 10 6 , at least about 5.5 × 10 6 , at least about 5.6 × 10 6 , at least about 5.7 × 10 6 , at least about 5.8 × 10 6 , at least about 5.9 × 10 6 , at least about 6 × 10 6 , at least about 6.5 × 10 6 , at least about 7 × 10 6 , at least about 7.5 × 10 6 , at least about 8 × 10 6 , at least about 8.5 × 10 6 , at least about 9 × 10 6 , at least about 9.5 × 10 6 , at least about 1 x 10 7 , at least about 1.5 x 10 7 , at least about 2 × 10 7 , at least about 2.5 x 10 7 , at least about 3 × 10 7 , at least about 3.5 x 10 7 , at least about 4 × 10 7 , at least about 4.5 x 10 7 , at least about 5 × 10 7 , at least about 5.5 × 10 7 , at least about 6 × 10 7 , at least about 6.5 × 10 7 , at least about 7 × 10 7 , at least about 7.5 × 10 7 , at least about 8 × 10 7 , at least about 8.5 × 10 7 , at least about 9 × 10 7 , at least about 9.5 × 10 7 , at least about 1 x 108 , at least about 1 x 10 8 , at least about 1.5 x 10 8 , at least about 2 × 10 8 , at least about 2.5 x 10 8 , at least about 3 × 10 8 , at least about 3.5 x 10 8 , at least about 4 × 10 7 , at least about 4.5 x 10 8 , at least about 5 × 10 8 , at least about 5.5 × 10 8 , at least about 6 × 10 8 , at least about 6.5 × 10 8 , at least about 7 × 10 8 , at least about 7.5 × 10 8 , at least about 8 × 10 8 , at least about 8.5 × 10 8 , at least about 9 × 10 8 , at least about 9.5 × 10 8 , at least about 1 x 10 9 The cell may contain 1 or more cells.

[0221] The first population of CD45+ cells may be up to about 1 x 10 first population of CD45+ cells and / or HSPCs (e.g., CD34+ cells) per kg of actual or ideal body weight of the recipient subject. 4 , up to about 1×10 5 , up to about 5×10 5 , up to about 6×10 5 , up to about 7×10 5 , up to about 8×10 5 , up to about 9×10 5 , up to about 1×10 6 , maximum approximately 1.1×10 6 , maximum approximately 1.2×10 6 , maximum approximately 1.3×10 6 , maximum approximately 1.4×10 6 , maximum approximately 1.5×10 6 , maximum approximately 1.6×10 6 , maximum approximately 1.7×10 6 , maximum approximately 1.8×10 6 , maximum approximately 1.9×10 6, maximum about 2×10 6 , the maximum is about 2.1×10 6 , the maximum is about 2.2×10 6 , the maximum is about 2.3×10 6 , the maximum is about 2.4×10 6 , maximum about 2.5×10 6 , the maximum is about 2.6×10 6 , the maximum is about 2.7×10 6 , the maximum is about 2.8×10 6 , the maximum is about 2.9×10 6 , maximum about 3×10 6 , the maximum is about 3.1×10 6 , the maximum is about 3.2×10 6 , the maximum is about 3.3×10 6 , the maximum is about 3.4×10 6 , the maximum is about 3.5×10 6 , the maximum is about 3.6×10 6 , the maximum is about 3.7×10 6 , the maximum is about 3.8×10 6 , the maximum is about 3.9×10 6 , maximum about 4×10 6 , the maximum is about 4.1×10 6 , the maximum is about 4.2×10 6 , the maximum is about 4.3×10 6 , the maximum is about 4.4×10 6 , the maximum is about 4.5×10 6 , the maximum is about 4.6×10 6 , the maximum is about 4.7×10 6 , the maximum is about 4.8×10 6 , the maximum is about 4.9×10 6 , maximum about 5×10 6 , the maximum is about 5.1×10 6 , the maximum is about 5.2×10 6 , the maximum is about 5.3×10 6 , the maximum is about 5.4×10 6 , the maximum is about 5.5×10 6 , the maximum is about 5.6×10 6 , the maximum is about 5.7×10 6 , the maximum is about 5.8×10 6 , the maximum is about 5.9×10 6 , maximum about 6×10 6 , the maximum is about 6.5×10 6 , maximum about 7×10 6 , maximum about 7.5×10 6, up to about 8×10 6 , maximum approximately 8.5×10 6 , up to about 9×10 6 , maximum approximately 9.5×10 6 , up to about 1×10 7 , maximum approximately 1.5×10 7 , up to about 2×10 7 , maximum approximately 2.5×10 7 , up to about 3×10 7 , maximum approximately 3.5×10 7 , up to about 4×10 7 , maximum approximately 4.5×10 7 , up to about 5×10 7 , maximum approximately 5.5×10 7 , up to about 6×10 7 , maximum approximately 6.5×10 7 , up to about 7×10 7 , maximum approximately 7.5×10 7 , up to about 8×10 7 , maximum approximately 8.5×10 7 , up to about 9×10 7 , maximum approximately 9.5×10 7 , up to about 1×10 8 , up to about 1×10 8 , maximum approximately 1.5×10 8 , up to about 2×10 8 , maximum approximately 2.5×10 8 , up to about 3×10 8 , maximum approximately 3.5×10 8 , up to about 4×10 7 , maximum approximately 4.5×10 8 , up to about 5×10 8 , maximum approximately 5.5×10 8 , up to about 6×10 8 , maximum approximately 6.5×10 8 , up to about 7×10 8 , maximum approximately 7.5×10 8 , up to about 8×10 8 , maximum approximately 8.5×10 8 , up to about 9×10 8 , maximum approximately 9.5×10 8 , or up to about 1 × 10 9 The cell may contain cells.

[0222] For example, the first population of CD45+ cells may be 1×10 of the first population of CD45+ cells and / or HSPCs (e.g., CD34+ cells) per kg of actual or ideal body weight of the recipient subject. 4 ~1×10 9 , 1×10 5 ~1×10 8 , 1×10 5 ~2×10 7 , 5×10 5 ~2×10 7 , 5×10 5 ~1.5×10 7 , 5×10 5 ~1×10 7 , 5×10 5 ~9×10 6 , 5×10 5 ~8×10 6 , 5×10 5 ~7×10 6 , 5×10 5 ~6×10 6 , 5×10 5 ~5×10 6 , 5×10 5 ~4×10 6 , 5×10 5 ~3×10 6 , 5×10 5 ~2×10 6 , 5×10 5 ~1×10 6 , 1×10 6 ~1.5×10 7 , 1×10 6 ~1×10 7 , 1×10 6 ~9×10 6 , 1×10 6 ~8×10 6 , 1×10 6 ~7×10 6 , 1×10 6 ~6×10 6 , 1×10 6 ~5×10 6 , 1×10 6 ~4×10 6 , 1×10 6 ~3×10 6 , 1×10 6 ~2×10 6 , 1.5×106 ~1.5×10 7 、1.5×10 6 ~1×10 7 、1.5×10 6 ~9×10 6 、1.5×10 6 ~8×10 6 、1.5×10 6 ~7×10 6 、1.5×10 6 ~6×10 6 、1.5×10 6 ~5×10 6 、1.5×10 6 ~4×10 6 、1.5×10 6 ~3×10 6 、1.5×10 6 ~2×10 6 、2×10 6 ~1.5×10 7 、2×10 6 ~1×10 7 、2×10 6 ~9×10 6 、2×10 6 ~8×10 6 、2×10 6 ~7×10 6 、2×10 6 ~6×10 6 、2×10 6 ~5×10 6 、2×10 6 ~4×10 6 、2×10 6 ~3×10 6 、2.5×10 6 ~1.5×10 7 、2.5×10 6 ~1×10 7 、2.5×10 6 ~9×10 6 、2.5×10 6 ~8×10 6 、2.5×10 6 ~7×10 6 、2.5×10 6 ~6×10 6 、2.5×10 6 ~5×10 6 、2.5×10 6~ 4×106 , or 2.5 × 10 6 ~3×10 6 The cell may contain cells.

[0223] The first population of CD45+ cells can have a specified level of purity for CD34+ cells. For example, the first population of CD45+ cells can have a specified level of purity for CD34+ cells, such as at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, as a percentage of total cells, as a percentage of nucleated cells, or as a percentage of CD45+ cells. The resulting CD34+ cells may comprise at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or a higher percentage of CD34+ cells.

[0224] The first population of CD45+ cells can have a defined level of contaminating CD3+ cells. In some embodiments, the first population of CD45+ cells can have a defined level of up to about 1 x 10 per kg of body weight or ideal body weight of the recipient subject. 2 , up to about 2×10 2 , up to about 3×102 , up to about 4×10 2 , up to about 5×10 2 , up to about 6×10 2 , up to about 7×10 2 , up to about 8×10 2 , up to about 9×10 2 , up to about 1×10 3 , up to about 2×10 3 , up to about 3×10 3 , up to about 4×10 3 , up to about 5×10 3 , up to about 6×10 3 , up to about 7×10 3 , up to about 8×10 3 , up to about 9×10 3 , up to about 1×10 4 , up to about 2×10 4 , up to about 3×10 4 , up to about 4×10 4 , up to about 5×10 4 , up to about 6×10 4 , up to about 7×10 4 , up to about 8×10 4 , up to about 9×10 4 , or up to about 1 × 10 5 CD3+ cells are present in the first population of CD45+ cells.

[0225] In some embodiments, the first population of CD45+ cells is at most about 0.001%, at most about 0.002%, at most about 0.003%, at most about 0.004%, at most about 0.005%, at most about 0.006%, at most about 0.007%, at most about 0.008%, 0.009%, at most about 0.01%, at most about 0.02%, at most about 0.03%, at most about 0.04%, at most about 0.05%, at most about 0.06%, at most about 0.07%, at most about 0.08%, at most about 0.09%, at most about 0.1%, at most about 0.2%, at most about 0.3%, at most about 0.4%, at most about 0.5%, at most about 0.6%, at most about 0.7%, at most about 0.8%, at most about 0.9%, as a percentage of total cells, as a percentage of nucleated cells, or as a percentage of CD45+ cells. Approximately 0.8%, maximum approximately 0.9%, maximum approximately 1%, maximum approximately 1.1%, maximum approximately 1.2%, maximum approximately 1.3%, maximum approximately 1.4%, maximum approximately 1.5%, maximum approximately 1.6%, maximum approximately 1.7%, Maximum approximately 1.8%, Maximum approximately 1.9%, Maximum approximately 2%, Maximum approximately 2.1%, Maximum approximately 2.2%, Maximum approximately 2.3%, Maximum approximately 2.4%, Maximum approximately 2.5%, Maximum approximately 2.6%, Maximum approximately 2.7 %, up to about 2.8%, up to about 2.9%, up to about 3%, up to about 3.1%, up to about 3.2%, up to about 3.3%, up to about 3.4%, up to about 3.5%, up to about 3.6%, up to about 3.7%, up to about 3.8%, up to about 3.9%, up to about 4%, up to about 5%, up to about 6%, up to about 7%, up to about 8%, up to about 9%, or up to about 10% CD3+ cells.

[0226] In some embodiments, the first population of CD45+ cells comprises less than about 5 EU of endotoxin per ml of solution, less than about 1 EU of endotoxin per ml of solution, and / or less than about 0.5 EU of endotoxin per ml of solution.

[0227] In embodiments, at least one of the cell populations contains less than about 5 EU of endotoxin per ml of each suspension.

[0228] The first population of CD45+ cells may contain between 0.5 EU / ml and 10 EU / ml of endotoxin. The first population of CD45+ cells may contain at least 0.5 EU / ml of endotoxin. The first population of CD45+ cells may contain up to 10 EU / ml of endotoxin.The first population of CD45+ cells was incubated with 10EU / ml endotoxin to 8EU / ml endotoxin, 10EU / ml endotoxin to 6EU / ml endotoxin, 10EU / ml endotoxin to 5EU / ml endotoxin, 10EU / ml endotoxin to 4EU / ml endotoxin, 10EU / ml endotoxin to 2EU / ml endotoxin, 10EU / ml endotoxin to 1EU / ml endotoxin, and 10EU / ml endotoxin to 0.5EU / ml endotoxin. U / ml endotoxin, 8EU / ml endotoxin ~ 6EU / ml endotoxin, 8EU / ml endotoxin ~ 5EU / ml endotoxin, 8EU / ml endotoxin ~ 4EU / ml endotoxin, 8EU / ml endotoxin ~ 2EU / ml endotoxin, 8EU / ml endotoxin ~ 1EU / ml endotoxin, 8EU / ml endotoxin ~ 0.5EU / ml endotoxin, 6EU / ml endotoxin ~ 5EU / ml endotoxin Endotoxin, 6EU / ml ~ 4EU / ml endotoxin, 6EU / ml ~ 2EU / ml endotoxin, 6EU / ml ~ 1EU / ml endotoxin, 6EU / ml ~ 0.5EU / ml endotoxin, 5EU / ml ~ 4EU / ml endotoxin, 5EU / ml ~ 2EU / ml endotoxin, 5EU / ml ~ 1EU / ml endotoxin, 5EU / ml The endotoxin concentration may be between 1 EU / ml and 0.5 EU / ml of endotoxin, between 4 EU / ml and 2 EU / ml of endotoxin, between 4 EU / ml and 1 EU / ml of endotoxin, between 4 EU / ml and 0.5 EU / ml of endotoxin, between 2 EU / ml and 1 EU / ml of endotoxin, between 2 EU / ml and 0.5 EU / ml of endotoxin, or between 1 EU / ml and 0.5 EU / ml of endotoxin.The first population of CD45+ cells may contain 10EU / ml endotoxin, 8EU / ml endotoxin, 6EU / ml endotoxin, 5EU / ml endotoxin, 4EU / ml endotoxin, 2EU / ml endotoxin, 1EU / ml endotoxin, or 0.5EU / ml endotoxin. The first population of CD45+ cells may contain at least 8EU / ml endotoxin, 6EU / ml endotoxin, 5EU / ml endotoxin, 4EU / ml endotoxin, 2EU / ml endotoxin, 1EU / ml endotoxin, or 0.5EU / ml endotoxin. The first population of CD45+ cells may contain up to 10 EU / ml endotoxin, 8 EU / ml endotoxin, 6 EU / ml endotoxin, 5 EU / ml endotoxin, 4 EU / ml endotoxin, 2 EU / ml endotoxin or 1 EU / ml endotoxin.

[0229] The first population of CD45+ cells may contain 0.5% to 10% w / w of non-binding reagents. These non-binding reagents may include any affinity reagents used in HSPC sorting, such as antibodies, or purification or magnetic particles. The first population of CD45+ cells may contain at least 0.5% w / w of non-binding reagents. The first population of CD45+ cells may contain up to 10% w / w of non-binding reagents. The first population of CD45+ cells is 10%w / w~8%w / w, 10%w / w~6%w / w, 10%w / w~5%w / w, 10%w / w~4%w / w, 10%w / w~2%w / w, 10%w / w~1%w / w, 10% w / w~0.5%w / w, 8%w / w~6%w / w, 8%w / w~5%w / w, 8%w / w~4%w / w, 8%w / w~2%w / w, 8%w / w~1%w / w, 8%w / w~0.5%w / w, 6%w / w~5%w / w , 6% w / w to 4% w / w, 6% w / w to 2% w / w, 6% w / w to 1% w / w, 6% w / w to 0.5% w / w, 5% w / w to 4% w / w, 5% w / w to 2% w / w, 5% w / w to 1% w / w, 5% w / w to 0.5% w / w, 4% w / w to 2% w / w, 4% w / w to 1% w / w, 4% w / w to 0.5% w / w, 2% w / w to 1% w / w, 2% w / w to 0.5% w / w, or 1% w / w to 0.5% w / w of non-binding reagent. The first population of CD45+ cells may comprise 10% w / w, 8% w / w, 6% w / w, 5% w / w, 4% w / w, 2% w / w, 1% w / w, or 0.5% w / w of non-binding reagent. The first population of CD45+ cells may comprise at least 8% w / w, 6% w / w, 5% w / w, 4% w / w, 2% w / w, 1% w / w, or 0.5% w / w of non-binding reagent. The first population of CD45+ cells may comprise up to 10% w / w, 8% w / w, 6% w / w, 5% w / w, 4% w / w, 2% w / w, or 1% w / w of non-binding reagent.

[0230] The first population of CD45+ cells was cultured at 5 x 10 cells per 3 ~90×10 3The first population of CD45+ cells may comprise at least 5×10 microbeads per cell. These microbeads may comprise microbeads used to purify the HSPC population, e.g., anti-CD34 antibody containing microbeads used to sort the HSPC population. The first population of CD45+ cells may comprise at least 5×10 microbeads per cell. 3 The first population of CD45+ cells may contain up to 90 x 10 microbeads per cell. 3 The first population of CD45+ cells may contain 90 x 10 microbeads per cell. 3 ~70×10 3 , 90×10 3 ~50×10 3 , 90×10 3 ~40×10 3 , 90×10 3 ~30×10 3 , 90×10 3 ~20×10 3 , 90×10 3 ~10×10 3 , 90×10 3 ~5×10 3 , 70×10 3 ~50×10 3 , 70×10 3 ~40×10 3 , 70×10 3 ~30×10 3 , 70×10 3 ~20×10 3 , 70×10 3 ~10×10 3 , 70×10 3 ~5×10 3 , 50×10 3 ~40×10 3 , 50×10 3 ~30×10 3 , 50×10 3 ~20×10 3 , 50×10 3 ~10×10 3 , 50×10 3 ~5×10 3 , 40×10 3 ~30×10 3 , 40×10 3 ~20×10 3 , 40×103 ~10×10 3 , 40×10 3 ~5×10 3 , 30×10 3 ~20×10 3 , 30×10 3 ~10×10 3 , 30×10 3 ~5×10 3 , 20×10 3 ~10×10 3 , 20×10 3 ~5×10 3 , or 10×10 3 ~5×10 3 The first population of CD45+ cells may contain 90 x 10 microbeads per cell. 3 , 70×10 3 , 50×10 3 , 40×10 3 , 30×10 3 , 20×10 3 , 10×10 3 , or 5 × 10 3 The first population of CD45+ cells may comprise at least 70 x 10 microbeads per cell. 3 , 50×10 3 , 40×10 3 , 30×10 3 , 20×10 3 , 10×10 3 , or 5 × 10 3 The first population of CD45+ cells may contain up to 90 x 10 microbeads per cell. 3 , 70×10 3 , 50×10 3 , 40×10 3 , 30×10 3 , 20×10 3 , or 10×10 3 The microbeads may include: Treg

[0231] A population of cells enriched for Tregs may be a population of cells enriched for Tregs per kg of actual or ideal body weight of a recipient subject and / or for Tregs (e.g., where Tregs are CD4+CD25+CD127dim, CD3+CD4+CD25+, CD3+ CD4+ CD25+ CD127dim, CD3+ CD4+ CD25+ CD127dim FOXP3+, CD3+ FOXP3+, CD3+ CD4+ CD25+ FOXP3+, CD3+ CD25+ FOXP3+, CD3+ CD25+ CD127dim, CD4+ CD25+, CD4+ CD25+ CD127dim FOXP3+, FOXP3+, CD4+ FOXP3+, CD4+ CD25+ FOXP3+, CD25+ FOXP3+, or CD25+ CD127dim), at least approximately 1 × 10 4 , at least about 1 x 10 5 , at least about 5 × 10 5 , at least about 6 × 10 5 , at least about 7 × 10 5 , at least about 8 × 10 5 , at least about 9 × 10 5 , at least about 1 x 10 6 , at least about 1.1 × 10 6 , at least about 1.2 × 10 6 , at least about 1.3 × 10 6 , at least about 1.4 × 10 6 , at least about 1.5 x 10 6 , at least about 1.6 × 10 6 , at least about 1.7 × 10 6 , at least about 1.8 × 10 6 , at least about 1.9 × 10 6 , at least about 2 × 10 6 , at least about 2.1 x 10 6 , at least about 2.2 × 10 6 , at least about 2.3 × 10 6 , at least about 2.4 × 10 6 , at least about 2.5 x 10 6 , at least about 2.6 × 10 6 , at least about 2.7 × 10 6, at least about 2.8 × 10 6 , at least about 2.9 × 10 6 , at least about 3 × 10 6 , at least about 3.1 × 10 6 , at least about 3.2 × 10 6 , at least about 3.3 × 10 6 , at least about 3.4 × 10 6 , at least about 3.5 x 10 6 , at least about 3.6 × 10 6 , at least about 3.7 × 10 6 , at least about 3.8 × 10 6 , at least about 3.9 × 10 6 , at least about 4 × 10 6 , at least about 4.1 × 10 6 , at least about 4.2 × 10 6 , at least about 4.3 × 10 6 , at least about 4.4 × 10 6 , at least about 4.5 x 10 6 , at least about 4.6 × 10 6 , at least about 4.7 × 10 6 , at least about 4.8 × 10 6 , at least about 4.9 × 10 6 , at least about 5 × 10 6 , at least about 5.1 × 10 6 , at least about 5.2 × 10 6 , at least about 5.3 × 10 6 , at least about 5.4 × 10 6 , at least about 5.5 × 10 6 , at least about 5.6 × 10 6 , at least about 5.7 × 10 6 , at least about 5.8 × 10 6 , at least about 5.9 × 10 6 , at least about 6 × 10 6 , at least about 6.5 × 10 6 , at least about 7 × 10 6 , at least about 7.5 × 10 6 , at least about 8 × 10 6 , at least about 8.5 × 10 6 , at least about 9 × 10 6, at least about 9.5 × 10 6 , at least about 1 x 10 7 , at least about 1.5 x 10 7 , at least about 2 × 10 7 , at least about 2.5 x 10 7 , at least about 3 × 10 7 , at least about 3.5 x 10 7 , at least about 4 × 10 7 , at least about 4.5 x 10 7 , at least about 5 × 10 7 , at least about 5.5 × 10 7 , at least about 6 × 10 7 , at least about 6.5 × 10 7 , at least about 7 × 10 7 , at least about 7.5 × 10 7 , at least about 8 × 10 7 , at least about 8.5 × 10 7 , at least about 9 × 10 7 , at least about 9.5 × 10 7 , at least about 1 x 10 8 , at least about 1 x 10 8 , at least about 1.5 x 10 8 , at least about 2 × 10 8 , at least about 2.5 x 10 8 , at least about 3 × 10 8 , at least about 3.5 x 10 8 , at least about 4 × 10 7 , at least about 4.5 x 10 8 , at least about 5 × 10 8 , at least about 5.5 × 10 8 , at least about 6 × 10 8 , at least about 6.5 × 10 8 , at least about 7 × 10 8 , at least about 7.5 × 10 8 , at least about 8 × 10 8 , at least about 8.5 × 10 8 , at least about 9 × 10 8 , at least about 9.5 × 10 8 , at least about 1 x 10 9 The cell may contain 1 or more cells.

[0232] A population of cells enriched for Tregs may be a population of cells enriched for Tregs per kg of actual or ideal body weight of a recipient subject and / or for Tregs (e.g., where Tregs are CD4+CD25+CD127dim, CD3+CD4+CD25+, CD3+ CD4+ CD25+ CD127dim, CD3+ CD4+ CD25+ CD127dim FOXP3+, CD3+ FOXP3+, CD3+ CD4+ CD25+ FOXP3+, CD3+ CD25+ FOXP3+, CD3+ CD25+ CD127dim, CD4+ CD25+, CD4+ CD25+ CD127dim FOXP3+, FOXP3+, CD4+ FOXP3+, CD4+ CD25+ FOXP3+, CD25+ FOXP3+, or CD25+ CD127dim), up to approximately 1 × 10 4 , up to about 1×10 5 , up to about 5×10 5 , up to about 6×10 5 , up to about 7×10 5 , up to about 8×10 5 , up to about 9×10 5 , up to about 1×10 6 , maximum approximately 1.1×10 6 , maximum approximately 1.2×10 6 , maximum approximately 1.3×10 6 , maximum approximately 1.4×10 6 , maximum approximately 1.5×10 6 , maximum approximately 1.6×10 6 , maximum approximately 1.7×10 6 , maximum approximately 1.8×10 6 , maximum approximately 1.9×10 6 , up to about 2×10 6 , maximum approximately 2.1×10 6 , maximum approximately 2.2×10 6 , maximum approximately 2.3×10 6 , maximum approximately 2.4×10 6 , maximum approximately 2.5×10 6 , maximum approximately 2.6×10 6 , maximum approximately 2.7×10 6 , maximum approximately 2.8×10 6 , maximum approximately 2.9×106 , maximum about 3×10 6 , the maximum is about 3.1×10 6 , the maximum is about 3.2×10 6 , the maximum is about 3.3×10 6 , the maximum is about 3.4×10 6 , the maximum is about 3.5×10 6 , the maximum is about 3.6×10 6 , the maximum is about 3.7×10 6 , the maximum is about 3.8×10 6 , the maximum is about 3.9×10 6 , maximum about 4×10 6 , the maximum is about 4.1×10 6 , the maximum is about 4.2×10 6 , the maximum is about 4.3×10 6 , the maximum is about 4.4×10 6 , the maximum is about 4.5×10 6 , the maximum is about 4.6×10 6 , the maximum is about 4.7×10 6 , the maximum is about 4.8×10 6 , the maximum is about 4.9×10 6 , maximum about 5×10 6 , the maximum is about 5.1×10 6 , the maximum is about 5.2×10 6 , the maximum is about 5.3×10 6 , the maximum is about 5.4×10 6 , the maximum is about 5.5×10 6 , the maximum is about 5.6×10 6 , the maximum is about 5.7×10 6 , the maximum is about 5.8×10 6 , the maximum is about 5.9×10 6 , maximum about 6×10 6 , the maximum is about 6.5×10 6 , maximum about 7×10 6 , maximum about 7.5×10 6 , maximum about 8×10 6 , the maximum is about 8.5×10 6 , maximum about 9×10 6 , the maximum is about 9.5×10 6 , maximum about 1×10 7 , the maximum is about 1.5×10 7 , maximum about 2×10 7 , maximum about 2.5×10 7 , maximum about 3×10 7 , the maximum is about 3.5×10 7, up to about 4×10 7 , maximum approximately 4.5×10 7 , up to about 5×10 7 , maximum approximately 5.5×10 7 , up to about 6×10 7 , maximum approximately 6.5×10 7 , up to about 7×10 7 , maximum approximately 7.5×10 7 , up to about 8×10 7 , maximum approximately 8.5×10 7 , up to about 9×10 7 , maximum approximately 9.5×10 7 , up to about 1×10 8 , up to about 1×10 8 , maximum approximately 1.5×10 8 , up to about 2×10 8 , maximum approximately 2.5×10 8 , up to about 3×10 8 , maximum approximately 3.5×10 8 , up to about 4×10 7 , maximum approximately 4.5×10 8 , up to about 5×10 8 , maximum approximately 5.5×10 8 , up to about 6×10 8 , maximum approximately 6.5×10 8 , up to about 7×10 8 , maximum approximately 7.5×10 8 , up to about 8×10 8 , maximum approximately 8.5×10 8 , up to about 9×10 8 , maximum approximately 9.5×10 8 pieces, or up to approximately 1 x 10 9 The cell may contain cells.

[0233] For example, a population of cells enriched for Tregs may be a population of cells enriched for Tregs per kg of recipient subject's actual or ideal body weight and / or per kg of recipient subject's actual or ideal body weight, and / or per kg of recipient subject's actual or ideal body weight. For example, a population of cells enriched for Tregs may be a population of cells enriched for Tregs per kg of recipient subject's actual or ideal body weight and / or per kg of recipient subject's actual or ideal body weight. For example, a population of cells enriched for Tregs per kg of recipient subject's actual or ideal body weight and / or ... CD127dim), 1 × 10 4 ~1×10 9 , 1×10 5 ~1×10 8 , 1×10 5 ~2×10 7 , 5×10 5 ~2×10 7 , 5×10 5 ~1.5×10 7 , 5×10 5 ~1×10 7 , 5×10 5 ~9×10 6 , 5×10 5 ~8×10 6 , 5×10 5 ~7×10 6 , 5×10 5 ~6×10 6 , 5×10 5 ~5×10 6 , 5×10 5 ~4×10 6 , 5×10 5 ~3×10 6 , 5×10 5 ~2×10 6 , 5×10 5 ~1×10 6 , 1×10 6 ~1.5×10 7 , 1×10 6 ~1×10 7 , 1×10 6~9×10 6 、1×10 6 ~8×10 6 、1×10 6 ~7×10 6 、1×10 6 ~6×10 6 、1×10 6 ~5×10 6 、1×10 6 ~4×10 6 、1×10 6 ~3×10 6 、1×10 6 ~2×10 6 、1.5×10 6 ~1.5×10 7 、1.5×10 6 ~1×10 7 、1.5×10 6 ~9×10 6 、1.5×10 6 ~8×10 6 、1.5×10 6 ~7×10 6 、1.5×10 6 ~6×10 6 、1.5×10 6 ~5×10 6 、1.5×10 6 ~4×10 6 、1.5×10 6 ~3×10 6 、1.5×10 6 ~2×10 6 、2×10 6 ~1.5×10 7 、2×10 6 ~1×10 7 、2×10 6 ~9×10 6 、2×10 6 ~8×10 6 、2×10 6 ~7×10 6 、2×10 6 ~6×10 6 、2×10 6 ~5×10 6 、2×10 6 ~4×10 6 、2×10 6 ~3×10 6 、2.5×10 6~1.5×10 7 , 2.5×10 6 ~1×10 7 , 2.5×10 6 ~9×10 6 , 2.5×10 6 ~8×10 6 , 2.5×10 6 ~7×10 6 , 2.5×10 6 ~6×10 6 , 2.5×10 6 ~5×10 6 , 2.5×10 6 ~4×10 6 , or 2.5 × 10 6 ~3×10 6 The cell may contain cells.

[0234] A population of cells enriched for Tregs may have a defined level of purity for Treg cells.For example, populations of cells enriched for Tregs of the present disclosure may be expressed as a percentage of total cells, as a percentage of nucleated cells, or as a percentage of CD45+ cells (e.g., where Tregs are CD4+CD25+CD127dim, CD3+CD4+CD25+, CD3+CD4+CD25+CD127dim, CD3+CD4+CD25+CD127dim FOXP3+, CD3+FOXP3+, CD3+CD4+FOXP3+, CD3+ CD4+CD25+FOXP3+, CD3+CD25+FOXP3+, CD3+CD25+CD127dim, CD4+CD25+, CD4+CD25+CD127dimFOXP3+, FOXP3+, CD4+FOXP3+, CD4+CD25+FOXP3+, CD25+FOXP3+, or CD25+ CD127dim), at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71 , at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or more percentage of Treg cells.

[0235] Populations of cells enriched for Tregs of the present disclosure can be expressed as a percentage of total cells, nucleated cells, or CD45+ cells (e.g., where Tregs are CD4+CD25+CD127dim, CD3+CD4+CD25+, CD3+CD4+CD25+CD127dim, CD3+CD4+CD25+CD127dim FOXP3+, CD3+FOXP3+, CD3+CD4+FOXP3+, CD3+CD4+CD25+FOXP3+, CD3+CD25+FOXP3+, CD3+CD25+CD127dim, CD4+CD25+, CD4+CD25+CD127dimFOXP3+, FOXP3+, CD4+FOXP3+, CD4+CD25+FOXP3+, CD25+FOXP3+, or CD25+ CD127dim), 50%~100%, 60%~100%, 70%~100%, 75%~100%, 80%~100%, 81%~100%, 82%~100%, 83%~100%, 84%~100%, 84%~100%, 86%~100%, 87%~100%, 88%~100%, 89%~100%, 90%~91%, 92%~100%, 93%~100%, 94%~100%, 95%~100%, 96%~100%, 97%~100%, 98%~100%, 99%~100%, 99.5%~100%, 50%~99%, 60%~99%, 70%~99%, 80%~99%, 81%~99%, 82%~99%, 83%~99%, 84%~99%, 85%~99%, 86%~99%, 87%~99%, 88%~99%, 89%~99%, 90%~99%, 91%~99%, 92%~99%, 94%~99%, 95%~99%, 96%~97%, 98%~99%, 50%~98%, 60%~98%, 70%~98%, 8 0%~98%, 81%~98%, 82%~98%, 83%~98%, 84%~98%, 85%~98%, 86%~98%, 87%~98%, 88%~98%, 89%~98%, 90%~98%, 91%~98%, 92%~98%, 94%~98%, 95%~98%, 96%~97%, 98%~98%, 50%~97%, 60%~97%, 70%~97%, 80%~97%, 81%~97%, 82%~97%, 83%~97%, 84% ~97%, 85%~97%, 86%~97%, 87%~97%, 88%~97%, 89%~97%, 90%~97%, 91%~97%, 92%~97%, 94%~97%, 95%~97%, 96%~97%, 50%~96%, 60%~96%, 70%~96%, 80%~96%, 81%~96%, 82%~96%, 83%~96%, 84%~96%, 85%~96%, 86%~96%, 87%~96%, 88%~96%, 89%~ The Tregs may comprise 96%, 90% to 96%, 91% to 96%, 92% to 96%, 94% to 96%, 95% to 96%, 50% to 95%, 60% to 95%, 70% to 95%, 80% to 95%, 81% to 95%, 82% to 95%, 83% to 95%, 84% to 95%, 85% to 95%, 86% to 95%, 87% to 95%, 88% to 95%, 89% to 95%, 90% to 95%, 91% to 95%, 92% to 95%, or 94% to 95%.

[0236] The populations of cells enriched for Tregs of the present disclosure can have a defined level of contaminating non-Treg cells. In some embodiments, up to about 1 x 10 per kg of body weight or ideal body weight. 2 , up to about 2×10 2 , up to about 3×10 2 , up to about 4×10 2 , up to about 5×10 2 , up to about 6×102 , up to about 7×10 2 , up to about 8×10 2 , up to about 9×10 2 , up to about 1×10 3 , up to about 2×10 3 , up to about 3×10 3 , up to about 4×10 3 , up to about 5×10 3 , up to about 6×10 3 , up to about 7×10 3 , up to about 8×10 3 , up to about 9×10 3 , up to about 1×10 4 , up to about 2×10 4 , up to about 3×10 4 , up to about 4×10 4 , up to about 5×10 4 , up to about 6×10 4 , up to about 7×10 4 , up to about 8×10 4 , up to about 9×10 4 , or up to about 1 × 10 5 Non-Treg cells are present in a population of cells enriched for Tregs of the present disclosure, where the non-Treg cells are FOXP3- or CD127+ for brightness.

[0237] In some embodiments, the population of cells enriched for Tregs of the present disclosure comprises up to about 0.001%, up to about 0.002%, up to about 0.003%, up to about 0.004%, up to about 0.005%, up to about 0.006%, up to about 0.007%, up to about 0.008%, 0.009%, up to about 0.01%, up to about 0.02%, up to about 0.03%, up to about 0.04%, up to about 0.05%, up to about 0.06%, up to about 0.07%, up to about 0.08%, 0.009%, up to about 0.01%, up to about 0.02%, up to about 0.03%, up to about 0.04%, up to about 0.05%, up to about 0.06%, up to about 0.07%, up to about 0.08%, 0.009%, up to about 0.01%, up to about 0.02%, up to about 0.03%, up to about 0.04%, up to about 0.05%, up to about 0.06%, up to about 0.07%, up to about 0.08%, up to about 0. ...6%, up to about 0.07%, up to about 0.08%, up to about 0.09%, up to about 0.01%, up to about 0.02%, up to about Approximately 0.04%, maximum approximately 0.05%, maximum approximately 0.06%, maximum approximately 0.07%, maximum approximately 0.08%, maximum approximately 0.09%, maximum approximately 0.1%, maximum approximately 0.2%, maximum approximately 0.3% , maximum approximately 0.4%, maximum approximately 0.5%, maximum approximately 0.6%, maximum approximately 0.7%, maximum approximately 0.8%, maximum approximately 0.9%, maximum approximately 1%, maximum approximately 1.1%, maximum approximately 1.2%, maximum approximately 1 .3%, maximum approximately 1.4%, maximum approximately 1.5%, maximum approximately 1.6%, maximum approximately 1.7%, maximum approximately 1.8%, maximum approximately 1.9%, maximum approximately 2%, maximum approximately 2.1%, maximum approximately 2.2%, maximum 2.3% maximum, 2.4% maximum, 2.5% maximum, 2.6% maximum, 2.7% maximum, 2.8% maximum, 2.9% maximum, 3% maximum, 3.1% maximum, 3.2 maximum %, up to about 3.3%, up to about 3.4%, up to about 3.5%, up to about 3.6%, up to about 3.7%, up to about 3.8%, up to about 3.9%, up to about 4%, up to about 5%, up to about 6%, up to about 7%, up to about 8%, up to about 9%, or up to about 10% non-Treg cells, wherein the non-Treg cells are FOXP3- or CD127+ for brightness.

[0238] In various embodiments, the population of cells enriched for Tregs contains less than about 5 EU of endotoxin per ml of solution, less than about 1 EU of endotoxin per ml of solution, and / or less than about 0.5 EU of endotoxin per ml of solution.

[0239] In some embodiments, at least one of the cell populations contains less than about 5 EU of endotoxin per ml of each suspension.

[0240] The population of cells enriched for Tregs may contain between 0.5EU / ml and 10EU / ml endotoxin. The population of cells enriched for Tregs may contain at least 0.5EU / ml endotoxin. The population of cells enriched for Tregs may contain up to 10EU / ml endotoxin.Populations of cells enriched for Tregs were incubated at 10EU / ml endotoxin to 8EU / ml endotoxin, 10EU / ml endotoxin to 6EU / ml endotoxin, 10EU / ml endotoxin to 5EU / ml endotoxin, 10EU / ml endotoxin to 4EU / ml endotoxin, 10EU / ml endotoxin to 2EU / ml endotoxin, 10EU / ml endotoxin to 1EU / ml endotoxin, 10EU / ml endotoxin to 0.5EU / ml endotoxin, 8EU / ml endotoxin to 6EU / ml endotoxin, 8EU / ml endotoxin to 5EU / ml endotoxin, 8EU / ml endotoxin to 4EU / ml endotoxin, 8EU / ml endotoxin to 2EU / ml endotoxin, 8EU / ml endotoxin to 1EU / ml endotoxin, 8EU / ml endotoxin to 0.5EU / ml endotoxin, 6EU / ml endotoxin to 5EU / ml endotoxin Endotoxin, 6EU / ml endotoxin ~ 4EU / ml endotoxin, 6EU / ml endotoxin ~ 2EU / ml endotoxin, 6EU / ml endotoxin ~ 1EU / ml endotoxin, 6EU / ml endotoxin ~ 0.5EU / ml endotoxin, 5EU / ml endotoxin ~ 4EU / ml endotoxin, 5EU / ml endotoxin ~ 2EU / ml endotoxin, 5EU / ml endotoxin ~ 1EU / ml endotoxin, 5EU The endotoxin concentration may be between 4 EU / ml and 0.5 EU / ml of endotoxin, between 4 EU / ml and 2 EU / ml of endotoxin, between 4 EU / ml and 1 EU / ml of endotoxin, between 4 EU / ml and 0.5 EU / ml of endotoxin, between 2 EU / ml and 1 EU / ml of endotoxin, between 2 EU / ml and 0.5 EU / ml of endotoxin, or between 1 EU / ml and 0.5 EU / ml of endotoxin.A population of cells enriched for Tregs may contain 10EU / ml endotoxin, 8EU / ml endotoxin, 6EU / ml endotoxin, 5EU / ml endotoxin, 4EU / ml endotoxin, 2EU / ml endotoxin, 1EU / ml endotoxin, or 0.5EU / ml endotoxin. A population of cells enriched for Tregs may contain at least 8EU / ml endotoxin, 6EU / ml endotoxin, 5EU / ml endotoxin, 4EU / ml endotoxin, 2EU / ml endotoxin, 1EU / ml endotoxin, or 0.5EU / ml endotoxin. A population of cells enriched for Tregs may contain up to 10EU / ml endotoxin, 8EU / ml endotoxin, 6EU / ml endotoxin, 5EU / ml endotoxin, 4EU / ml endotoxin, 2EU / ml endotoxin, or 1EU / ml endotoxin.

[0241] The population of cells enriched for Tregs may contain 0.5% w / w to 10% w / w of non-binding reagents. These non-binding reagents may include any affinity reagent used in Treg selection, such as antibodies, or purification or magnetic particles. The population of cells enriched for Tregs may contain at least 0.5% w / w of non-binding reagents. The population of cells enriched for Tregs may contain up to 10% w / w of non-binding reagents. The cell populations enriched for Tregs were 10% w / w to 8% w / w, 10% w / w to 6% w / w, 10% w / w to 5% w / w, 10% w / w to 4% w / w, 10% w / w to 2% w / w, 10% w / w to 1% w / w, 10% w / w to 0.5% w / w, 8% w / w to 6% w / w, 8% w / w to 5% w / w, 8% w / w to 4% w / w, 8% w / w to 2% w / w, 8% w / w to 1% w / w, 8% w / w to 0.5% w / w, 6% w / w to 5% The non-binding reagent may be present in an amount of 6% to 4% w / w, 6% to 2% w / w, 6% to 1% w / w, 6% to 0.5% w / w, 5% to 4% w / w, 5% to 2% w / w, 5% to 1% w / w, 5% to 0.5% w / w, 4% to 2% w / w, 4% to 1% w / w, 4% to 0.5% w / w, 2% to 1% w / w, 2% to 0.5% w / w, or 1% to 0.5% w / w. A population of cells enriched for Tregs may contain 10%, 8%, 6%, 5%, 4%, 2%, 1%, or 0.5% of the non-binding reagent. A population of cells enriched for Tregs may contain at least 8%, 6%, 5%, 4%, 2%, 1%, or 0.5% of the non-binding reagent. A population of cells enriched for Tregs may contain up to 10%, 8%, 6%, 5%, 4%, 2%, or 1% of the non-binding reagent.

[0242] The population of cells enriched for Tregs was 1 × 10 per cell. 3 ~50×10 3The microbeads may comprise microbeads used to purify the Treg population, such as anti-CD25 antibody containing microbeads used to select the Treg population, or anti-CD4 antibody containing microbeads used to select the Treg population, and / or anti-CD127 antibody containing microbeads used to select the Treg population. The population of cells enriched for Tregs may comprise at least 1 x 10 cells. 3 The population of cells enriched for Tregs may contain up to 50 x 10 microbeads per cell. 3 The population of cells enriched for Tregs may contain 50 x 10 microbeads per cell. 3 ~40×10 3 , 50×10 3 ~30×10 3 , 50×10 3 ~20×10 3 , 50×10 3 ~10×10 3 , 50×10 3 ~5×10 3 , 50×10 3 ~4×10 3 , 50×10 3 ~2×10 3 , 50×10 3 ~1×10 3 , 40×10 3 ~30×10 3 , 40×10 3 ~20×10 3 , 40×10 3 ~10×10 3 , 40×10 3 ~5×10 3 , 40×10 3 ~4×10 3 , 40×10 3 ~2×10 3 , 40×10 3 ~1×10 3 , 30×10 3 ~20×10 3 , 30×10 3 ~10×10 3 , 30×10 3 ~5×103 , 30×10 3 ~4×10 3 , 30×10 3 ~2×10 3 , 30×10 3 ~1×10 3 , 20×10 3 ~10×10 3 , 20×10 3 ~5×10 3 , 20×10 3 ~4×10 3 , 20×10 3 ~2×10 3 , 20×10 3 ~1×10 3 , 10×10 3 ~5×10 3 , 10×10 3 ~4×10 3 , 10×10 3 ~2×10 3 , 10×10 3 ~1×10 3 , 5×10 3 ~4×10 3 , 5×10 3 ~2×10 3 , 5×10 3 ~1×10 3 , 4×10 3 ~2×10 3 , 4×10 3 ~1×10 3 , or 2 × 10 3 ~1×10 3 The population of cells enriched for Tregs may contain 50 x 10 microbeads per cell. 3 , 40×10 3 , 30×10 3 , 20×10 3 , 10×10 3 , 5×10 3 , 4×10 3 , 2 × 10 3 , or 1 × 10 3 The microbeads may include: Tcon

[0243] The second population of CD45+ cells comprising at least Tcon is at least about 1 x 10 of the second population of CD45+ cells and / or Tcon (e.g., where Tcon is CD3+ or CD3+ CD127+ for brightness) per kg of actual or ideal body weight of the recipient subject. 4 , at least about 1 x 10 5 , at least about 5 × 10 5 , at least about 6 × 10 5 , at least about 7 × 10 5 , at least about 8 × 10 5 , at least about 9 × 10 5 , at least about 1 x 10 6 , at least about 1.1 × 10 6 , at least about 1.2 × 10 6 , at least about 1.3 × 10 6 , at least about 1.4 × 10 6 , at least about 1.5 x 10 6 , at least about 1.6 × 10 6 , at least about 1.7 × 10 6 , at least about 1.8 × 10 6 , at least about 1.9 × 10 6 , at least about 2 × 10 6 , at least about 2.1 x 10 6 , at least about 2.2 × 10 6 , at least about 2.3 × 10 6 , at least about 2.4 × 10 6 , at least about 2.5 x 10 6 , at least about 2.6 × 10 6 , at least about 2.7 × 10 6 , at least about 2.8 × 10 6 , at least about 2.9 × 10 6 , at least about 3 × 10 6 , at least about 3.1 × 10 6 , at least about 3.2 × 10 6 , at least about 3.3 × 10 6 , at least about 3.4 × 10 6 , at least about 3.5 x 10 6 , at least about 3.6 × 10 6, at least about 3.7 × 10 6 , at least about 3.8 × 10 6 , at least about 3.9 × 10 6 , at least about 4 × 10 6 , at least about 4.1 × 10 6 , at least about 4.2 × 10 6 , at least about 4.3 × 10 6 , at least about 4.4 × 10 6 , at least about 4.5 x 10 6 , at least about 4.6 × 10 6 , at least about 4.7 × 10 6 , at least about 4.8 × 10 6 , at least about 4.9 × 10 6 , at least about 5 × 10 6 , at least about 5.1 × 10 6 , at least about 5.2 × 10 6 , at least about 5.3 × 10 6 , at least about 5.4 × 10 6 , at least about 5.5 × 10 6 , at least about 5.6 × 10 6 , at least about 5.7 × 10 6 , at least about 5.8 × 10 6 , at least about 5.9 × 10 6 , at least about 6 × 10 6 , at least about 6.5 × 10 6 , at least about 7 × 10 6 , at least about 7.5 × 10 6 , at least about 8 × 10 6 , at least about 8.5 × 10 6 , at least about 9 × 10 6 , at least about 9.5 × 10 6 , at least about 1 x 10 7 , at least about 1.5 x 10 7 , at least about 2 × 10 7 , at least about 2.5 x 10 7 , at least about 3 × 10 7 , at least about 3.5 x 10 7 , at least about 4 × 10 7 , at least about 4.5 x 10 7, at least about 5 × 10 7 , at least about 5.5 × 10 7 , at least about 6 × 10 7 , at least about 6.5 × 10 7 , at least about 7 × 10 7 , at least about 7.5 × 10 7 , at least about 8 × 10 7 , at least about 8.5 × 10 7 , at least about 9 × 10 7 , at least about 9.5 × 10 7 , at least about 1 x 10 8 , at least about 1 x 10 8 , at least about 1.5 x 10 8 , at least about 2 × 10 8 , at least about 2.5 x 10 8 , at least about 3 × 10 8 , at least about 3.5 x 10 8 , at least about 4 × 10 7 , at least about 4.5 x 10 8 , at least about 5 × 10 8 , at least about 5.5 × 10 8 , at least about 6 × 10 8 , at least about 6.5 × 10 8 , at least about 7 × 10 8 , at least about 7.5 × 10 8 , at least about 8 × 10 8 , at least about 8.5 × 10 8 , at least about 9 × 10 8 , at least about 9.5 × 10 8 , at least about 1 x 10 9 The cell may contain 1 or more cells.

[0244] The second population of CD45+ cells comprising at least Tcon may be up to about 1 x 10 of the second population of CD45+ cells and / or Tcon (e.g., where Tcon is CD3+ or CD3+ CD127+ for brightness) per kg of actual or ideal body weight of the recipient subject. 4 , up to about 1×10 5 , up to about 5×10 5, maximum about 6×10 5 , maximum about 7×10 5 , maximum about 8×10 5 , maximum about 9×10 5 , maximum about 1×10 6 , the maximum is about 1.1×10 6 , the maximum is about 1.2×10 6 , the maximum is about 1.3×10 6 , the maximum is about 1.4×10 6 , the maximum is about 1.5×10 6 , the maximum is about 1.6×10 6 , the maximum is about 1.7×10 6 , the maximum is about 1.8×10 6 , the maximum is about 1.9×10 6 , maximum about 2×10 6 , the maximum is about 2.1×10 6 , the maximum is about 2.2×10 6 , the maximum is about 2.3×10 6 , the maximum is about 2.4×10 6 , maximum about 2.5×10 6 , the maximum is about 2.6×10 6 , the maximum is about 2.7×10 6 , the maximum is about 2.8×10 6 , the maximum is about 2.9×10 6 , maximum about 3×10 6 , the maximum is about 3.1×10 6 , the maximum is about 3.2×10 6 , the maximum is about 3.3×10 6 , the maximum is about 3.4×10 6 , the maximum is about 3.5×10 6 , the maximum is about 3.6×10 6 , the maximum is about 3.7×10 6 , the maximum is about 3.8×10 6 , the maximum is about 3.9×10 6 , maximum about 4×10 6 , the maximum is about 4.1×10 6 , the maximum is about 4.2×10 6 , the maximum is about 4.3×10 6 , the maximum is about 4.4×10 6 , the maximum is about 4.5×10 6 , the maximum is about 4.6×10 6 , the maximum is about 4.7×10 6 , the maximum is about 4.8×10 6 , the maximum is about 4.9×10 6, maximum about 5×10 6 , the maximum is about 5.1×10 6 , the maximum is about 5.2×10 6 , the maximum is about 5.3×10 6 , the maximum is about 5.4×10 6 , the maximum is about 5.5×10 6 , the maximum is about 5.6×10 6 , the maximum is about 5.7×10 6 , the maximum is about 5.8×10 6 , the maximum is about 5.9×10 6 , maximum about 6×10 6 , the maximum is about 6.5×10 6 , maximum about 7×10 6 , maximum about 7.5×10 6 , maximum about 8×10 6 , the maximum is about 8.5×10 6 , maximum about 9×10 6 , the maximum is about 9.5×10 6 , maximum about 1×10 7 , the maximum is about 1.5×10 7 , maximum about 2×10 7 , maximum about 2.5×10 7 , maximum about 3×10 7 , the maximum is about 3.5×10 7 , maximum about 4×10 7 , the maximum is about 4.5×10 7 , maximum about 5×10 7 , the maximum is about 5.5×10 7 , maximum about 6×10 7 , the maximum is about 6.5×10 7 , maximum about 7×10 7 , maximum about 7.5×10 7 , maximum about 8×10 7 , the maximum is about 8.5×10 7 , maximum about 9×10 7 , the maximum is about 9.5×10 7 , maximum about 1×10 8 , maximum about 1×10 8 , the maximum is about 1.5×10 8 , maximum about 2×10 8 , maximum about 2.5×10 8 , maximum about 3×10 8 , the maximum is about 3.5×10 8 , maximum about 4×10 7 , the maximum is about 4.5×10 8, up to about 5×10 8 , maximum approximately 5.5×10 8 , up to about 6×10 8 , maximum approximately 6.5×10 8 , up to about 7×10 8 , maximum approximately 7.5×10 8 , up to about 8×10 8 , maximum approximately 8.5×10 8 , up to about 9×10 8 , maximum approximately 9.5×10 8 pieces, or up to approximately 1 x 10 9 The cell may contain cells.

[0245] For example, the second population of CD45+ cells comprising at least Tcon may be 1×10 for the second population of CD45+ cells and / or Tcon (e.g., where Tcon is CD3+ or CD3+CD127+ for brightness) per kg of actual or ideal body weight of the recipient subject. 4 ~1×10 9 , 1×10 5 ~1×10 8 , 1×10 5 ~2×10 7 , 5×10 5 ~2×10 7 , 5×10 5 ~1.5×10 7 , 5×10 5 ~1×10 7 , 5×10 5 ~9×10 6 , 5×10 5 ~8×10 6 , 5×10 5 ~7×10 6 , 5×10 5 ~6×10 6 , 5×10 5 ~5×10 6 , 5×10 5 ~4×10 6 , 5×10 5 ~3×10 6 , 5×10 5 ~2×10 6 , 5×10 5 ~1×10 6 , 1×10 6 ~1.5×107 、1×10 6 ~1×10 7 、1×10 6 ~9×10 6 、1×10 6 ~8×10 6 、1×10 6 ~7×10 6 、1×10 6 ~6×10 6 、1×10 6 ~5×10 6 、1×10 6 ~4×10 6 、1×10 6 ~3×10 6 、1×10 6 ~2×10 6 、1.5×10 6 ~1.5×10 7 、1.5×10 6 ~1×10 7 、1.5×10 6 ~9×10 6 、1.5×10 6 ~8×10 6 、1.5×10 6 ~7×10 6 、1.5×10 6 ~6×10 6 、1.5×10 6 ~5×10 6 、1.5×10 6 ~4×10 6 、1.5×10 6 ~3×10 6 、1.5×10 6 ~2×10 6 、2×10 6 ~1.5×10 7 、2×10 6 ~1×10 7 、2×10 6 ~9×10 6 、2×10 6 ~8×10 6 、2×10 6 ~7×10 6 、2×10 6 ~6×10 6 、2×10 6 ~5×10 6 、2×10 6 ~4×106 , 2 × 10 6 ~3×10 6 , 2.5×10 6 ~1.5×10 7 , 2.5×10 6 ~1×10 7 , 2.5×10 6 ~9×10 6 , 2.5×10 6 ~8×10 6 , 2.5×10 6 ~7×10 6 , 2.5×10 6 ~6×10 6 , 2.5×10 6 ~5×10 6 , 2.5×10 6 ~4×10 6 , or 2.5 × 10 6 ~3×10 6 The cell may contain cells.

[0246] The second population of CD45+ cells of the present disclosure can have a specified level of purity for Tcon cells. For example, the second population of CD45+ cells of the present disclosure can have a specified level of purity for Tcon cells, as a percentage of total cells, as a percentage of nucleated cells, or as a percentage of CD45+ cells (e.g., where Tcon is CD3+ or CD3+CD127+ for brightness), of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about The Tcon cells may comprise 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or a higher percentage of Tcon cells.

[0247] The second population of CD45+ cells of the present disclosure may be 50% to 100%, 60% to 100%, 70% to 100%, 75% to 100%, 80% to 100%, 81% to 100%, 82% to 83%, 84% to 85%, 86% to 87%, 88% to 89%, 90% to 91%, 91% to 92%, 92% to 93%, 93% to 94%, 94% to 95%, 95% to 96%, 96% to 97%, 97% to 98%, 98% to 99%, 99% to 100%, 100% to 101%, 101% to 102%, 102% to 103%, 103% to 104%, 104% to 10 100%, 83%~100%, 84%~100%, 84%~100%, 86%~100%, 87%~100%, 88%~100%, 89%~100%, 90%~91%, 92%~100%, 93%~100%, 94%~100%, 95%~100%, 96%~100%, 97%~100%, 98%~100%, 99%~100%, 99.5%~100%, 50%~99%, 60%~99%, 70%~99%, 80%~99%, 81%~99%, 82%~99%, 83%~99%, 84%~99%, 85%~99%, 86%~99%, 87%~99%, 88%~99%, 89%~99%, 90%~99%, 91%~99%, 92%~99%, 94%~99%, 95%~99%, 96%~97%, 98%~99%, 50%~98%, 60%~98%, 70%~98%, 8 0%~98%, 81%~98%, 82%~98%, 83%~98%, 84%~98%, 85%~98%, 86%~98%, 87%~98%, 88%~98%, 89%~98%, 90%~98%, 91%~98%, 92%~98%, 94%~98%, 95%~98%, 96%~97%, 98%~98%, 50%~97%, 60%~97%, 70%~97%, 80%~97%, 81%~97%, 82%~97%, 83%~97%, 84% ~97%, 85%~97%, 86%~97%, 87%~97%, 88%~97%, 89%~97%, 90%~97%, 91%~97%, 92%~97%, 94%~97%, 95%~97%, 96%~97%, 50%~96%, 60%~96%, 70%~96%, 80%~96%, 81%~96%, 82%~96%, 83%~96%, 84%~96%, 85%~96%, 86%~96%, 87%~96%, 88%~96%, 89%~ It may include a Tcon of 96%, 90%-96%, 91%-96%, 92%-96%, 94%-96%, 95%-96%, 50%-95%, 60%-95%, 70%-95%, 80%-95%, 81%-95%, 82%-95%, 83%-95%, 84%-95%, 85%-95%, 86%-95%, 87%-95%, 88%-95%, 89%-95%, 90%-95%, 91%-95%, 92%-95%, or 94%-95%.

[0248] The second population of CD45+ cells of the present disclosure can have a defined level of contaminating non-Tcon cells, in some embodiments, up to about 1 x 10 per kg of actual or ideal body weight of the recipient subject. 2 , up to about 2×10 2 , up to about 3×10 2 , up to about 4×10 2 , up to about 5×10 2, up to about 6×10 2 , up to about 7×10 2 , up to about 8×10 2 , up to about 9×10 2 , up to about 1×10 3 , up to about 2×10 3 , up to about 3×10 3 , up to about 4×10 3 , up to about 5×10 3 , up to about 6×10 3 , up to about 7×10 3 , up to about 8×10 3 , up to about 9×10 3 , up to about 1×10 4 , up to about 2×10 4 , up to about 3×10 4 , up to about 4×10 4 , up to about 5×10 4 , up to about 6×10 4 , up to about 7×10 4 , up to about 8×10 4 , up to about 9×10 4 , or up to about 1 × 10 5 The non-Tcon cells are present in a second population of CD45+ cells of the present disclosure (eg, where the non-Tcon cells are CD3- or CD3+CD127dim).

[0249] In some embodiments, the second population of CD45+ cells of the present disclosure is at most about 0.001%, at most about 0.002%, at most about 0.003%, at most about 0.004%, at most about 0.005%, at most about 0.006%, at most about 0.007%, at most about 0.008%, 0.009%, at most about 0.01%, at most about 0.02%, at most about 0.03%, at most about 0.04%. %, maximum approximately 0.05%, maximum approximately 0.06%, maximum approximately 0.07%, maximum approximately 0.08%, maximum approximately 0.09%, maximum approximately 0.1%, maximum approximately 0.2%, maximum approximately 0.3%, maximum approximately 0 .4%, maximum approximately 0.5%, maximum approximately 0.6%, maximum approximately 0.7%, maximum approximately 0.8%, maximum approximately 0.9%, maximum approximately 1%, maximum approximately 1.1%, maximum approximately 1.2%, maximum approximately 1.3%, maximum 1.4% maximum, 1.5% maximum, 1.6% maximum, 1.7% maximum, 1.8% maximum, 1.9% maximum, 2% maximum, 2.1% maximum, 2.2% maximum, 2.3% maximum %, maximum approximately 2.4%, maximum approximately 2.5%, maximum approximately 2.6%, maximum approximately 2.7%, maximum approximately 2.8%, maximum approximately 2.9%, maximum approximately 3%, maximum approximately 3.1%, maximum approximately 3.2%, maximum approximately 3.3%, up to about 3.4%, up to about 3.5%, up to about 3.6%, up to about 3.7%, up to about 3.8%, up to about 3.9%, up to about 4%, up to about 5%, up to about 6%, up to about 7%, up to about 8%, up to about 9%, or up to about 10% non-Tcon cells (e.g., where the non-Tcon cells are CD3- or CD3+CD127dim).

[0250] In some cases, the population of cells enriched for Tregs contains less than about 5 EU of endotoxin per ml of solution, less than about 1 EU of endotoxin per ml of solution, and / or less than about 0.5 EU of endotoxin per ml of solution.

[0251] In embodiments, at least one of the cell populations contains less than about 5 EU of endotoxin per ml of each suspension.

[0252] The second population of CD45+ cells comprising at least Tcon may contain between 0.5 EU / ml and 10 EU / ml of endotoxin. The second population of CD45+ cells may contain at least 0.5 EU / ml of endotoxin. The second population of CD45+ cells may contain up to 10 EU / ml of endotoxin.The second population of CD45+ cells was incubated with 10EU / ml endotoxin to 8EU / ml endotoxin, 10EU / ml endotoxin to 6EU / ml endotoxin, 10EU / ml endotoxin to 5EU / ml endotoxin, 10EU / ml endotoxin to 4EU / ml endotoxin, 10EU / ml endotoxin to 2EU / ml endotoxin, 10EU / ml endotoxin to 1EU / ml endotoxin, and 10EU / ml endotoxin to 0.5EU / ml endotoxin. U / ml endotoxin, 8EU / ml endotoxin ~ 6EU / ml endotoxin, 8EU / ml endotoxin ~ 5EU / ml endotoxin, 8EU / ml endotoxin ~ 4EU / ml endotoxin, 8EU / ml endotoxin ~ 2EU / ml endotoxin, 8EU / ml endotoxin ~ 1EU / ml endotoxin, 8EU / ml endotoxin ~ 0.5EU / ml endotoxin, 6EU / ml endotoxin ~ 5EU / ml endotoxin Endotoxin, 6EU / ml ~ 4EU / ml endotoxin, 6EU / ml ~ 2EU / ml endotoxin, 6EU / ml ~ 1EU / ml endotoxin, 6EU / ml ~ 0.5EU / ml endotoxin, 5EU / ml ~ 4EU / ml endotoxin, 5EU / ml ~ 2EU / ml endotoxin, 5EU / ml ~ 1EU / ml endotoxin, 5EU / ml The endotoxin concentration may be between 1 EU / ml and 0.5 EU / ml of endotoxin, between 4 EU / ml and 2 EU / ml of endotoxin, between 4 EU / ml and 1 EU / ml of endotoxin, between 4 EU / ml and 0.5 EU / ml of endotoxin, between 2 EU / ml and 1 EU / ml of endotoxin, between 2 EU / ml and 0.5 EU / ml of endotoxin, or between 1 EU / ml and 0.5 EU / ml of endotoxin.The second population of CD45+ cells may contain about 10EU / ml endotoxin, 8EU / ml endotoxin, 6EU / ml endotoxin, 5EU / ml endotoxin, 4EU / ml endotoxin, 2EU / ml endotoxin, 1EU / ml endotoxin, or 0.5EU / ml endotoxin. The second population of CD45+ cells may contain at least 8EU / ml endotoxin, 6EU / ml endotoxin, 5EU / ml endotoxin, 4EU / ml endotoxin, 2EU / ml endotoxin, 1EU / ml endotoxin, or 0.5EU / ml endotoxin. The second population of CD45+ cells may contain up to 10 EU / ml endotoxin, 8 EU / ml endotoxin, 6 EU / ml endotoxin, 5 EU / ml endotoxin, 4 EU / ml endotoxin, 2 EU / ml endotoxin or 1 EU / ml endotoxin.

[0253] The second population of CD45+ cells may contain less than 0.1% w / w to 3% w / w of non-binding reagents. These non-binding reagents may include any affinity reagents, such as antibodies, or purification or magnetic particles, used to select Tcon or other cell populations. The second population of CD45+ cells may contain less than about 0.1% w / w of non-binding reagents. The second population of CD45+ cells may contain less than 3% w / w to 2% w / w, 3% w / w to 1% w / w, 3% w / w to 0.5% w / w, 3% w / w to 0.25% w / w, 3% w / w to 0.1% w / w, 2% w / w to 1% w / w, 2% w / w to 0.5% w / w, 2% w / w to 0.25% w / w, 2% w / w to 0.1% w / w, 1% w / w to 0.5% w / w, 1% w / w to 0.25% w / w, 1% w / w to 0.1% w / w, 0.5% w / w to 0.25% w / w, 0.5% w / w to 0.1% w / w, or 0.25% w / w to 0.1% w / w of unbound reagent. The second population of CD45+ cells may contain less than about 3% w / w, 2% w / w, 1% w / w, 0.5% w / w, 0.25% w / w, or 0.1% w / w of unbound reagent.

[0254] The second population of CD45+ cells may contain fewer than 50 to 2,000 microbeads per cell. These microbeads may include microbeads used to purify Tcon or other cell populations, such as CD25, CD4, CD127, or CD34 microbeads used to sort cell populations. The second population of CD45+ cells may contain fewer than 2,000 microbeads per cell. The second population of CD45+ cells may contain less than 2,000 to 1,000, 2,000 to 700, 2,000 to 500, 2,000 to 300, 2,000 to 100, 2,000 to 50, 1,000 to 700, 1,000 to 500, 1,000 to 300, 1,000 to 100, 1,000 to 50, 700 to 500, 700 to 300, 700 to 100, 700 to 50, 500 to 300, 500 to 100, 500 to 50, 300 to 100, 300 to 50, or 100 to 50 microbeads per cell. The second population of CD45+ cells may contain about 2,000, 1,000, 700, 500, 300, 100, or 50 microbeads per cell. The second population of CD45+ cells may contain 0 microbeads per cell.

[0255] In the second population of CD45+ cells, the ratio of Tcon:Treg administered to the subject can be, for example, about 1:100, 1:50, 1:25, 1:20, 1:15, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2.5, 1:2, 1.5:2, 1:1.5, 1:1, 1.5:1, 2:1, 2:1.5, 2.5:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 50:1, or 100:1.

[0256] The cells of the second population of CD45+ cells containing at least Tcon can be cryopreserved for any length of time. The cells of the second population of CD45+ cells may be cryopreserved for at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 7 hours, at least about 8 hours, at least about 9 hours, at least about 10 hours, at least about 11 hours, at least about 12 hours, at least about 14 hours, at least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, at least about 24 hours, at least about 30 hours, at least about 36 hours, at least about 48 hours, at least about 50 hours, at least about 55 hours, at least about 60 hours, at least about 61 hours, at least about 62 hours, at least about 65 hours, at least about 70 hours, at least about 72 hours, at least about 80 hours, at least about 90 hours, at least about 96 hours, at least about 120 hours, at least about 150 hours, at least about 200 hours, at least about 300 hours, or longer, prior to thawing and administration to a subject.

[0257] In some embodiments, the cells of the second population of CD45+ cells comprising at least Tcon are cryopreserved for up to about 1 hour, up to about 2 hours, up to about 3 hours, up to about 4 hours, up to about 5 hours, up to about 6 hours, up to about 7 hours, up to about 8 hours, up to about 9 hours, up to about 10 hours, up to about 11 hours, up to about 12 hours, up to about 14 hours, up to about 16 hours, up to about 18 hours, up to about 20 hours, up to about 22 hours, up to about 24 hours, up to about 30 hours, up to about 36 hours, up to about 48 hours, up to about 50 hours, up to about 55 hours, up to about 60 hours, up to about 61 hours, up to about 62 hours, up to about 65 hours, up to about 70 hours, up to about 72 hours, up to about 80 hours, up to about 90 hours, up to about 96 hours, up to about 120 hours, up to about 150 hours, up to about 200 hours, or up to about 300 hours prior to thawing and administration to a subject.

[0258] In some embodiments, the cells of the second population of CD45+ cells are cryopreserved for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 10 days, at least about 14 days, at least about 21 days, at least about 28 days, at least about 50 days, at least about 60 days, or at least about 96 days, or more, prior to thawing and administration to a subject.

[0259] In some embodiments, the cells of the second population of CD45+ cells are cryopreserved for up to about 1 day, up to about 2 days, up to about 3 days, up to about 4 days, up to about 5 days, up to about 6 days, up to about 7 days, up to about 10 days, up to about 14 days, up to about 21 days, up to about 28 days, up to about 50 days, up to about 60 days, or up to about 96 days prior to thawing and administration to a subject. iNKT

[0260] The cell population comprising a population of iNKT cells (e.g., where iNKT cells are CD3+Vα24Jα18+) is at least about 1×10 per kg of actual or ideal body weight of the recipient subject. 4 , at least about 1 x 10 5 , at least about 5 × 10 5 , at least about 6 × 10 5 , at least about 7 × 10 5 , at least about 8 × 10 5 , at least about 9 × 10 5 , at least about 1 x 10 6 , at least about 1.1 × 10 6 , at least about 1.2 × 10 6 , at least about 1.3 × 10 6 , at least about 1.4 × 10 6 , at least about 1.5 x 10 6 , at least about 1.6 × 10 6 , at least about 1.7 × 10 6 , at least about 1.8 × 10 6 , at least about 1.9 × 10 6 , at least about 2 × 10 6 , at least about 2.1 x 10 6, at least about 2.2 × 10 6 , at least about 2.3 × 10 6 , at least about 2.4 × 10 6 , at least about 2.5 x 10 6 , at least about 2.6 × 10 6 , at least about 2.7 × 10 6 , at least about 2.8 × 10 6 , at least about 2.9 × 10 6 , at least about 3 × 10 6 , at least about 3.1 × 10 6 , at least about 3.2 × 10 6 , at least about 3.3 × 10 6 , at least about 3.4 × 10 6 , at least about 3.5 x 10 6 , at least about 3.6 × 10 6 , at least about 3.7 × 10 6 , at least about 3.8 × 10 6 , at least about 3.9 × 10 6 , at least about 4 × 10 6 , at least about 4.1 × 10 6 , at least about 4.2 × 10 6 , at least about 4.3 × 10 6 , at least about 4.4 × 10 6 , at least about 4.5 x 10 6 , at least about 4.6 × 10 6 , at least about 4.7 × 10 6 , at least about 4.8 × 10 6 , at least about 4.9 × 10 6 , at least about 5 × 10 6 , at least about 5.1 × 10 6 , at least about 5.2 × 10 6 , at least about 5.3 × 10 6 , at least about 5.4 × 10 6 , at least about 5.5 × 10 6 , at least about 5.6 × 10 6 , at least about 5.7 × 10 6 , at least about 5.8 × 10 6 , at least about 5.9 × 10 6 , at least about 6 × 106 , at least about 6.5 × 10 6 , at least about 7 × 10 6 , at least about 7.5 × 10 6 , at least about 8 × 10 6 , at least about 8.5 × 10 6 , at least about 9 × 10 6 , at least about 9.5 × 10 6 , at least about 1 x 10 7 , at least about 1.5 x 10 7 , at least about 2 × 10 7 , at least about 2.5 x 10 7 , at least about 3 × 10 7 , at least about 3.5 x 10 7 , at least about 4 × 10 7 , at least about 4.5 x 10 7 , at least about 5 × 10 7 , at least about 5.5 × 10 7 , at least about 6 × 10 7 , at least about 6.5 × 10 7 , at least about 7 × 10 7 , at least about 7.5 × 10 7 , at least about 8 × 10 7 , at least about 8.5 × 10 7 , at least about 9 × 10 7 , at least about 9.5 × 10 7 , at least about 1 x 10 8 , at least about 1 x 10 8 , at least about 1.5 x 10 8 , at least about 2 × 10 8 , at least about 2.5 x 10 8 , at least about 3 × 10 8 , at least about 3.5 x 10 8 , at least about 4 × 10 7 , at least about 4.5 x 10 8 , at least about 5 × 10 8 , at least about 5.5 × 10 8 , at least about 6 × 10 8 , at least about 6.5 × 10 8 , at least about 7 × 10 8 , at least about 7.5 × 108 , at least about 8 × 10 8 , at least about 8.5 × 10 8 , at least about 9 × 10 8 , at least about 9.5 × 10 8 , at least about 1 x 10 9 It may contain one or more iNKTs.

[0261] A cell population containing a population of iNKT cells may be present at up to about 1 x 10 cells per kg of actual or ideal body weight of the recipient subject (e.g., where iNKT cells are CD3+Vα24Jα18+). 4 , up to about 1×10 5 , up to about 5×10 5 , up to about 6×10 5 , up to about 7×10 5 , up to about 8×10 5 , up to about 9×10 5 , up to about 1×10 6 , maximum approximately 1.1×10 6 , maximum approximately 1.2×10 6 , maximum approximately 1.3×10 6 , maximum approximately 1.4×10 6 , maximum approximately 1.5×10 6 , maximum approximately 1.6×10 6 , maximum approximately 1.7×10 6 , maximum approximately 1.8×10 6 , maximum approximately 1.9×10 6 , up to about 2×10 6 , maximum approximately 2.1×10 6 , maximum approximately 2.2×10 6 , maximum approximately 2.3×10 6 , maximum approximately 2.4×10 6 , maximum approximately 2.5×10 6 , maximum approximately 2.6×10 6 , maximum approximately 2.7×10 6 , maximum approximately 2.8×10 6 , maximum approximately 2.9×10 6 , up to about 3×10 6 , maximum approximately 3.1×10 6 , maximum approximately 3.2×10 6 , maximum approximately 3.3×10 6 , maximum approximately 3.4×10 6 , maximum approximately 3.5×106 , the maximum is about 3.6×10 6 , the maximum is about 3.7×10 6 , the maximum is about 3.8×10 6 , the maximum is about 3.9×10 6 , maximum about 4×10 6 , the maximum is about 4.1×10 6 , the maximum is about 4.2×10 6 , the maximum is about 4.3×10 6 , the maximum is about 4.4×10 6 , the maximum is about 4.5×10 6 , the maximum is about 4.6×10 6 , the maximum is about 4.7×10 6 , the maximum is about 4.8×10 6 , the maximum is about 4.9×10 6 , maximum about 5×10 6 , the maximum is about 5.1×10 6 , the maximum is about 5.2×10 6 , the maximum is about 5.3×10 6 , the maximum is about 5.4×10 6 , the maximum is about 5.5×10 6 , the maximum is about 5.6×10 6 , the maximum is about 5.7×10 6 , the maximum is about 5.8×10 6 , the maximum is about 5.9×10 6 , maximum about 6×10 6 , the maximum is about 6.5×10 6 , maximum about 7×10 6 , maximum about 7.5×10 6 , maximum about 8×10 6 , the maximum is about 8.5×10 6 , maximum about 9×10 6 , the maximum is about 9.5×10 6 , maximum about 1×10 7 , the maximum is about 1.5×10 7 , maximum about 2×10 7 , maximum about 2.5×10 7 , maximum about 3×10 7 , the maximum is about 3.5×10 7 , maximum about 4×10 7 , the maximum is about 4.5×10 7 , maximum about 5×10 7 , the maximum is about 5.5×10 7 , maximum about 6×10 7 , the maximum is about 6.5×10 7, up to about 7×10 7 , maximum approximately 7.5×10 7 , up to about 8×10 7 , maximum approximately 8.5×10 7 , up to about 9×10 7 , maximum approximately 9.5×10 7 , up to about 1×10 8 , up to about 1×10 8 , maximum approximately 1.5×10 8 , up to about 2×10 8 , maximum approximately 2.5×10 8 , up to about 3×10 8 , maximum approximately 3.5×10 8 , up to about 4×10 7 , maximum approximately 4.5×10 8 , up to about 5×10 8 , maximum approximately 5.5×10 8 , up to about 6×10 8 , maximum approximately 6.5×10 8 , up to about 7×10 8 , maximum approximately 7.5×10 8 , up to about 8×10 8 , maximum approximately 8.5×10 8 , up to about 9×10 8 , maximum approximately 9.5×10 8 pieces, or up to approximately 1 x 10 9 It may contain iNKT.

[0262] For example, a cell population containing a population of iNKT cells may be administered at a concentration of 1×10 per kg of actual or ideal body weight of the recipient subject (e.g., where iNKT cells are CD3+Vα24Jα18+). 4 ~1×10 9 , 1×10 5 ~1×10 8 , 1×10 5 ~2×10 7 , 5×10 5 ~2×10 7 , 5×10 5 ~1.5×10 7 , 5×10 5 ~1×10 7 , 5×10 5 ~9×10 6 , 5×10 5 ~8×10 6 , 5×105 ~7×10 6 、5×10 5 ~6×10 6 、5×10 5 ~5×10 6 、5×10 5 ~4×10 6 、5×10 5 ~3×10 6 、5×10 5 ~2×10 6 、5×10 5 ~1×10 6 、1×10 6 ~1.5×10 7 、1×10 6 ~1×10 7 、1×10 6 ~9×10 6 、1×10 6 ~8×10 6 、1×10 6 ~7×10 6 、1×10 6 ~6×10 6 、1×10 6 ~5×10 6 、1×10 6 ~4×10 6 、1×10 6 ~3×10 6 、1×10 6 ~2×10 6 、1.5×10 6 ~1.5×10 7 、1.5×10 6 ~1×10 7 、1.5×10 6 ~9×10 6 、1.5×10 6 ~8×10 6 、1.5×10 6 ~7×10 6 、1.5×10 6 ~6×10 6 、1.5×10 6 ~5×10 6 、1.5×10 6 ~4×10 6 、1.5×10 6 ~3×10 6 、1.5×10 6 ~2×10 6 、2×106 ~1.5×10 7 , 2 × 10 6 ~1×10 7 , 2 × 10 6 ~9×10 6 , 2 × 10 6 ~8×10 6 , 2 × 10 6 ~7×10 6 , 2 × 10 6 ~6×10 6 , 2 × 10 6 ~5×10 6 , 2 × 10 6 ~4×10 6 , 2 × 10 6 ~3×10 6 , 2.5×10 6 ~1.5×10 7 , 2.5×10 6 ~1×10 7 , 2.5×10 6 ~9×10 6 , 2.5×10 6 ~8×10 6 , 2.5×10 6 ~7×10 6 , 2.5×10 6 ~6×10 6 , 2.5×10 6 ~5×10 6 , 2.5×10 6 ~4×10 6 , or 2.5 × 10 6 ~3×10 6 It may contain iNKT.

[0263] The iNKT populations of the present disclosure can have a specified level of purity for iNKT cells. For example, the iNKT populations of the present disclosure can have a specified level of purity for iNKT cells, as a percentage of total cells, as a percentage of nucleated cells, or as a percentage of CD45+ cells (e.g., where the iNKT is CD3+Vα24Jα18+), of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about The iNKT cells may comprise about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or a higher percentage of iNKT cells.

[0264] The iNKT population of the present disclosure may be 50% to 100%, 60% to 100%, 70% to 100%, 75% to 100%, 80% to 100%, 81% to 100%, 82% to 100%, 83% to 84%, 85% to 85%, 86% to 87%, 88% to 89%, 89% to 90%, 90% to 91%, 91% to 92%, 92% to 93%, 93% to 94%, 94% to 95%, 95% to 96%, 96% to 97%, 97% to 98%, 98% to 99%, 99% to 100%, 100% to 101%, 100% to 102%, 100% to 103%, 100% ~100%, 84%~100%, 84%~100%, 86%~100%, 87%~100%, 88%~100%, 89%~100%, 90%~91%, 92%~100%, 93%~100%, 94%~100%, 95%~100%, 96%~100%, 97%~100%, 98%~100%, 99%~100%, 99.5%~100%, 50%~99%, 60%~99%, 70%~99%, 80%~99%, 81%~99%, 82%~99%, 83%~99%, 84%~99%, 85%~99%, 86%~99%, 87%~99%, 88%~99%, 89%~99%, 90%~99%, 91%~99%, 92%~99%, 94%~99%, 95%~99%, 96%~97%, 98%~99%, 50%~98%, 60%~98%, 70%~98%, 8 0%~98%, 81%~98%, 82%~98%, 83%~98%, 84%~98%, 85%~98%, 86%~98%, 87%~98%, 88%~98%, 89%~98%, 90%~98%, 91%~98%, 92%~98%, 94%~98%, 95%~98%, 96%~97%, 98%~98%, 50%~97%, 60%~97%, 70%~97%, 80%~97%, 81%~97%, 82%~97%, 83%~97%, 84 %~97%, 85%~97%, 86%~97%, 87%~97%, 88%~97%, 89%~97%, 90%~97%, 91%~97%, 92%~97%, 94%~97%, 95%~97%, 96%~97%, 50%~96%, 60%~96%, 70%~96%, 80%~96%, 81%~96%, 82%~96%, 83%~96%, 84%~96%, 85%~96%, 86%~96%, 87%~96%, 88%~96%, 89% The iNKT may comprise up to 96%, 90%-96%, 91%-96%, 92%-96%, 94%-96%, 95%-96%, 50%-95%, 60%-95%, 70%-95%, 80%-95%, 81%-95%, 82%-95%, 83%-95%, 84%-95%, 85%-95%, 86%-95%, 87%-95%, 88%-95%, 89%-95%, 90%-95%, 91%-95%, 92%-95%, or 94%-95%.

[0265] The iNKT populations of the present disclosure can have a defined level of contaminating non-iNKT cells. In some embodiments, up to about 1 x 10 per kg of actual or ideal body weight of the recipient subject. 2 , up to about 2×10 2 , up to about 3×10 2 , up to about 4×10 2 , up to about 5×10 2 , up to about 6×102 , up to about 7×10 2 , up to about 8×10 2 , up to about 9×10 2 , up to about 1×10 3 , up to about 2×10 3 , up to about 3×10 3 , up to about 4×10 3 , up to about 5×10 3 , up to about 6×10 3 , up to about 7×10 3 , up to about 8×10 3 , up to about 9×10 3 , up to about 1×10 4 , up to about 2×10 4 , up to about 3×10 4 , up to about 4×10 4 , up to about 5×10 4 , up to about 6×10 4 , up to about 7×10 4 , up to about 8×10 4 , up to about 9×10 4 , or up to about 1 × 10 5 non-iNKT cells are present in the iNKT population of the present disclosure (e.g., where the non-iNKT cells are Vα24Jα18-).

[0266] In some embodiments, the population of iNKT of the present disclosure is up to about 0.001%, up to about 0.002%, up to about 0.003%, up to about 0.004%, up to about 0.005%, up to about 0.006%, up to about 0.007%, up to about 0.008%, 0.009%, up to about 0.01%, up to about 0.02%, up to about 0.03%, up to about 0.04%, Maximum of approximately 0.05%, Maximum of approximately 0.06%, Maximum of approximately 0.07%, Maximum of approximately 0.08%, Maximum of approximately 0.09%, Maximum of approximately 0.1%, Maximum of approximately 0.2%, Maximum of approximately 0.3%, Maximum of approximately 0 .4%, maximum approximately 0.5%, maximum approximately 0.6%, maximum approximately 0.7%, maximum approximately 0.8%, maximum approximately 0.9%, maximum approximately 1%, maximum approximately 1.1%, maximum approximately 1.2%, maximum approximately 1.3% , maximum approximately 1.4%, maximum approximately 1.5%, maximum approximately 1.6%, maximum approximately 1.7%, maximum approximately 1.8%, maximum approximately 1.9%, maximum approximately 2%, maximum approximately 2.1%, maximum approximately 2.2%, maximum Approximately 2.3%, maximum approximately 2.4%, maximum approximately 2.5%, maximum approximately 2.6%, maximum approximately 2.7%, maximum approximately 2.8%, maximum approximately 2.9%, maximum approximately 3%, maximum approximately 3.1%, maximum approximately 3. 2%, up to about 3.3%, up to about 3.4%, up to about 3.5%, up to about 3.6%, up to about 3.7%, up to about 3.8%, up to about 3.9%, up to about 4%, up to about 5%, up to about 6%, up to about 7%, up to about 8%, up to about 9%, or up to about 10% non-iNKT cells (e.g., where the non-iNKT cells are Vα24Jα18-). Tmem

[0267] The cell population comprising a population of Tmem is at least about 1 x 10 (e.g., where Tmem is CD3+CD45RA-CD45RO+) per kg of actual or ideal body weight of the recipient subject. 4 , at least about 1 x 10 5 , at least about 5 × 10 5 , at least about 6 × 10 5 , at least about 7 × 10 5 , at least about 8 × 10 5 , at least about 9 × 10 5 , at least about 1 x 10 6 , at least about 1.1 × 10 6 , at least about 1.2 × 10 6 , at least about 1.3 × 10 6, at least about 1.4 × 10 6 , at least about 1.5 x 10 6 , at least about 1.6 × 10 6 , at least about 1.7 × 10 6 , at least about 1.8 × 10 6 , at least about 1.9 × 10 6 , at least about 2 × 10 6 , at least about 2.1 x 10 6 , at least about 2.2 × 10 6 , at least about 2.3 × 10 6 , at least about 2.4 × 10 6 , at least about 2.5 x 10 6 , at least about 2.6 × 10 6 , at least about 2.7 × 10 6 , at least about 2.8 × 10 6 , at least about 2.9 × 10 6 , at least about 3 × 10 6 , at least about 3.1 × 10 6 , at least about 3.2 × 10 6 , at least about 3.3 × 10 6 , at least about 3.4 × 10 6 , at least about 3.5 x 10 6 , at least about 3.6 × 10 6 , at least about 3.7 × 10 6 , at least about 3.8 × 10 6 , at least about 3.9 × 10 6 , at least about 4 × 10 6 , at least about 4.1 × 10 6 , at least about 4.2 × 10 6 , at least about 4.3 × 10 6 , at least about 4.4 × 10 6 , at least about 4.5 x 10 6 , at least about 4.6 × 10 6 , at least about 4.7 × 10 6 , at least about 4.8 × 10 6 , at least about 4.9 × 10 6 , at least about 5 × 10 6 , at least about 5.1 × 10 6 , at least about 5.2 × 106 , at least about 5.3 × 10 6 , at least about 5.4 × 10 6 , at least about 5.5 × 10 6 , at least about 5.6 × 10 6 , at least about 5.7 × 10 6 , at least about 5.8 × 10 6 , at least about 5.9 × 10 6 , at least about 6 × 10 6 , at least about 6.5 × 10 6 , at least about 7 × 10 6 , at least about 7.5 × 10 6 , at least about 8 × 10 6 , at least about 8.5 × 10 6 , at least about 9 × 10 6 , at least about 9.5 × 10 6 , at least about 1 x 10 7 , at least about 1.5 x 10 7 , at least about 2 × 10 7 , at least about 2.5 x 10 7 , at least about 3 × 10 7 , at least about 3.5 x 10 7 , at least about 4 × 10 7 , at least about 4.5 x 10 7 , at least about 5 × 10 7 , at least about 5.5 × 10 7 , at least about 6 × 10 7 , at least about 6.5 × 10 7 , at least about 7 × 10 7 , at least about 7.5 × 10 7 , at least about 8 × 10 7 , at least about 8.5 × 10 7 , at least about 9 × 10 7 , at least about 9.5 × 10 7 , at least about 1 x 10 8 , at least about 1 x 10 8 , at least about 1.5 x 10 8 , at least about 2 × 10 8 , at least about 2.5 x 10 8 , at least about 3 × 10 8, at least about 3.5 x 10 8 , at least about 4 × 10 7 , at least about 4.5 x 10 8 , at least about 5 × 10 8 , at least about 5.5 × 10 8 , at least about 6 × 10 8 , at least about 6.5 × 10 8 , at least about 7 × 10 8 , at least about 7.5 × 10 8 , at least about 8 × 10 8 , at least about 8.5 × 10 8 , at least about 9 × 10 8 , at least about 9.5 × 10 8 , at least about 1 x 10 9 It may contain one or more Tmems.

[0268] A cell population comprising a population of Tmem may be present at up to about 1 x 10 cells per kg of actual or ideal body weight of the recipient subject (e.g., where Tmem is CD3+CD45RA-CD45RO+). 4 , up to about 1×10 5 , up to about 5×10 5 , up to about 6×10 5 , up to about 7×10 5 , up to about 8×10 5 , up to about 9×10 5 , up to about 1×10 6 , maximum approximately 1.1×10 6 , maximum approximately 1.2×10 6 , maximum approximately 1.3×10 6 , maximum approximately 1.4×10 6 , maximum approximately 1.5×10 6 , maximum approximately 1.6×10 6 , maximum approximately 1.7×10 6 , maximum approximately 1.8×10 6 , maximum approximately 1.9×10 6 , up to about 2×10 6 , maximum approximately 2.1×10 6 , maximum approximately 2.2×10 6 , maximum approximately 2.3×10 6 , maximum approximately 2.4×10 6 , maximum approximately 2.5×10 6, the maximum is about 2.6×10 6 , the maximum is about 2.7×10 6 , the maximum is about 2.8×10 6 , the maximum is about 2.9×10 6 , maximum about 3×10 6 , the maximum is about 3.1×10 6 , the maximum is about 3.2×10 6 , the maximum is about 3.3×10 6 , the maximum is about 3.4×10 6 , the maximum is about 3.5×10 6 , the maximum is about 3.6×10 6 , the maximum is about 3.7×10 6 , the maximum is about 3.8×10 6 , the maximum is about 3.9×10 6 , maximum about 4×10 6 , the maximum is about 4.1×10 6 , the maximum is about 4.2×10 6 , the maximum is about 4.3×10 6 , the maximum is about 4.4×10 6 , the maximum is about 4.5×10 6 , the maximum is about 4.6×10 6 , the maximum is about 4.7×10 6 , the maximum is about 4.8×10 6 , the maximum is about 4.9×10 6 , maximum about 5×10 6 , the maximum is about 5.1×10 6 , the maximum is about 5.2×10 6 , the maximum is about 5.3×10 6 , the maximum is about 5.4×10 6 , the maximum is about 5.5×10 6 , the maximum is about 5.6×10 6 , the maximum is about 5.7×10 6 , the maximum is about 5.8×10 6 , the maximum is about 5.9×10 6 , maximum about 6×10 6 , the maximum is about 6.5×10 6 , maximum about 7×10 6 , maximum about 7.5×10 6 , maximum about 8×10 6 , the maximum is about 8.5×10 6 , maximum about 9×10 6 , the maximum is about 9.5×10 6 , maximum about 1×10 7 , the maximum is about 1.5×10 7, up to about 2×10 7 , maximum approximately 2.5×10 7 , up to about 3×10 7 , maximum approximately 3.5×10 7 , up to about 4×10 7 , maximum approximately 4.5×10 7 , up to about 5×10 7 , maximum approximately 5.5×10 7 , up to about 6×10 7 , maximum approximately 6.5×10 7 , up to about 7×10 7 , maximum approximately 7.5×10 7 , up to about 8×10 7 , maximum approximately 8.5×10 7 , up to about 9×10 7 , maximum approximately 9.5×10 7 , up to about 1×10 8 , up to about 1×10 8 , maximum approximately 1.5×10 8 , up to about 2×10 8 , maximum approximately 2.5×10 8 , up to about 3×10 8 , maximum approximately 3.5×10 8 , up to about 4×10 7 , maximum approximately 4.5×10 8 , up to about 5×10 8 , maximum approximately 5.5×10 8 , up to about 6×10 8 , maximum approximately 6.5×10 8 , up to about 7×10 8 , maximum approximately 7.5×10 8 , up to about 8×10 8 , maximum approximately 8.5×10 8 , up to about 9×10 8 , maximum approximately 9.5×10 8 pieces, or up to approximately 1 x 10 9 It may contain Tmems.

[0269] For example, a cell population comprising a population of Tmem may be administered at a concentration of 1 x 10 per kg of actual or ideal body weight of the recipient subject (e.g., where Tmem is CD3+CD45RA-CD45RO+). 4 ~1×10 9 , 1×10 5 ~1×10 8、1×10 5 ~2×10 7 、5×10 5 ~2×10 7 、5×10 5 ~1.5×10 7 、5×10 5 ~1×10 7 、5×10 5 ~9×10 6 、5×10 5 ~8×10 6 、5×10 5 ~7×10 6 、5×10 5 ~6×10 6 、5×10 5 ~5×10 6 、5×10 5 ~4×10 6 、5×10 5 ~3×10 6 、5×10 5 ~2×10 6 、5×10 5 ~1×10 6 、1×10 6 ~1.5×10 7 、1×10 6 ~1×10 7 、1×10 6 ~9×10 6 、1×10 6 ~8×10 6 、1×10 6 ~7×10 6 、1×10 6 ~6×10 6 、1×10 6 ~5×10 6 、1×10 6 ~4×10 6 、1×10 6 ~3×10 6 、1×10 6 ~2×10 6 、1.5×10 6 ~1.5×10 7 、1.5×10 6 ~1×10 7 、1.5×10 6 ~9×10 6 、1.5×10 6 ~8×10 6 、1.5×106 ~7×10 6 , 1.5×10 6 ~6×10 6 , 1.5×10 6 ~5×10 6 , 1.5×10 6 ~4×10 6 , 1.5×10 6 ~3×10 6 , 1.5×10 6 ~2×10 6 , 2 × 10 6 ~1.5×10 7 , 2 × 10 6 ~1×10 7 , 2 × 10 6 ~9×10 6 , 2 × 10 6 ~8×10 6 , 2 × 10 6 ~7×10 6 , 2 × 10 6 ~6×10 6 , 2 × 10 6 ~5×10 6 , 2 × 10 6 ~4×10 6 , 2 × 10 6 ~3×10 6 , 2.5×10 6 ~1.5×10 7 , 2.5×10 6 ~1×10 7 , 2.5×10 6 ~9×10 6 , 2.5×10 6 ~8×10 6 , 2.5×10 6 ~7×10 6 , 2.5×10 6 ~6×10 6 , 2.5×10 6 ~5×10 6 , 2.5×10 6 ~4×10 6 , or 2.5 × 10 6 ~3×10 6 It may contain Tmems.

[0270] The populations of Tmems of the present disclosure can have a specified level of purity for Tmem cells. For example, the populations of Tmems of the present disclosure can have at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, or less as a percentage of total cells, as a percentage of nucleated cells, or as a percentage of CD45+ cells (e.g., where a Tmem is CD3+CD45RA-CD45RO+). In some embodiments, the Tmem cells may comprise at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or more.

[0271] The population of Tmem of the present disclosure may be expressed as a percentage of total cells, nucleated cells, or CD45+ cells (e.g., where Tmem is CD3+CD45RA-CD45RO+), and may be expressed as 50% to 100%, 60% to 100%, 70% to 100%, 75% to 100%, 80% to 100%, 81% to 100%, 82% to 100%, 83% to 100%, 84% to 100%, 85% to 100%, 86% to 100%, 87% to 100%, 88% to 100%, 89% to 100%, 90% to 100%, 91% to 100%, 92% to 100%, 93% to 100%, 94% to 100%, 95 3%~100%, 84%~100%, 84%~100%, 86%~100%, 87%~100%, 88%~100%, 89%~100%, 90%~91%, 92%~100%, 93%~100%, 94%~100%, 95%~100%, 96%~100%, 97%~100%, 98%~100%, 99%~100%, 99.5%~100%, 50%~99%, 60%~99%, 70%~99%, 80%~99%, 81%~99%, 82%~99%, 83%~99%, 84%~99%, 85%~99%, 86%~99%, 87%~99%, 88%~99%, 89%~99%, 90%~99%, 91%~99%, 92%~99%, 94%~99%, 95%~99%, 96%~97%, 98%~99%, 50%~98%, 60%~98%, 70%~98%, 8 0%~98%, 81%~98%, 82%~98%, 83%~98%, 84%~98%, 85%~98%, 86%~98%, 87%~98%, 88%~98%, 89%~98%, 90%~98%, 91%~98%, 92%~98%, 94%~98%, 95%~98%, 96%~97%, 98%~98%, 50%~97%, 60%~97%, 70%~97%, 80%~97%, 81%~97%, 82%~97%, 83%~97%, 84 %~97%, 85%~97%, 86%~97%, 87%~97%, 88%~97%, 89%~97%, 90%~97%, 91%~97%, 92%~97%, 94%~97%, 95%~97%, 96%~97%, 50%~96%, 60%~96%, 70%~96%, 80%~96%, 81%~96%, 82%~96%, 83%~96%, 84%~96%, 85%~96%, 86%~96%, 87%~96%, 88%~96%, 89% It may contain up to 96%, 90% to 96%, 91% to 96%, 92% to 96%, 94% to 96%, 95% to 96%, 50% to 95%, 60% to 95%, 70% to 95%, 80% to 95%, 81% to 95%, 82% to 95%, 83% to 95%, 84% to 95%, 85% to 95%, 86% to 95%, 87% to 95%, 88% to 95%, 89% to 95%, 90% to 95%, 91% to 95%, 92% to 95%, or 94% to 95% Tmem.

[0272] The population of Tmems of the present disclosure can have a defined level of contaminating non-Tmem cells, in some embodiments, up to about 1 x 10 per kg of actual or ideal body weight of the recipient subject. 2 , up to about 2×10 2 , up to about 3×10 2 , up to about 4×10 2 , up to about 5×10 2 , up to about 6×102 , up to about 7×10 2 , up to about 8×10 2 , up to about 9×10 2 , up to about 1×10 3 , up to about 2×10 3 , up to about 3×10 3 , up to about 4×10 3 , up to about 5×10 3 , up to about 6×10 3 , up to about 7×10 3 , up to about 8×10 3 , up to about 9×10 3 , up to about 1×10 4 , up to about 2×10 4 , up to about 3×10 4 , up to about 4×10 4 , up to about 5×10 4 , up to about 6×10 4 , up to about 7×10 4 , up to about 8×10 4 , up to about 9×10 4 , or up to about 1 × 10 5 non-Tmem cells are present in a population of Tmems of the present disclosure (eg, where the non-Tmem cells are CD45RO-).

[0273] In some embodiments, the population of Tmem of the present disclosure is up to about 0.001%, up to about 0.002%, up to about 0.003%, up to about 0.004%, up to about 0.005%, up to about 0.006%, up to about 0.007%, up to about 0.008%, 0.009%, up to about 0.01%, up to about 0.02%, up to about 0.03%, up to about 0.04% , maximum approximately 0.05%, maximum approximately 0.06%, maximum approximately 0.07%, maximum approximately 0.08%, maximum approximately 0.09%, maximum approximately 0.1%, maximum approximately 0.2%, maximum approximately 0.3%, maximum approximately 0.4%, maximum approximately 0.5%, maximum approximately 0.6%, maximum approximately 0.7%, maximum approximately 0.8%, maximum approximately 0.9%, maximum approximately 1%, maximum approximately 1.1%, maximum approximately 1.2%, maximum approximately 1.3 up to about 1.6%, up to about 1.7%, up to about 1.8%, up to about 1.9%, up to about 2%, up to about 2.1%, up to about 2.2%, up to about 2.3%, up to about 2.4%, up to about 2.5%, up to about 2.6%, up to about 2.7%, up to about 2.8%, up to about 2.9%, up to about 3%, up to about 3.1%, up to about 3.2%, up to about 3.3%, up to about 3.4%, up to about 3.5%, up to about 3.6%, up to about 3.7%, up to about 3.8%, up to about 3.9%, up to about 4%, up to about 5%, up to about 6%, up to about 7%, up to about 8%, up to about 9%, or up to about 10% non-Tmem cells (e.g., where the non-Tmem cells are CD45RO-). D. Sequence and Timing of Administration of Cell Populations

[0274] Embodiments provide a multi-component pharmaceutical treatment administered to a human subject in need thereof, the multi-component treatment comprising: (a) a solution comprising a first population of CD45+ cells, including hematopoietic stem progenitor cells (HSPCs) and granulocytes, wherein up to about 10% of the first population of CD45+ cells comprises granulocytes; (b) a solution comprising a population of cells enriched for regulatory T cells (Tregs); (c) a solution comprising a second population of CD45+ cells, wherein the second population of CD45+ cells comprises at least about 20% CD3+ conventional T cells (Tcon), at least about 10% monocytes, and at least about 10% granulocytes; and (d) one or more doses of a graft-versus-host disease (GVHD) prophylactic agent.

[0275] Another embodiment provides a method of treating a human subject diagnosed with a hematological malignancy. The method includes administering to the human subject a solution comprising a first population of CD45+ cells, a solution comprising a population of cells enriched for regulatory T cells (Tregs), a solution comprising a second population of CD45+ cells, and one or more doses of a GVHD prophylactic agent. In this embodiment, the solution comprising the first population of CD45+ cells, the solution comprising the population of cells enriched for regulatory Tregs, the solution comprising the second population of CD45+ cells, and the solution comprising one or more doses of a GVHD prophylactic agent are as defined according to any of the multi-component pharmaceutical treatments disclosed herein.

[0276] Disclosed herein is a method for enhancing allogeneic hematopoietic stem cell transplantation, the method comprising administering to a subject a solution comprising a population of cells.

[0277] In some embodiments, a cell population is administered to a subject, the cell population comprising a first population of CD45+ cells comprising at least HSPCs, a population of cells enriched for regulatory T cells (Tregs), and a second population of CD45+ cells comprising at least Tcon.

[0278] The first population of CD45+ cells and the population of cells enriched for Tregs can be administered at the same or similar time, or at different times, hi some embodiments, the first population of CD45+ cells and the population of cells enriched for Tregs are administered on the same day.

[0279] In various embodiments, the first population of CD45+ cells and the population of cells enriched for Tregs are administered before the second population of CD45+ cells.

[0280] The first population of CD45+ cells and the population of cells enriched for Tregs can be administered up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, or 48 hours apart.

[0281] The second population of CD45+ cells can be administered to the subject after the first population of CD45+ cells.

[0282] The second population of CD45+ cells is at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later, the subject may be administered the

[0283] In some embodiments, the second population of CD45+ cells is up to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, 21, 22, 23, 24, 2 or 120 hours later.

[0284] The second population of CD45+ cells may be, for example, approximately 6-96, 12-84, 12-72, 12-66, 12-60, 12-54, 12-48, 12-42, 12-36, 12-30, 12-24, 12-18, 18-72, 18-66, 18-60, 18-54, 18-48, 18-42, 18-36, 18-30, 18-24, 24-72, 24-66, 24-60, 24-54, 24-48, 24-42, 24-44, 24-56, 24-66, 24-60, 24-54, 24-48, 24-42, 24-56, 24-66, 24-72, 24-66, 24-60, 24-54, 24-48, 24-42, 24-56, 24-66, 24-42, 24-56 ...56, 24-56, 24-56, 24-56 The compound may be administered to the subject within 36, 24 to 30, 30 to 72, 30 to 66, 30 to 60, 30 to 54, 30 to 48, 30 to 42, 30 to 36, 36 to 72, 36 to 66, 36 to 60, 36 to 54, 36 to 48, 36 to 42, 42 to 72, 42 to 66, 42 to 60, 42 to 54, 42 to 48, 48 to 72, 48 to 66, 48 to 60, 48 to 54, 54 to 72, 54 to 66, 54 to 60, 60 to 72, 60 to 66, or 66 to 72 hours later.

[0285] The second population of CD45+ cells can be administered to the subject after the population of cells enriched for Tregs.

[0286] The population of Tcon is at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, The compound can be administered to the subject more than 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later.

[0287] In some embodiments, the second population of CD45+ cells comprises up to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, 21, 22, 23, 24, 2 , 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later, the subject is administered the

[0288] The second population of CD45+ cells may be, for example, approximately 6-96, 12-84, 12-72, 12-66, 12-60, 12-54, 12-48, 12-42, 12-36, 12-30, 12-24, 12-18, 18-72, 18-66, 18-60, 18-54, 18-48, 18-42, 18-36, 18-30, 18-24, 24-72, 24-66, 24-60, 24-54, 24-48, 24-42, The subject may be administered 24 to 36, 24 to 30, 30 to 72, 30 to 66, 30 to 60, 30 to 54, 30 to 48, 30 to 42, 30 to 36, 36 to 72, 36 to 66, 36 to 60, 36 to 54, 36 to 48, 36 to 42, 42 to 72, 42 to 66, 42 to 60, 42 to 54, 42 to 48, 48 to 72, 48 to 66, 48 to 60, 48 to 54, 54 to 72, 54 to 66, 54 to 60, 60 to 72, 60 to 66, or 66 to 72 hours later.

[0289] The second population of CD45+ cells can be administered to the subject after the first population of CD45+ cells and the population of cells enriched for Tregs.

[0290] The second population of CD45+ cells can be, for example, at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 of the first population of CD45+ cells and the population of cells enriched for Tregs. , 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours after administration to the subject.

[0291] In some embodiments, the second population of CD45+ cells is up to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 1 and the administered dose is administered to the subject 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later.

[0292] The second population of CD45+ cells may be, for example, approximately 6-96, 12-84, 12-72, 12-66, 12-60, 12-54, 12-48, 12-42, 12-36, 12-30, 12-24, 12-18, 18-72, 18-66, 18-60, 18-54, 18-48, 18-42, 18-36, 18-30, 18-24, 24-72, 24-66, 24-60, 24-54, 24-48, 24-54, 24-66, 24-60, 24-54, 24-48 ... The subject may be administered 8, 24-42, 24-36, 24-30, 30-72, 30-66, 30-60, 30-54, 30-48, 30-42, 30-36, 36-72, 36-66, 36-60, 36-54, 36-48, 36-42, 42-72, 42-66, 42-60, 42-54, 42-48, 48-72, 48-66, 48-60, 48-54, 54-72, 54-66, 54-60, 60-72, 60-66, or 66-72 hours later.

[0293] In some embodiments, a population of hematopoietic stem progenitor cells (HSPCs), a population of cells enriched for regulatory T cells (Tregs), a population of conventional T cells (Tcon), and a population of invariant natural killer T cells (iNKTs) are administered to a subject.

[0294] The population of iNKT can be administered to the subject at the same time as or at a similar time to the first population of CD45+ cells. In some embodiments, the population of iNKT is administered to the subject after the first population of CD45+ cells.

[0295] The iNKT population is at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 1109, 1109, 1111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 1 The compound can be administered to the subject more than 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later.

[0296] In some embodiments, the population of iNKT cells is up to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124 , 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later, the subject is administered the

[0297] The iNKT population may be, for example, approximately 6-96, 12-84, 12-72, 12-66, 12-60, 12-54, 12-48, 12-42, 12-36, 12-30, 12-24, 12-18, 18-72, 18-66, 18-60, 18-54, 18-48, 18-42, 18-36, 18-30, 18-24, 24-72, 24-66, 24-60, 24-54, 24-48, 24-42, 24-36 of the first population of CD45+ cells. , 24 to 30, 30 to 72, 30 to 66, 30 to 60, 30 to 54, 30 to 48, 30 to 42, 30 to 36, 36 to 72, 36 to 66, 36 to 60, 36 to 54, 36 to 48, 36 to 42, 42 to 72, 42 to 66, 42 to 60, 42 to 54, 42 to 48, 48 to 72, 48 to 66, 48 to 60, 48 to 54, 54 to 72, 54 to 66, 54 to 60, 60 to 72, 60 to 66, or 66 to 72 hours later.

[0298] The population of iNKT can be administered to the subject at the same time as or at the same time as the population of cells enriched for Tregs. In some embodiments, the population of iNKT is administered to the subject after the population of cells enriched for Tregs.

[0299] The iNKT population is at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, The compound can be administered to the subject more than 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later.

[0300] In some embodiments, the population of iNKT cells is up to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124 , 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later, the subject is administered the

[0301] The iNKT population may be, for example, approximately 6-96, 12-84, 12-72, 12-66, 12-60, 12-54, 12-48, 12-42, 12-36, 12-30, 12-24, 12-18, 18-72, 18-66, 18-60, 18-54, 18-48, 18-42, 18-36, 18-30, 18-24, 24-72, 24-66, 24-60, 24-54, 24-48, 24-42, 24- The subject may be administered 36, 24-30, 30-72, 30-66, 30-60, 30-54, 30-48, 30-42, 30-36, 36-72, 36-66, 36-60, 36-54, 36-48, 36-42, 42-72, 42-66, 42-60, 42-54, 42-48, 48-72, 48-66, 48-60, 48-54, 54-72, 54-66, 54-60, 60-72, 60-66, or 66-72 hours later.

[0302] In some embodiments, a population of hematopoietic stem progenitor cells (HSPCs), a population of cells enriched for regulatory T cells (Tregs), a population of conventional T cells (Tcon), and a population of memory T cells (Tmem) are administered to a subject.

[0303] The population of Tmems can be administered to the subject at the same time as or at a similar time to the first population of CD45+ cells. In some embodiments, the population of Tmems is administered to the subject after the first population of CD45+ cells.

[0304] The Tmem population is at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 1109, 1109, 1111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 1 The compound can be administered to the subject more than 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later.

[0305] In some embodiments, the population of Tmem is up to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, 21, 22, 23, 24, 25, , 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later, the subject is administered the

[0306] The Tmem population may be, for example, approximately 6-96, 12-84, 12-72, 12-66, 12-60, 12-54, 12-48, 12-42, 12-36, 12-30, 12-24, 12-18, 18-72, 18-66, 18-60, 18-54, 18-48, 18-42, 18-36, 18-30, 18-24, 24-72, 24-66, 24-60, 24-54, 24-48, 24-42, 24-36 of the first population of CD45+ cells. , 24 to 30, 30 to 72, 30 to 66, 30 to 60, 30 to 54, 30 to 48, 30 to 42, 30 to 36, 36 to 72, 36 to 66, 36 to 60, 36 to 54, 36 to 48, 36 to 42, 42 to 72, 42 to 66, 42 to 60, 42 to 54, 42 to 48, 48 to 72, 48 to 66, 48 to 60, 48 to 54, 54 to 72, 54 to 66, 54 to 60, 60 to 72, 60 to 66, or 66 to 72 hours later.

[0307] The population of Tmems can be administered to the subject at the same time as or at a similar time to the population of cells enriched for Tregs, hi some embodiments, the population of Tmems is administered to the subject after the population of cells enriched for Tregs.

[0308] The population of Tmem is at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, The compound can be administered to the subject more than 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later.

[0309] In some embodiments, the population of Tmem is up to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, , 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96 hours later, the subject is administered the

[0310] The Tmem population is, for example, approximately 6-96, 12-84, 12-72, 12-66, 12-60, 12-54, 12-48, 12-42, 12-36, 12-30, 12-24, 12-18, 18-72, 18-66, 18-60, 18-54, 18-48, 18-42, 18-36, 18-30, 18-24, 24-72, 24-66, 24-60, 24-54, 24-48, 24-42, 24- The subject may be administered 36, 24-30, 30-72, 30-66, 30-60, 30-54, 30-48, 30-42, 30-36, 36-72, 36-66, 36-60, 36-54, 36-48, 36-42, 42-72, 42-66, 42-60, 42-54, 42-48, 48-72, 48-66, 48-60, 48-54, 54-72, 54-66, 54-60, 60-72, 60-66, or 66-72 hours later.

[0311] In some embodiments, the population of Tcon is administered at least about 12 hours after the population of HSPCs, e.g., the population of Tcon is administered about 24 to about 96 hours after the population of HSPCs, or the population of Tcon is administered about 36 to about 60 hours after the population of HSPCs.

[0312] In embodiments, the population of Tcon is administered at least about 12 hours after the population of cells comprising Tregs, for example, the population of Tcon is administered about 24 to about 96 hours after the population of cells comprising Tregs, or the population of Tcon is administered about 36 to about 60 hours after the population of cells comprising Tregs. Heterogeneous cell populations

[0313] A further embodiment provides a method for transplanting a population of conventional T cells (Tcon) as part of a treatment regimen for a hematological malignancy, the method reducing the risk and / or severity of adverse events associated with the treatment regimen. The method comprises administering to a patient a population of regulatory T cells (Tregs) comprising Tregs and a liquid suspending the Tregs; and administering to the patient a heterogeneous cell population comprising lymphocytes, granulocytes, monocytes, and a liquid suspending the cells. In this embodiment, at least about 30% of the lymphocytes comprise Tcon, and after administration of the cell population, the patient has a reduced risk and / or severity of adverse events compared to a patient with a hematological malignancy who received Tcon but not Tregs.

[0314] A still further embodiment provides a method for transplanting a cell population into a human patient as part of a treatment regimen for a hematological malignancy, the method reducing the risk and / or severity of adverse events associated with the treatment regimen. The method includes the steps of: providing a population of hematopoietic stem progenitor cells (HSPCs) for administration to the patient, wherein the population of HSPCs comprises HSPCs and a liquid suspending the HSPCs; providing a population of regulatory T cells (Tregs) for administration to the patient, wherein the population of Tregs comprises Tregs and a liquid suspending the Tregs; and providing a heterogeneous cell population for administration to the patient, wherein the heterogeneous cell population comprises lymphocytes, granulocytes, monocytes, and a liquid suspending the cells. In this embodiment, at least about 30% of the lymphocytes comprise conventional T cells (Tcon), and following administration of the cell population, the patient has a reduced risk and / or severity of adverse events compared to a patient with a hematological malignancy who received the Tcon cell population but not the T-reg cell population.

[0315] In various embodiments, the heterogeneous cell population comprises about 0.2 to about 2.0 percent hematopoietic stem progenitor cells.

[0316] In some embodiments, the hematological malignancy is acute lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, multiple myeloma, lymphoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

[0317] In embodiments, the gene expression levels of T-reg cells correlate to cells harvested from a donor within about 60 hours prior to administration to a patient.

[0318] In various embodiments, the number of T-reg cells in the T-reg population is approximately equal to the number of T-con cells in the heterogeneous cell population. In some cases, the T-reg cells in the T-reg population inhibit activation of conventional T cells in the heterogeneous cell population by up to about 20 percent, depending on the patient's healthy tissue.

[0319] In some embodiments, the peripheral blood of the patient exhibits an elevated ratio of Tregs to CD4+ T cells up to about 100 days after administration of the cell population, compared to a healthy human subject who has not received the cell population.

[0320] In embodiments, at least about 50% of the cells in the HSPC cell population are colony forming units.

[0321] In various embodiments, at least one of the cell populations has an elevated amount of granulocyte colony-stimulating factor compared to unmobilized blood. In some cases, at least one cell population is a heterogeneous cell population.

[0322]

[0003] An embodiment provides a method for transplanting a cell population into a human patient as part of a treatment regimen for a hematological malignancy, the method comprising the steps of: administering to the patient a population of hematopoietic stem progenitor cells (HSPCs), the population of HSPCs comprising the HSPCs and a liquid suspending the HSPCs; administering to the patient a population of regulatory T cells (Tregs), the population of Tregs comprising the Tregs and a liquid suspending the Tregs, administered to the patient; and administering to the patient a heterogeneous cell population, the heterogeneous cell population comprising lymphocytes, granulocytes, monocytes and a liquid suspending the cells, administered to the patient, wherein at least about 3% of the lymphocytes are grafted onto the patient. 0% comprise conventional T cells (Tcon); and administering to the patient a single graft-versus-host disease (GVHD) prophylaxis (GVHDPA) comprising tacrolimus (tacrolimus GHVDPA) for a period of up to about 180 days, wherein the tacrolimus GHVDPA is administered to maintain a tacrolimus concentration in the patient's blood above a threshold level during the period, thereby significantly reducing the risk and / or severity of GHVD associated with a treatment regimen for a hematologic malignancy.

[0323] In some embodiments, a heterogeneous cell population may be administered to a subject. The heterogeneous cell population may include many different cell types found in the peripheral blood of a human donor. The heterogeneous cell population may include granulocytes, monocytes, and lymphocytes. The heterogeneous cell population may include T cells (e.g., Tcon, Treg, Tmem, naive T cells, CD4+ T cells, NK-T cells), B cells, NK cells, HSPCs, dendritic cells (e.g., plasmacytoid dendritic cells and myeloid dendritic cells), and other cell populations found in peripheral blood. The heterogeneous cell population may be administered to a subject in addition to other populations described herein. For example, the heterogeneous cell population may be administered together with HSPCs described herein. In some cases, the heterogeneous cell population may be administered together with HSPCs and Tregs described herein. In some cases, the heterogeneous cell population may be administered together with Tregs described herein. In some cases, the heterogeneous cell population may be administered together with Tcon described herein. In some cases, the heterogeneous cell population may be administered in place of the Tcon population described herein.

[0324] In some embodiments, the heterogeneous cell population administered to a subject may comprise a combination of granulocytes and monocytes. The combination of granulocytes and monocytes may comprise 30% to 80% of the heterogeneous cell population. At least 30% of the heterogeneous cell population may comprise a combination of granulocytes and monocytes. Up to 80% of the heterogeneous cell population may comprise a combination of granulocytes and monocytes. In some cases, 30% to 40%, 30% to 50%, 30% to 60%, 30% to 70%, 30% to 80%, 40% to 50%, 40% to 60%, 40% to 70%, 40% to 80%, 50% to 60%, 50% to 70%, 50% to 80%, 60% to 70%, 60% to 80%, or 70% to 80% of the heterogeneous cell population may comprise a combination of granulocytes and monocytes. In some cases, 30%, 40%, 50%, 60%, 70%, or 80% of the heterogeneous cell population may comprise a combination of granulocytes and monocytes. In some cases, at least 30%, 40%, 50%, 60%, or 70% of the heterogeneous cell population may comprise a combination of granulocytes and monocytes. In some cases, up to 40%, 50%, 60%, 70%, or 80% of the heterogeneous cell population may comprise a combination of granulocytes and monocytes.

[0325] In some embodiments, the heterogeneous cell population administered to a subject may comprise lymphocytes. Lymphocytes include CD45+ cells. Lymphocytes may comprise 8% to 50% of the heterogeneous cell population. In some cases, at least 8% of the heterogeneous cell population may comprise lymphocytes. In some cases, up to 50% of the heterogeneous cell population may comprise lymphocytes. In some cases, 8% to 10%, 8% to 20%, 8% to 25%, 8% to 30%, 8% to 40%, 8% to 45%, 8% to 50%, 10% to 20%, 10% to 25%, 10% to 30%, 10% to 40%, 10% to 45%, 10% to 50%, 20% to 25%, 20% to 30%, 20% to 40%, 20% to 45%, 20% to 50%, 25% to 30%, 25% to 40%, 25% to 45%, 25% to 50%, 30% to 40%, 30% to 45%, 30% to 50%, 40% to 45%, 40% to 50%, or 45% to 50% of the heterogeneous cell population may comprise lymphocytes. In some cases, 8%, 10%, 20%, 25%, 30%, 40%, 45%, or 50% of the heterogeneous cell population may comprise lymphocytes. In some cases, at least 8%, 10%, 20%, 25%, 30%, 40%, or 45% of the heterogeneous cell population may comprise lymphocytes. In some cases, up to 10%, 20%, 25%, 30%, 40%, 45%, or 50% of the heterogeneous cell population may comprise lymphocytes.

[0326] In some embodiments, lymphocytes in a heterogeneous cell population may comprise Tcon. Tcon may comprise 40% to 85% of the lymphocyte subsets of the heterogeneous cell population. In some cases, at least 40% of the lymphocyte subsets may comprise Tcon. In some cases, up to 85% of the lymphocyte subsets may comprise Tcon. In some cases, 40%-50%, 40%-60%, 40%-65%, 40%-70%, 40%-75%, 40%-80%, 40%-85%, 50%-60%, 50%-65%, 50%-70%, 50%-75%, 50%-80%, 50%-85%, 60%-65%, 60%-70%, 60%-75%, 60%-80%, 60%-85%, 65%-70%, 65%-75%, 65%-80%, 65%-85%, 70%-75%, 70%-80%, 70%-85%, 75%-80%, 75%-85%, or 80%-85% of a lymphocyte subset may comprise Tcon. In some cases, 40%, 50%, 60%, 65%, 70%, 75%, 80%, or 85% of lymphocyte subsets may comprise Tcon. In some cases, at least 40%, 50%, 60%, 65%, 70%, 75%, or 80% of lymphocyte subsets may comprise Tcon. In some cases, up to 50%, 60%, 65%, 70%, 75%, 80%, or 85% of lymphocyte subsets may comprise Tcon.

[0327] In some embodiments, the CD3+ lymphocytes in the heterogeneous cell population may comprise CD4+ T cells. In some cases, 30% to 70% of the CD3+ lymphocyte subset may comprise CD4+ T cells. In some cases, at least 30% of the CD3+ lymphocyte subset may comprise CD4+ T cells. In some cases, up to 70% of the CD3+ lymphocyte subset may comprise CD4+ T cells. In some cases, 30% to 40%, 30% to 50%, 30% to 60%, 30% to 70%, 40% to 50%, 40% to 60%, 40% to 70%, 50% to 60%, 50% to 70%, or 60% to 70% of the CD3+ lymphocyte subset may comprise CD4+ T cells. In some cases, 30%, 40%, 50%, 60%, or 70% of the CD3+ lymphocyte subset may comprise CD4+ T cells. In some cases, at least 30%, 40%, 50%, or 60% of the CD3+ lymphocyte subset may comprise CD4+ T cells. In some cases, up to 40%, 50%, 60%, or 70% of the CD3+ lymphocyte subset may comprise CD4+ T cells.

[0328] In some embodiments, the CD3+ lymphocytes in the heterogeneous cell population may include CD8+ T cells. In some cases, 20% to 65% of the CD3+ lymphocyte subset may include CD8+ T cells. In some cases, at least 20% of the CD3+ lymphocyte subset may include CD8+ T cells. In some cases, up to 65% of the CD3+ lymphocyte subset may include CD8+ T cells. In some cases, 20% to 30%, 20% to 40%, 20% to 50%, 20% to 60%, 20% to 65%, 30% to 40%, 30% to 50%, 30% to 60%, 30% to 65%, 40% to 50%, 40% to 60%, 40% to 65%, 50% to 60%, 50% to 65%, or 60% to 65% of the CD3+ lymphocyte subset may comprise CD8+ T cells. In some cases, 20%, 30%, 40%, 50%, 60%, or 65% of the CD3+ lymphocyte subset may comprise CD8+ T cells. In some cases, at least 20%, 30%, 40%, 50%, or 60% of the CD3+ lymphocyte subset may comprise CD8+ T cells. In some cases, up to 30%, 40%, 50%, 60%, or 65% of the CD3+ lymphocyte subset may comprise CD8+ T cells.

[0329] In some embodiments, lymphocytes in the heterogeneous cell population may comprise B cells. In some cases, 4% to 35% of the lymphocyte subset may comprise B cells. In some cases, at least 4% of the lymphocyte subset may comprise B cells. In some cases, up to 35% of the lymphocyte subset may comprise B cells. In some cases, 4% to 5%, 4% to 10%, 4% to 20%, 4% to 30%, 4% to 35%, 5% to 10%, 5% to 20%, 5% to 30%, 5% to 35%, 10% to 20%, 10% to 30%, 10% to 35%, 20% to 30%, 20% to 35%, or 30% to 35% of the lymphocyte subset may comprise B cells. In some cases, 4%, 5%, 10%, 20%, 30%, or 35% of the lymphocyte subset may comprise B cells. In some cases, at least 4%, 5%, 10%, 20%, or 30% of the lymphocyte subset may comprise B cells. In some cases, up to 5%, 10%, 20%, 30%, or 35% of the lymphocyte subset may comprise B cells. B cells may be CD45+CD19+ or CD45+CD19+CD3- cells.

[0330] In some embodiments, lymphocytes in the heterogeneous cell population may comprise NK cells. In some cases, 4% to 35% of the lymphocyte subset may comprise NK cells. In some cases, at least 4% of the lymphocyte subset may comprise NK cells. In some cases, up to 35% of the lymphocyte subset may comprise NK cells. In some cases, 4% to 5%, 4% to 10%, 4% to 20%, 4% to 30%, 4% to 35%, 5% to 10%, 5% to 20%, 5% to 30%, 5% to 35%, 10% to 20%, 10% to 30%, 10% to 35%, 20% to 30%, 20% to 35%, or 30% to 35% of the lymphocyte subset may comprise NK cells. In some cases, 4%, 5%, 10%, 20%, 30%, or 35% of the lymphocyte subset may comprise NK cells. In some cases, at least 4%, 5%, 10%, 20%, or 30% of the lymphocyte subset may comprise NK cells. In some cases, up to 5%, 10%, 20%, 30%, or 35% of the lymphocyte subset may comprise NK cells. NK cells may be CD45+CD56+ or CD45+CD56+CD3- cells.

[0331] In some embodiments, the CD3+ lymphocytes in the heterogeneous cell population may comprise NK-T cells. In some cases, 3% to 30% of the CD3+ lymphocyte subset may comprise NK-T cells. In some cases, at least 4% of the CD3+ lymphocyte subset may comprise NK-T cells. In some cases, up to 35% of the CD3+ lymphocyte subset may comprise NK-T cells. In some cases, 3% to 5%, 3% to 10%, 3% to 20%, 3% to 30%, 5% to 10%, 5% to 20%, 5% to 30%, 10% to 20%, 10% to 30%, or 20% to 30% of the CD3+ lymphocyte subset may comprise NK-T cells. In some cases, 3%, 5%, 10%, 20%, or 30% of the CD3+ lymphocyte subset may comprise NK-T cells. In some cases, at least 3%, 5%, 10%, or 20% of the CD3+ lymphocyte subset may comprise NK-T cells. In some cases, up to 10%, 20%, or 30% of the CD3+ lymphocyte subset may comprise NK-T cells. NK-T cells may be CD45+ CD56+ or CD45+ CD56+ CD3+ cells.

[0332] In some embodiments, lymphocytes in a heterogeneous cell population may comprise CD34+ cells. In some cases, 0.1% to 2% of a lymphocyte subset may comprise CD34+ cells. In some cases, at least 0.1% of a lymphocyte subset may comprise CD34+ cells. In some cases, up to 2% of a lymphocyte subset may comprise CD34+ cells. In some cases, 0.1% to 0.5%, 0.1% to 1%, 0.1% to 1.5%, 0.1% to 2%, 0.5% to 1%, 0.5% to 1.5%, 0.5% to 2%, 1% to 1.5%, 1% to 2%, or 1.5% to 2% of a lymphocyte subset may comprise CD34+ cells. In some cases, 0.1%, 0.5%, 1%, 1.5%, or 2% of a lymphocyte subset may comprise CD34+ cells. In some cases, at least 0.1%, 0.5%, 1%, or 1.5% of the lymphocyte subset may comprise CD34+ cells, and in some cases, up to 0.5%, 1%, 1.5%, or 2% of the lymphocyte subset may comprise CD34+ cells. II. GVHD prophylaxis

[0333] Subjects administered a composition of the present disclosure (e.g., a cellular component including a cell population described herein) and a GVHD prophylactic agent (e.g., a single GVHD prophylactic agent) exhibit a low incidence of Grade 1 or higher aGVHD, e.g., a lower incidence of Grade 1 or higher aGVHD than subjects administered an alternative composition. The single GVHD prophylactic agent can be a calcineurin inhibitor such as tacrolimus or another agent that acts on the same target as tacrolimus or contains an active fragment of tacrolimus. In some embodiments, the low-dose GVHD prophylactic agent is tacrolimus with a target trough level of about 5 ng / mL to about 10 ng / mL. In some embodiments, the low-dose GVHD prophylactic agent is tacrolimus with a target trough level of about 4 ng / mL to about 6 ng / mL.

[0334] The single GVHD prophylactic agent can be sirolimus. In some embodiments, the low-dose GVHD prophylactic agent is sirolimus with a target trough level of about 3 ng / mL to about 8 ng / mL. In some embodiments, the low-dose GVHD prophylactic agent is sirolimus with a target trough level of about 4 ng / mL to about 8 ng / mL.

[0335] The disclosed methods for alloHCT utilize tacrolimus, which, when combined with one or more cell populations in the alloHCT regimens disclosed herein, has been shown to result in surprising improvements in clinical outcomes.

[0336] Embodiments provide a multi-component pharmaceutical treatment administered to a human subject in need thereof, the multi-component treatment comprising: (a) a solution comprising a first population of CD45+ cells, including hematopoietic stem progenitor cells (HSPCs) and granulocytes, wherein up to about 10% of the first population of CD45+ cells comprises granulocytes; (b) a solution comprising a population of cells enriched for regulatory T cells (Tregs); (c) a solution comprising a second population of CD45+ cells, wherein the second population of CD45+ cells comprises at least about 20% CD3+ conventional T cells (Tcon), at least about 10% monocytes, and at least about 10% granulocytes; and (d) one or more doses of a graft-versus-host disease (GVHD) prophylactic agent, wherein the GVHD prophylactic agent is tacrolimus.

[0337] In various embodiments, tacrolimus is administered in an amount to maintain a target blood level of at least about 3 ng / ml for at least about 20 days after administration of the second population of CD45+ cells, in an amount to maintain a target blood level of about 4 ng / ml or higher for at least about 40 days after administration of the second population of CD45+ cells, and / or in an amount to maintain a target blood level of about 4 ng / ml or higher for at least about 40 days after administration of the second population of CD45+ cells. In some cases, tacrolimus is administered in an amount to maintain a target blood level of up to about 10 ng / ml for at least 30 days after administration of the second population of CD45+ cells.

[0338] In some embodiments, tacrolimus is administered for at least about 60 days after administration of the second population of CD45+ cells, at least about 90 days after administration of the second population of CD45+ cells, up to about 150 days after administration of the second population of CD45+ cells, or up to about 120 days after administration of the second population of CD45+ cells.

[0339] In some embodiments, the tacrolimus is formulated for oral or intravenous administration.

[0340] In embodiments, the methods disclosed herein further include administering to the patient a single graft-versus-host disease (GVHD) prophylaxis (GVHDPA) comprising tacrolimus (tacrolimus GHVDPA) for a period of up to about 180 days, wherein the tacrolimus GHVDPA is administered to maintain a tacrolimus concentration in the patient's blood above a threshold level during the period; the risk and / or severity of GHVD is significantly reduced. In various embodiments, the threshold level is greater than about 4 ng of tacrolimus per ml of the patient's blood, or the threshold level is greater than about 5 ng of tacrolimus per ml of the patient's blood. In some embodiments, the tacrolimus GHVDPA is administered to maintain a tacrolimus concentration in the patient's blood below an upper threshold level during the period. In some cases, the upper threshold level is less than about 10 ng of tacrolimus per ml of the patient's blood.

[0341] In embodiments, the tacrolimus graft-versus-host disease (GVHD) prophylaxis (GVHDPA) is administered intravenously or orally. In various embodiments, administration of the tacrolimus graft-versus-host disease (GVHD) prophylaxis (GVHDPA) is initiated about 12 to about 24 hours after administration of Tcon. In some cases, the tacrolimus GHVDPA is administered for a period of up to about 90 days, and for a period of up to about 60 days. In some embodiments, the tacrolimus GHVDPA is initially administered to the patient at about 0.03 mg / kg of the patient's actual or ideal body weight per day. In some cases, the dose of tacrolimus GVHDPA administered to the patient is tapered beginning about 90 days after the first dose is administered to the patient, or is tapered beginning about 45 days after the first dose is administered to the patient.

[0342] Tacrolimus is a macrolide that can exhibit immunosuppressive activity in vivo and can prevent or reduce T-lymphocyte activation in response to antigen or mitogenic stimulation. Therefore, tacrolimus can be used to reduce the risk of GVHD in alloHCT recipient subjects. However, the methods disclosed herein utilizing tacrolimus as a single-agent prophylactic agent achieve superior clinical outcomes compared to those observed in other alloHCT methods utilizing tacrolimus GVHD prophylaxis. For example, in some embodiments, the disclosed alloHCT methods utilizing tacrolimus achieve superior relapse-free survival compared to standard treatment regimens including more potent GVHD prophylaxis with methotrexate and tacrolimus, and even compared to alloHCT methods utilizing a drug with a similar target and mechanism of action (sirolimus). Thus, although tacrolimus may be referred to herein as a GVHD prophylaxis, it may also contribute additional therapeutic benefits other than or not directly related to GVHD prophylaxis. Therefore, as used herein, the term "tacrolimus as a single-agent GVHD prophylactic agent" also includes "tacrolimus as a single-agent prophylactic agent for an additional therapeutic effect." In other words, the terms "tacrolimus as a single-agent prophylactic agent" and "tacrolimus as a single-agent GVHD prophylactic agent" are synonymous.

[0343] Treatment with tacrolimus as a single-agent prophylactic agent can, for example, result in reduced cytokine production and reduced T cell signaling. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity. This prevents or reduces the dephosphorylation and translocation of nuclear factor of activated T cells (NFAT), a nuclear component thought to initiate gene transcription for lymphokine expression. Tacrolimus also inhibits the transcription of genes encoding IL-3, IL-4, IL-5, GM-CSF, and TNF (all of which are involved in the early stages of T cell activation).

[0344] In some embodiments, tacrolimus as a single-agent prophylactic agent is administered orally to a subject. Absorption of tacrolimus from the gastrointestinal tract after oral administration can be incomplete and variable. The absolute bioavailability of tacrolimus in healthy subjects after oral administration can be 18±5%. The rate and extent of absorption can vary depending on whether tacrolimus is given with or without food. In some embodiments, tacrolimus is administered parenterally, for example, intravenously or subcutaneously. In some embodiments, tacrolimus is administered topically, intramuscularly, intradermally, intraperitoneally, intrathecally, or epidurally. Tacrolimus can be administered as an extended-release formulation. In some embodiments, tacrolimus is used as a free base. In some embodiments, tacrolimus is used as a pharmaceutically acceptable salt.

[0345] In some embodiments, the method of the present disclosure may allow the use of low-dose tacrolimus. In some embodiments, low-dose tacrolimus may improve donor T cell chimerism in subjects. In some embodiments, low-dose tacrolimus may improve the engraftment of alloHCT disclosed herein. In some embodiments, low-dose tacrolimus may reduce the incidence or relative risk of adverse effects that may be associated with high-dose tacrolimus, such as blurred vision, liver and kidney toxicity, seizures, tremors, hypertension, hypomagnesemia, diabetes mellitus, hyperkalemia, pruritus, insomnia, and confusion.

[0346] In some embodiments, as disclosed herein, tacrolimus is initially administered to a human subject at about 0.03 mg per kg of the human subject's actual or ideal body weight per day, or tacrolimus is initially administered about 12 hours to about 24 hours after said administration of said second population of CD45+ cells.

[0347] The circulating level of tacrolimus can be monitored, and the dose can be adjusted accordingly to achieve the target concentration.For example, the whole blood concentration of tacrolimus can be monitored, and the dose can be adjusted and administered to achieve the target trough level.The target trough level of tacrolimus can be, for example, less than about 25ng / mL, less than about 20ng / mL, less than about 15ng / mL, less than about 14ng / mL, less than about 13ng / mL, less than about 12ng / mL, less than about 11ng / mL, less than about 10ng / mL, less than about 9ng / mL, less than about 8ng / mL, less than about 7ng / mL, less than about 6ng / mL, less than about 5ng / mL, less than about 4ng / mL, less than about 3ng / mL, less than about 2ng / mL or less than about 1ng / mL.

[0348] In some embodiments, the target trough level of tacrolimus is about 1-25 ng / mL, about 1-20 ng / mL, about 1-15 ng / mL, about 1-12 ng / mL, about 1-11 ng / mL, about 1-10 ng / mL, about 1-9 ng / mL, about 1-8 ng / mL, about 1-7 ng / mL, about 1-6 ng / mL, about 1-5 ng / mL, about 1-4 ng / mL, about 1-3 ng / mL, about 1-2 ng / mL, about 2-25 ng / mL, about 2-20 ng / mL, about 2-15 ng / mL, about 2-12 ng / mL, about 2-11 ng / mL g / mL, about 2-10ng / mL, about 2-9ng / mL, about 2-8ng / mL, about 2-7ng / mL, about 2-6ng / mL, about 2-5ng / mL, about 2-4ng / mL, about 2-3ng / mL, about 3-25ng / mL, about 3-20ng / mL, about 3-1 5ng / mL, about 3-12ng / mL, about 3-11ng / mL, about 3-10ng / mL, about 3-9ng / mL, about 3-8ng / mL, about 3-7ng / mL, about 3-6ng / mL, about 3-5ng / mL, about 3-4ng / mL, about 4-25ng / mL, about 4~20ng / mL, approx. 4~15ng / mL, approx. 4~12ng / mL, approx. 4~11ng / mL, approx. 4~10ng / mL, approx. 4~9ng / mL, approx. 4~8ng / mL, approx. 4~7ng / mL, approx. 4~6ng / mL, approx. 4~5ng / mL, approx. 5~25ng / mL, approximately 5~20ng / mL, approximately 5~15ng / mL, approximately 5~12ng / mL, approximately 5~11ng / mL, approximately 5~10ng / mL, approximately 5~9ng / mL, approximately 5~8ng / mL, approximately 5~7ng / mL, approximately 5~6ng / mL, approximately 6~25g / mL, approximately 6~ 20ng / mL, about 6 to 15ng / mL, about 6 to 12ng / mL, about 6 to 11ng / mL, about 6 to 10ng / mL, about 6 to 9ng / mL, about 6 to 8ng / mL, about 6 to 7ng / mL, about 8 to 25ng / mL, about 8 to 20ng / mL, about 8 to 15ng / mL, about 8 to 12ng / mL, about 8 to 11ng / mL, about 8 to 10ng / mL, about 8 to 9ng / mL, about 10 to 25ng / mL, about 10 to 20ng / mL, about 10 to 15ng / mL, about 10 to 12ng / mL, or about 10 to 11ng / mL.

[0349] In some embodiments, the target trough level of tacrolimus is about 6 ng / mL to about 10 ng / mL. In some embodiments, the target trough level of tacrolimus is about 6 ng / mL to about 9 ng / mL. In some embodiments, the target trough level of tacrolimus is about 6 ng / mL to about 8 ng / mL. In some embodiments, the target trough level of tacrolimus is about 5 ng / mL to about 10 ng / mL. In some embodiments, the target trough level of tacrolimus is about 5 ng / mL to about 9 ng / mL. In some embodiments, the target trough level of tacrolimus is about 5 ng / mL to about 8 ng / mL. In some embodiments, the target trough level of tacrolimus is about 4 ng / mL to about 10 ng / mL. In some embodiments, the target trough level of tacrolimus is about 4 ng / mL to about 9 ng / mL. In some embodiments, the target trough level of tacrolimus is about 4 ng / mL to about 8 ng / mL.

[0350] In some embodiments, the dose of tacrolimus as a single agent prophylactic agent or the target trough level of tacrolimus can be adjusted based on the clinical parameters disclosed herein. For example, in some cases, a subject may experience lower than desired donor T cell chimerism, e.g., after a suitable time has elapsed after administration of a cell population of the present disclosure, e.g., about 14, 15, 20, 21, 25, 28, 30, 35, 40, 42, 45, 49, 50, 55, 56, 60, 63, 65, 70, 75, 77, 80, 84, 85 days after administration of a cell population of the present disclosure (e.g., a first population of CD45+ cells). The dose or target trough level of tacrolimus may be reduced if the subject exhibits a percent of CD3+ cells from the peripheral blood donor that is less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, or less than 45% when assessed after 90, 91, 95, 98, 100, 110, 120, 130, 140, 150, 160, 170, 180 days, or 1 year. In some embodiments, the target trough level of tacrolimus may be increased if the subject exhibits symptoms of GVHD as disclosed herein.

[0351] In some embodiments, the subject achieves at least about 80% chimerism at about day 30. In some embodiments, the subject achieves at least about 80% chimerism at about day 30 and has a target trough level of tacrolimus between about 6.5 ng / mL and about 9 ng / mL.

[0352] Administration of tacrolimus to a subject can begin before or after administration of a cell population disclosed herein (e.g., a first population of CD45+ cells). In some embodiments, administration of tacrolimus to a subject begins before administration of a cell population disclosed herein (e.g., a first population of CD45+ cells). In some embodiments, administration of tacrolimus to a subject begins after administration of a cell population disclosed herein (e.g., a first population of CD45+ cells). In some embodiments, administration of tacrolimus to a subject begins approximately simultaneously with administration of a cell population disclosed herein (e.g., a first population of CD45+ cells).

[0353] In some embodiments, administration of tacrolimus to a subject begins at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 10 days, at least 14 days, or at least 20 days before administration of a cell population disclosed herein (e.g., a population of CD45+ cells). In some embodiments, administration of tacrolimus to a subject begins up to 1 day, up to 2 days, up to 3 days, up to 4 days, up to 5 days, up to 6 days, up to 7 days, up to 10 days, up to 14 days, or up to 20 days before administration of a cell population disclosed herein (e.g., a population of CD45+ cells). In some embodiments, administration of tacrolimus to a subject begins 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, or 20 days before administration of a cell population disclosed herein (e.g., a population of CD45+ cells). In some embodiments, administration of tacrolimus to the subject begins one day before administration of the first population of CD45+ cells. In some embodiments, administration of tacrolimus to the subject begins one day before administration of the second population of CD45+ cells.

[0354] In embodiments, as disclosed herein, tacrolimus is initially administered to a human subject at about 0.03 mg per kg of the human subject's actual or ideal body weight per day, or tacrolimus is initially administered about 12 hours to about 24 hours after said administration of said second population of CD45+ cells.

[0355] In some embodiments, administration of tacrolimus to a subject begins at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 10 days, at least 14 days, or at least 20 days after administration of a cell population disclosed herein (e.g., a population of CD45+ cells). In some embodiments, administration of tacrolimus to a subject begins up to 1 day, up to 2 days, up to 3 days, up to 4 days, up to 5 days, up to 6 days, up to 7 days, up to 10 days, up to 14 days, or up to 20 days after administration of a cell population disclosed herein (e.g., a population of CD45+ cells). In some embodiments, administration of tacrolimus to a subject begins 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, or 20 days after administration of a cell population disclosed herein (e.g., a population of CD45+ cells). In some embodiments, administration of tacrolimus to the subject begins one day after administration of the population of CD45+ cells. In some embodiments, administration of tacrolimus to the subject begins one day after administration of the second population of CD45+ cells. In some embodiments, administration of tacrolimus to the subject begins on the same day that the cell population of the present disclosure is administered.

[0356] Tacrolimus can be administered to a subject any time after administration of a cell population (e.g., a population of CD45+ cells) of the present disclosure. In some embodiments, tacrolimus is administered to a subject for the first 7 days, 14 days, the first 20 days, 30 days, 40 days, 50 days, 60 days, 70 days, 80 days, 90 days, 100 days, 110 days, 120 days, 150 days, 200 days, 365 days, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 2 years, 2.5 years, 3 years, 3.5 years, 4 years, 4.5 years, or 5 years after administration of a cell population (e.g., a population of CD45+ cells) of the present disclosure.

[0357] In some embodiments, tacrolimus is administered to the subject less than about 20 days, less than about 30 days, less than about 40 days, less than about 50 days, less than about 60 days, less than about 70 days, less than about 80 days, less than about 90 days, less than about 100 days, less than about 110 days, less than about 120 days, less than about 150 days, less than about 200 days, less than about 365 days, less than about 13 months, less than about 14 months, less than about 15 months, less than about 16 months, less than about 17 months, less than about 18 months, less than about 19 months, less than about 20 months, less than about 21 months, less than about 22 months, less than about 23 months, less than about 2 years, less than about 2.5 years, less than about 3 years, less than about 3.5 years, less than about 4 years, less than about 4.5 years, or less than about 5 years after administration of a cell population of the present disclosure (e.g., a population of CD45+ cells).

[0358] In various embodiments, the dose of tacrolimus is tapered beginning about 90 days after the first dose is administered to the human subject, or the dose of tacrolimus is tapered beginning about 45 days after the first dose is administered to the human subject.

[0359] In some embodiments, the subject achieves at least about 80% chimerism at about day 30. In some embodiments, the subject achieves at least about 80% chimerism at about day 30 and has target trough levels of about 6.5 ng / mL and about 9 ng / mL. III. Subject

[0360] Provided herein is a composition for administration to a recipient subject with cancer, and a method for administering the composition.The composition and method can be useful for treating or reducing cancer in a subject.In some embodiments, a second population of CD45+ cells comprising at least Tcon is administered to a subject to induce the immune response of graft-versus-tumor reaction (GVT), and is accompanied by the reduction of graft-versus-host disease (GVHD).

[0361] In some embodiments, the subject is at least 13 years old, at least 14 years old, at least 15 years old, at least 16 years old, at least 17 years old, at least 18 years old, at least 19 years old, at least 20 years old, at least 21 years old, at least 22 years old, at least 23 years old, at least 24 years old, or at least 25 years old. In some embodiments, the subject is at least 18 years old. In some embodiments, the subject is at least 16 years old. In some embodiments, the subject is at least 13 years old.

[0362] In some embodiments, the subject is up to 50 years old, up to 55 years old, up to 60 years old, up to 65 years old, up to 70 years old, up to 75 years old, or up to 80 years old. In some embodiments, the subject is up to 65 years old. In some embodiments, the subject is up to 70 years old. A. Conditions

[0363] Another embodiment provides a method of treating a human subject diagnosed with a hematological malignancy. The method includes administering to the human subject a solution comprising a first population of CD45+ cells, a solution comprising a population of cells enriched for regulatory T cells (Tregs), a solution comprising a second population of CD45+ cells, and one or more doses of a GVHD prophylactic agent (e.g., tacrolimus). In this embodiment, the solution comprising the first population of CD45+ cells, the solution comprising the population of cells enriched for regulatory Tregs, the solution comprising the second population of CD45+ cells, and the solution comprising one or more doses of a GVHD prophylactic agent are as defined according to any of the multi-component pharmaceutical treatments disclosed herein.

[0364] A further embodiment provides a method for transplanting a population of conventional T cells (Tcon) as part of a treatment regimen for a hematological malignancy, the method reducing the risk and / or severity of adverse events associated with the treatment regimen. The method comprises administering to a patient a population of regulatory T cells (Tregs) comprising Tregs and a liquid suspending the Tregs; and administering to the patient a heterogeneous cell population comprising lymphocytes, granulocytes, monocytes, and a liquid suspending the cells. In this embodiment, at least about 30% of the lymphocytes comprise Tcon, and after administration of the cell population, the patient has a reduced risk and / or severity of adverse events compared to a patient with a hematological malignancy who received Tcon but not Tregs.

[0365] A still further embodiment provides a method for transplanting a cell population into a human patient as part of a treatment regimen for a hematological malignancy, the method reducing the risk and / or severity of adverse events associated with the treatment regimen. The method includes the steps of: providing a population of hematopoietic stem progenitor cells (HSPCs) for administration to the patient, wherein the population of HSPCs comprises HSPCs and a liquid suspending the HSPCs; providing a population of regulatory T cells (Tregs) for administration to the patient, wherein the population of Tregs comprises Tregs and a liquid suspending the Tregs; and providing a heterogeneous cell population for administration to the patient, wherein the heterogeneous cell population comprises lymphocytes, granulocytes, monocytes, and a liquid suspending the cells. In this embodiment, at least about 30% of the lymphocytes comprise conventional T cells (Tcon), and following administration of the cell population, the patient has a reduced risk and / or severity of adverse events compared to a patient with a hematological malignancy who received the Tcon cell population but not the T-reg cell population.

[0366] Another aspect provides a method for transplanting a cell population into a human patient as part of a treatment regimen for a hematological malignancy, the method comprising the steps of: administering to the patient a population of hematopoietic stem progenitor cells (HSPCs), the population of HSPCs comprising the HSPCs and a liquid suspending the HSPCs; administering to the patient a population of regulatory T cells (Tregs), the population of Tregs comprising the Tregs and a liquid suspending the Tregs, administered to the patient; and administering to the patient a heterogeneous cell population, the heterogeneous cell population comprising lymphocytes, granulocytes, monocytes and a liquid suspending the cells, administered to the patient, wherein at least about 3% of the lymphocytes are erythrocytes. 0% comprise conventional T cells (Tcon); and administering to the patient a single graft-versus-host disease (GVHD) prophylaxis (GVHDPA) comprising tacrolimus (tacrolimus GHVDPA) for a period of up to about 180 days, wherein the tacrolimus GHVDPA is administered to maintain a tacrolimus concentration in the patient's blood above a threshold level during the period, thereby significantly reducing the risk and / or severity of GHVD associated with a treatment regimen for a hematologic malignancy.

[0367] The methods of the present disclosure can be used to treat a subject (e.g., a human subject) with cancer. In some embodiments, the subject has received treatment for cancer, for example, by treatment with a chemotherapy drug or radiation. The methods of the present disclosure can be useful for treating hematological malignancies, such as leukemia or lymphoma. Examples of hematological malignancies that can be treated by the methods of the present disclosure include, but are not limited to, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), multiple myeloma, and lymphomas such as Hodgkin's and non-Hodgkin's lymphoma. The cancer can be a solid tumor. In some embodiments, the cancer is a primary or metastatic tumor.

[0368] The types of cancer that can be treated using the methods of the present invention include, but are not limited to, leukemia, lymphoma, adrenocortical carcinoma, anal cancer, aplastic anemia, bile duct cancer, bladder cancer, bone cancer, bone metastasis, brain cancer, central nervous system (CNS) cancer, peripheral nervous system (PNS) cancer, breast cancer, cervical cancer, childhood non-Hodgkin's lymphoma, colorectal cancer, endometrial cancer, esophageal cancer, Ewing's family of tumors, tumors) (e.g., Ewing's sarcoma), eye cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gestational trophoblastic disease, hairy cell leukemia, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal and pharyngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, childhood leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, liver cancer, lung cancer, pulmonary carcinoid tumors, male breast cancer, malignant mesothelioma, multiple myeloma, myelodysplastic syndromes, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, upper respiratory tract cancer, and pancreatic cancer. These include pharyngeal cancer, neuroblastoma, oral cavity and pharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, melanoma skin cancer, non-melanoma skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, uterine cancer (e.g., uterine sarcoma), transitional cell carcinoma, vaginal cancer, vulvar cancer, mesothelioma, squamous cell or epidermoid carcinoma, bronchial adenoma, choriocarcinoma, head and neck cancer, teratocarcinoma, and Waldenstrom's macroglobulinemia.

[0369] Patients with high-risk hematologic malignancies, such as leukemia or lymphoma that has progressed after initial remission or that has undergone a refractory relapse, are rarely cured with standard chemotherapy.

[0370] In some embodiments, the human subject or patient has been previously treated or is concurrently treated for a hematological malignancy.

[0371] Subjects receiving the compositions of the present disclosure may have, for example, acute myeloid leukemia, acute lymphocytic leukemia, mixed phenotype leukemia, myelofibrosis, high-risk myelodysplastic syndrome, very-high-risk myelodysplastic syndrome, myelofibrosis (MF) eligible for transplant according to the National Comprehensive Cancer Network Guidelines, intermediate-2 or high-risk MF according to the IPSS, DIPSS, or DIPSS-plus scoring systems, intermediate-1 risk MF with high-risk features such as high symptom burden, low platelet count, or complex cytogenetics, primary myelofibrosis, myelofibrosis evolving from another myeloproliferative neoplasm, myelodysplastic syndrome, non-Hodgkin's lymphoma, or a non-malignant indication for allogeneic hematopoietic stem cell transplantation (alloHCT).

[0372] In some embodiments, the subject has acute myeloid leukemia. In some embodiments, the subject has acute lymphocytic leukemia. In some embodiments, the subject has mixed phenotype leukemia. In some embodiments, the subject has high-risk myelodysplastic syndrome. In some embodiments, the subject has very high-risk myelodysplastic syndrome. In some embodiments, the subject has transplant-eligible myelofibrosis (MF) according to the National Comprehensive Cancer Network Guidelines. In some embodiments, the subject has intermediate-2 or high-risk myelofibrosis according to the IPSS, DIPSS, or DIPSS-plus scoring system. In some embodiments, the subject has intermediate-1 risk myelofibrosis with high-risk features such as high symptom burden, low platelet count, or complex cytogenetics. In some embodiments, the subject has primary myelofibrosis. In some embodiments, the subject has myelofibrosis. In some embodiments, the subject has myelofibrosis that has evolved from another myeloproliferative neoplasm. In some embodiments, the subject has myelodysplastic syndrome. In some embodiments, the subject has non-Hodgkin's lymphoma. In some embodiments, the subject has a non-malignant indication for alloHCT.

[0373] The subject may be in complete remission (CR). The subject may be in complete remission with incomplete hematologic recovery (CRi), e.g., in the absence of known minimal residual disease. The subject may have minimal residual disease. The subject may have no evidence of minimal residual disease. The subject may have active disease. The subject may have leukemia (e.g., acute myeloid, acute lymphoid, or mixed phenotype) that is not in morphologic CR with 10% or less bone marrow infiltration by leukemic blasts. The subject may have leukemia (e.g., acute myeloid, acute lymphoid, or mixed phenotype) that is in morphologic CR with evidence of minimal residual positivity by either multiparameter flow cytometry analysis or nucleic acid-based techniques.

[0374] Complete remission (CR) for acute myeloid, lymphoid, or mixed phenotype leukemia can be demonstrated by fulfilling all of the following criteria: (i) bone marrow blasts <5%; (ii) absence of circulating blasts and blasts with Auer rods; (ii) absence of extramedullary disease. ANC ≥ 1.0 × 10 9 / L(1,000 / μL); (iii) Platelet count ≧100×10 9 / L (100,000 / μL); and (iv) red blood cell transfusion independence. A complete response with incomplete hematologic recovery (CRi) was defined as a reduction in neutropenia (<1.0 × 10 9 / L) or thrombocytopenia (<100 × 10 9 This can be demonstrated by meeting all CR criteria except for persistence of CR (1 / L). B. Sensitivity

[0375] In some embodiments, the subject does not have a known allergy or hypersensitivity to, or intolerance to, tacrolimus. In some embodiments, the subject does not have a known allergy or hypersensitivity to, or intolerance to, sirolimus.

[0376] In some embodiments, the subject is not sensitive to iron dextran (e.g., a subject with a sensitivity to iron dextran is not eligible to receive the compositions of the present disclosure. In some cases, this may be due to the magnetic beads used in some embodiments to isolate, deplete, and / or purify cell types).

[0377] In some embodiments, the subject is not sensitive to products derived from cyanine dyes (e.g., subjects with sensitivity to products derived from cyanine dyes are not eligible to receive the compositions of the present disclosure).

[0378] In some embodiments, the subject is not sensitive to protein products derived from murine sources (e.g., a subject with a sensitivity to protein products derived from murine sources is not eligible to receive a composition of the present disclosure).

[0379] In some embodiments, the subject is not sensitive to protein products derived from bovine sources (e.g., a subject with a sensitivity to protein products derived from bovine sources is not eligible to receive a composition of the present disclosure).

[0380] In some embodiments, the subject is not sensitive to protein products derived from algal sources (e.g., a subject with a sensitivity to protein products derived from algal sources is not eligible to receive the compositions of the present disclosure).

[0381] In some embodiments, the subject is not sensitive to a protein product derived from Streptomyces avidinii (e.g., a subject with sensitivity to a protein product derived from Streptomyces avidinii is not eligible to receive a composition of the present disclosure). C. Organ Function and Biomarkers

[0382] The subject may have an estimated glomerular filtration rate (eGFR) > 30 mL / min. The subject may have an estimated glomerular filtration rate (eGFR) > 40 mL / min. The subject may have an eGFR > 50 mL / min. The subject may have an estimated glomerular filtration rate (eGFR) > 60 mL / min.

[0383] Subjects may have a resting cardiac ejection fraction of 45% or greater by echocardiogram or radionuclide scan (MUGA), or a fractional shortening of 27% or greater.

[0384] The subject may have a diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) of 50% or greater.

[0385] Subjects may have a negative serum or urine beta-HCG test within three weeks of enrollment, for example in women of childbearing potential.

[0386] The subject may have a total bilirubin less than two times the upper limit of normal (ULN).

[0387] The subject may have Gilbert's syndrome with hemolysis excluded.

[0388] The subject may have an ALT reading within 3 times the upper limit of normal (ULN). The subject may have an AST reading within 3 times the upper limit of normal (ULN). D. Additional Treatments and Other Target Characteristics

[0389] In some embodiments, the subject has not undergone a prior allo-HCT. In some embodiments, the subject is not a candidate for autologous transplant. In some embodiments, the subject is not receiving corticosteroids or other immunosuppressive therapy. In some embodiments, the subject is receiving topical or oral systemic corticosteroid doses less than or equal to 10 mg / day. In some embodiments, the subject is not receiving donor lymphocyte infusion (DLI). In some embodiments, the subject is not receiving a T cell depleting medication, such as post-transplant cyclophosphamide (Cy), peri-transplant antithymocyte globulin (ATG), or alemtuzumab. In some embodiments, subjects previously exposed to a T cell depleting agent have a 5 half-life washout of the agent prior to day 0 of the planned transplant (the day of infusion of the Treg and HSPC components of the graft). In some embodiments, the subject is not positive for anti-donor HLA antibodies against mismatched alleles in the selected donor, as determined by either (a) a positive crossmatch test of any titer; or (b) the presence of anti-donor HLA antibodies against any HLA locus. In some embodiments, the subject has a Karnofsky Performance Score of ≥ 70%. In some embodiments, the subject does not have a hematopoietic cell transplantation-specific comorbidity index (HCT-CI) of > 4. In some embodiments, the subject does not have an uncontrolled bacterial, viral, or fungal infection. In some embodiments, the subject is not taking antimicrobial therapy and has progression in the infection or no clinical improvement. In some embodiments, the subject is not seropositive for HIV-1 or -2, HTLV-1 or -2, hepatitis B sAg, or hepatitis C antibodies. In some embodiments, the subject does not have an uncontrolled autoimmune disease requiring active immunosuppressive treatment. In some embodiments, the subject has not had a concurrent malignancy or active disease within one year, excluding, for example, curatively excised non-melanoma skin cancer. In some embodiments, the subject does not exhibit psychosocial circumstances that prevent the patient from proceeding to transplant or being able to responsibly participate in follow-up care. In some embodiments, the subject is not pregnant or breastfeeding.In some embodiments, the subject does not have a serious medical condition or abnormality in clinical laboratory tests that, in the judgment of a medical professional, would prevent the subject from receiving the composition of the present disclosure. In some embodiments, the subject is eligible for myeloablative allo-HCT.

[0390] In some embodiments, the subject receives prophylactic agents to reduce the risk of bacterial, fungal and / or viral infection, for example, during the peri-transplant period.

[0391] In some embodiments, the subject receives supportive care for HCT-associated toxicity. In some embodiments, the subject does not receive supportive care for HCT-associated toxicity. In some embodiments, the subject receives a growth factor. In some embodiments, the subject does not receive a growth factor. In some embodiments, the subject receives intravenous immune globulin. In some embodiments, the subject does not receive intravenous immune globulin. In some embodiments, the subject receives an analgesic. In some embodiments, the subject does not receive an analgesic. In some embodiments, the subject receives an antiemetic. In some embodiments, the subject does not receive an antiemetic. In some embodiments, the subject receives electrolyte supplementation. In some embodiments, the subject does not receive electrolyte supplementation. In some embodiments, the subject receives a tyrosine kinase inhibitor (e.g., an FLT3 inhibitor). In some embodiments, the subject does not receive a tyrosine kinase inhibitor (e.g., an FLT3 inhibitor). In some embodiments, the subject receives prednisone or its equivalent, e.g., at a dose of ≦10 mg / day. In some embodiments, the subject does not receive prednisone or its equivalent. In some embodiments, the subject receives corticosteroid treatment to manage GVHD. In some embodiments, the subject does not receive corticosteroid treatment to manage GVHD. In some embodiments, the subject receives high-dose corticosteroid treatment to manage GVHD. In some embodiments, the subject does not receive high-dose corticosteroid treatment to manage GVHD. In some embodiments, the subject receives corticosteroid treatment to manage adrenal insufficiency, hypersensitivity reactions, or other non-cancer-related conditions, including premedication for known hypersensitivity reactions for contrast on the scan. In some embodiments, the subject does not receive corticosteroid treatment. In some embodiments, the subject receives immunosuppressive medication. In some embodiments, the subject does not receive immunosuppressive medication. In some embodiments, the subject receives donor lymphocyte infusion. In some embodiments, the subject does not receive donor lymphocyte infusion. E. Conditioning Regimen

[0392] Conditioning regimens can be used as part of the allo-HCT regimen of the present disclosure. Chemotherapy and / or irradiation administered immediately prior to transplantation is referred to as a conditioning regimen. The conditioning regimen can help eradicate the patient's disease before infusion of HSPCs, suppress the immune response, and allow donor HSPCs to reconstitute the empty hematopoietic compartment resulting from the conditioning regimen. In some embodiments of the methods of the present disclosure, the subject can be treated with myeloablative conditioning before infusion of the cell populations described herein. In some embodiments of the methods of the present disclosure, the subject can be treated with myeloreductive conditioning before infusion of the cell populations described herein. In some embodiments of the methods of the present disclosure, the subject can be treated with reduced-intensity myeloablative conditioning before infusion of the cell populations described herein. In some embodiments of the methods of the present disclosure, the subject can be treated with non-myeloablative conditioning before administration of the cell population(s) described herein.

[0393] As used herein, the term conditioning regimen and similar terms apply to myeloablative conditioning, myeloreductive conditioning, reduced-intensity myeloablative treatment / conditioning, and / or non-myeloablative conditioning. As used herein, the term myeloablative treatment / conditioning also includes myeloreductive conditioning and reduced-intensity myeloablative conditioning.

[0394] In aspects and embodiments, the treatment and / or method further comprises a conditioning regimen administered prior to administration of one of: (a) a solution comprising a first population of CD45+ cells comprising hematopoietic stem progenitor cells (HSPCs) and granulocytes, wherein up to about 10% of the first population of CD45+ cells comprises granulocytes; (b) a solution comprising a population of cells enriched for regulatory T cells (Tregs); and (c) a solution comprising a second population of CD45+ cells, wherein the second population of CD45+ cells comprises at least about 20% CD3+ conventional T cells (Tcon), at least about 10% monocytes, and at least about 10% granulocytes; and (d) one or more doses of a solution comprising a graft-versus-host disease (GVHD) prophylactic agent. In embodiments, the conditioning regimen is a myeloablative conditioning regimen. In some instances, the conditioning regimen includes at least three conditioning reagents, of which at least one conditioning reagent is thiotepa. In various embodiments, the myeloablative conditioning regimen includes at least one dose of thiotepa, e.g., at least about 5 milligrams of thiotepa per kilogram of actual or ideal body weight of the human subject, or at least about 10 milligrams of thiotepa per kilogram of actual or ideal body weight of the human subject. In some embodiments, the conditioning regimen includes one or more doses of busulfan, fludarabine, and thiotepa. In embodiments, the one or more doses include about 5 to about 12 mg of thiotepa per kilogram of actual or ideal body weight of the human subject, about 7 to about 11 mg of busulfan per kilogram of actual or ideal body weight of the human subject, and about 10 to about 12 mg of thiotepa per kilogram of actual or ideal body weight of the human subject, respectively. 2 Each tablet contains approximately 100 to 200 mg of fludarabine.

[0395] In various embodiments, the method further comprises administering a myeloablative conditioning regimen to the patient prior to administration of either cell population, the conditioning regimen comprising administration of at least one conditioning agent to the patient.

[0396] In some embodiments, the patient does not receive any irradiation as part of the myeloablative conditioning regimen.

[0397] In embodiments, the at least one conditioning agent is administered about 2 to about 10 days prior to administration of any of the cell populations, hi some instances, the at least one conditioning agent is administered about 5 days prior to administration of any of the cell populations.

[0398] In various embodiments, the human subject undergoes a myeloablative conditioning regimen prior to administration of either cell population, and the adverse event is associated with the myeloablative conditioning.

[0399] In some embodiments, the at least one conditioning agent comprises thiotepa. In some cases, the dose of thiotepa administered to a patient is in the range of about 5 to about 10 mg per kilogram of actual or ideal body weight.

[0400] In embodiments, the at least one conditioning agent comprises busulfan and fludarabine. In some cases, the doses of thiotepa, busulfan, and fludarabine administered to a patient are about 10 mg per kilogram of the patient's actual or ideal body weight, about 9.6 mg per kilogram of the patient's actual or ideal body weight, and about 10 mg per square meter of body surface area, respectively. 2 Contains approximately 150 mg per serving.

[0401] In some embodiments, the subject has been conditioned with radiation, chemotherapy, recombinant protein, antibody or toxin-conjugated antibody, or any combination thereof, prior to administration of the cell population(s) described herein. In some embodiments, the subject is conditioned for cell transplantation therapy by first treating the subject with a myeloablative therapy. Exemplary myeloablative therapies include chemotherapy or radiation therapy. Myeloablative therapy is believed to provide therapeutic benefit by debulking tumors and / or reducing the number of cancer cells. Myeloablative regimens eradicate sufficient numbers of HSCs that patients would otherwise have an increased chance of developing GVHD. When HSPCs are subsequently administered to the myeloablative subject, the donor cells can further attack cancer and / or reconstitute the subject's blood and immune system.

[0402] In some embodiments, the myeloablative therapy comprises administration of thiotepa (TTP), busulfan, cyclophosphamide, total body irradiation (TBI), fludarabine, etoposide, or any combination thereof. In some embodiments, the myeloablative therapy comprises administration of an anti-cKIT antibody. In some embodiments, the myeloablative therapy comprises administration of an antibody-drug conjugate. The antibody-drug conjugate may be, for example, an anti-CD45-saporin or anti-cKit-saporin therapeutic antibody. In some embodiments, the myeloablative therapy is reduced-intensity conditioning therapy. Exemplary conditioning regimens are listed in Table 15.

[0403] The conditioning regimen of the present disclosure may include one or more doses of busulfan. The conditioning regimen of the present disclosure may include fludarabine. The conditioning regimen of the present disclosure may include one or more doses of cyclophosphamide. The conditioning regimen of the present disclosure may include one or more doses of melphalan. The conditioning regimen of the present disclosure may include one or more doses of etoposide.

[0404] The methods of the present disclosure can include administering a combination of conditioning reagents prior to administering cells. The conditioning regimens described herein can include administering one, two, three, or four different conditioning reagents. As used herein, a conditioning reagent can be an alkylating agent. As used herein, a conditioning reagent can be myeloablative. As used herein, a conditioning reagent can be non-myeloablative. As used herein, a conditioning reagent can be myeloreducing. As used herein, a conditioning reagent can be a form of chemotherapy.

[0405] The conditioning regimens described herein can include the administration of an alkylating agent such as thiotepa (TTP). Conditioning regimens of the present disclosure that include TTP can also include at least one other conditioning agent. The conditioning agent administered to the subject in addition to TTP can include one or more agents selected from busulfan, dimethylmyleran, prednisone, methylprednisolone, azathioprine, cyclophosphamide, cyclosparine, monoclonal antibodies against T cells, antilymphocyte globulin and antithymocyte globulin, fludarabine, etoposide, radiation, and total body irradiation (TBI). Aspects and embodiments include any combination of one or more conditioning agents with TTP. In some embodiments, a subject is administered a conditioning regimen that includes thiotepa, busulfan, and fludarabine. In some embodiments, a subject is administered a conditioning regimen that includes thiotepa, fludarabine, and TBI (e.g., HFTBI).

[0406] The conditioning regimens described herein can include administration of an alkylating agent, such as TTP. In some cases, the conditioning regimens of the present disclosure can include administration of TTP for more than one day. The conditioning regimens of the present disclosure can include administering 2 mg / kg to 14 mg / kg of TTP to a subject. The conditioning regimens of the present disclosure can include administering at least 3 mg / kg of TTP to a subject. The conditioning regimens of the present disclosure can include administering up to 14 mg / kg of TTP to a subject. The conditioning regimens of the present disclosure include 2mg / kg to 5mg / kg, 2mg / kg to 6mg / kg, 2mg / kg to 8mg / kg, 2mg / kg to 10mg / kg, 2mg / kg to 12mg / kg, 2mg / kg to 14mg / kg, 5mg / kg to 6mg / kg, 5mg / kg to 8mg / kg, 5mg / kg to 10mg / kg, 5mg / kg to 12mg / kg, 5mg / kg to 14mg / kg, The conditioning regimen of the present disclosure can include administering to the subject 6 mg / kg to 8 mg / kg, 6 mg / kg to 10 mg / kg, 6 mg / kg to 12 mg / kg, 6 mg / kg to 14 mg / kg, 8 mg / kg to 10 mg / kg, 8 mg / kg to 12 mg / kg, 8 mg / kg to 14 mg / kg, 10 mg / kg to 12 mg / kg, 10 mg / kg to 14 mg / kg, or 12 mg / kg to 14 mg / kg of TTP. The conditioning regimen of the present disclosure can include administering to the subject 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 8 mg / kg, 10 mg / kg, 12 mg / kg, or 14 mg / kg of TTP. The conditioning regimen of the present disclosure can include administering up to 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 8 mg / kg, 10 mg / kg, or 12 mg / kg of TTP to a subject.The conditioning regimen of the present disclosure can include administering at least 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 8 mg / kg, 10 mg / kg, 12 mg / kg, or 14 mg / kg of TTP to a subject.

[0407] As used herein, the recited doses, e.g., #mg / kg, may be relative to the subject's actual body weight (in kg) or relative to the subject's ideal body weight (in kg). Alternatively, if the subject's actual body weight is greater than 120% of their ideal body weight (IBW), the recited doses may be relative to the subject's adjusted body weight (ABW).

[0408] A subject receiving one or more cell populations described herein may be administered one or more doses of TTP prior to cell transplantation. A subject receiving one or more cell populations described herein may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses of TTP prior to cell transplantation. In some cases, each dose of TTP has the same concentration. In some cases, one or more doses of TTP have different concentrations. A subject may be administered 1 mg / kg to 10 mg / kg of TTP in a single dose. A subject may be administered at least 1 mg / kg of TTP in a single dose. A subject may be administered up to 10 mg / kg of TTP in a single dose. Subjects were randomly assigned to receive a single dose of 1mg / kg to 2mg / kg, 1mg / kg to 3mg / kg, 1mg / kg to 4mg / kg, 1mg / kg to 5mg / kg, 1mg / kg to 6mg / kg, 1mg / kg to 7mg / kg, 1mg / kg to 8mg / kg, 1mg / kg to 9mg / kg, 1mg / kg to 10mg / kg, 2mg / kg to 3mg / kg, 2mg / kg to 4mg / kg, 2mg / kg to 5mg / kg, 2mg / kg to 6mg / kg, 2mg / kg to 7mg / kg, 2mg / kg to 8mg / kg, 2mg / kg to 9mg / kg, 2mg / kg to 10mg / kg, 3mg / kg to 4mg / kg, 3mg / kg to 5mg / kg, 3mg / kg to 6mg / kg, 3mg / kg to 7mg / kg, 3mg / kg to 8mg / kg, 3mg / kg to 9mg / kg, 3mg / kg to 10mg / kg, 4mg / kg to 5mg / kg, 4mg / kg to 6mg / kg, 4mg / kg to 7mg / kg, 4mg / kg to 8mg / kg, 4mg / kg to 9mg / kg, 4mg / kg to 10mg / kg, 5mg / kg to 6mg / kg, 5mg / kg to 7mg / kg, 5mg / kg to 8mg / kg, 5mg / kg to 9mg / kg, 5mg / kg to 10mg / kg, 6mg / kg to 7mg / kg, 6mg / kg to 8mg / kg, 6mg / kg to 9mg / kg, 6mg / kg to 10mg / kg, 7mg / kg to 8mg / kg, 7mg / kg to 9mg / kg, 7mg / kg to 10mg / kg, 8mg / kg to 9mg / kg, 8mg / kg to 10mg / kg, or 9mg / kg to 10mg / kg of TTP.A subject may be administered 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg of TTP in a single dose. A subject may be administered up to 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg of TTP in a single dose. A subject may be administered at least 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg of TTP in a single dose.

[0409] The methods of the present disclosure can include administering a combination of conditioning reagents prior to administering cells. The conditioning regimens described herein can include administering one, two, three, or four different conditioning reagents. As used herein, a conditioning reagent can be an alkylating agent. As used herein, a conditioning reagent can be myeloablative. As used herein, a conditioning reagent can be non-myeloablative. As used herein, a conditioning reagent can be myeloreducing. As used herein, a conditioning reagent can be a form of chemotherapy.

[0410] The conditioning regimen of the present disclosure can include one or more doses of busulfan. The one or more doses of busulfan can be administered to a subject before administration of one or more doses of another conditioning reagent, such as TTP. The one or more doses of busulfan can be administered to a subject after administration of one or more doses of another conditioning reagent, such as TTP. The one or more doses of busulfan can be administered to a subject together with administration of one or more doses of another conditioning reagent, such as TTP.

[0411] The conditioning regimen of the present disclosure can include administering about 6 mg / kg to about 12 mg / kg of busulfan to a subject. The conditioning regimen of the present disclosure can include administering at least about 6 mg / kg of busulfan to a subject. The conditioning regimen of the present disclosure can include administering up to about 12 mg / kg of busulfan to a subject. The conditioning regimen of the present disclosure can include administering about 6 mg / kg to about 7 mg / kg, about 6 mg / kg to about 8 mg / kg, about 6 mg / kg to about 9 mg / kg, about 6 mg / kg to about 10 mg / kg, about 6 mg / kg to about 11 mg / kg, about 6 mg / kg to about 12 mg / kg, about 7 mg / kg to about 8 mg / kg, about 7 mg / kg to about 9 mg / kg, about 7 mg / kg to about 10 mg / kg, about 7 mg / kg to about 11 mg / kg, about 7 mg / kg to about 12 mg / kg, The conditioning regimen of the present disclosure may include administering to the subject about 8 mg / kg to about 9 mg / kg, about 8 mg / kg to about 10 mg / kg, about 8 mg / kg to about 11 mg / kg, about 8 mg / kg to about 12 mg / kg, about 9 mg / kg to about 10 mg / kg, about 9 mg / kg to about 11 mg / kg, about 9 mg / kg to about 12 mg / kg, about 10 mg / kg to about 11 mg / kg, about 10 mg / kg to about 12 mg / kg, or about 11 mg / kg to about 12 mg / kg of busulfan. The conditioning regimen of the present disclosure may include administering to the subject 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, or 12 mg / kg of busulfan. The conditioning regimens of the present disclosure can include administering at least 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, or 11 mg / kg of busulfan to the subject. The conditioning regimens of the present disclosure can include administering at most 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, or 12 mg / kg of busulfan to the subject.

[0412] Subjects receiving one or more cell populations described herein may be administered one or more doses of busulfan prior to cell transplantation. Subjects receiving one or more cellular components described herein may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses of busulfan prior to cell transplantation. In some cases, each dose of busulfan has the same concentration. In some cases, one or more doses of busulfan have different concentrations. Subjects may be administered 1 mg / kg to 10 mg / kg of busulfan in a single dose. Subjects may be administered at least 1 mg / kg of busulfan in a single dose. Subjects may be administered at least 2 mg / kg of busulfan in a single dose. Subjects may be administered at least 3 mg / kg of busulfan in a single dose.

[0413] The conditioning regimen of the present disclosure can include one or more doses of fludarabine.One or more doses of fludarabine can be administered to a subject before the administration of one or more doses of another conditioning reagent, such as TTP.One or more doses of fludarabine can be administered to a subject after the administration of one or more doses of another conditioning reagent, such as TTP.One or more doses of fludarabine can be administered to a subject together with the administration of one or more doses of another conditioning reagent, such as TTP.

[0414] The conditioning regimen of the present disclosure is based on the surface area of ​​the subject and is administered at a dose of 20 mg / m 2 ~180mg / m 2 The conditioning regimen of the present disclosure may include administering to the subject at least 20 mg / m of fludarabine. 2 The conditioning regimen of the present disclosure may include administering to the subject up to 180 mg / m of fludarabine. 2 The conditioning regimen of the present disclosure can include administering to the subject 20 mg / m of fludarabine. 2 ~30mg / m 2、20mg / m 2 ~40mg / m 2 、20mg / m 2 ~50mg / m 2 、20mg / m 2 ~60mg / m 2 、20mg / m 2 ~80mg / m 2 、20mg / m 2 ~100mg / m 2 、20mg / m 2 ~120mg / m 2 、20mg / m 2 ~150mg / m 2 、20mg / m 2 ~180mg / m 2 、30mg / m 2 ~40mg / m 2 、30mg / m 2 ~50mg / m 2 、30mg / m 2 ~60mg / m 2 、30mg / m 2 ~80mg / m 2 、30mg / m 2 ~100mg / m 2 、30mg / m 2 ~120mg / m 2 、30mg / m 2 ~150mg / m 2 、30mg / m 2 ~180mg / m 2 、40mg / m 2 ~50mg / m 2 、40mg / m 2 ~60mg / m 2 、40mg / m 2 ~80mg / m 2 、40mg / m 2 ~100mg / m 2 、40mg / m 2 ~120mg / m 2 、40mg / m 2 ~150mg / m 2 、40mg / m 2 ~180mg / m 2 、50mg / m 2 ~60mg / m 2 、50mg / m 2 ~80mg / m2 , 50 mg / m 2 ~100mg / m 2 , 50 mg / m 2 ~120mg / m 2 , 50 mg / m 2 ~150mg / m 2 , 50 mg / m 2 ~180mg / m 2 , 60 mg / m 2 ~80mg / m 2 , 60 mg / m 2 ~100mg / m 2 , 60 mg / m 2 ~120mg / m 2 , 60 mg / m 2 ~150mg / m 2 , 60 mg / m 2 ~180mg / m 2 , 80 mg / m 2 ~100mg / m 2 , 80 mg / m 2 ~120mg / m 2 , 80 mg / m 2 ~150mg / m 2 , 80 mg / m 2 ~180mg / m 2 , 100 mg / m 2 ~120mg / m 2 , 100 mg / m 2 ~150mg / m 2 , 100 mg / m 2 ~180mg / m 2 , 120 mg / m 2 ~150mg / m 2 , 120 mg / m 2 ~180mg / m 2 or 150 mg / m 2 ~180mg / m 2 The conditioning regimen of the present disclosure can include administering to the subject 20 mg / m of fludarabine. 2 , 30 mg / m 2 , 40 mg / m 2 , 50 mg / m 2 , 60 mg / m 2 , 80 mg / m 2 , 100 mg / m 2 , 120 mg / m2 , 150 mg / m 2 or 180 mg / m 2 The conditioning regimen of the present disclosure may include administering to the subject at least 20 mg / m of fludarabine. 2 , 30 mg / m 2 , 40 mg / m 2 , 50 mg / m 2 , 60 mg / m 2 , 80 mg / m 2 , 100 mg / m 2 , 120 mg / m 2 or 150 mg / m 2 The conditioning regimen of the present disclosure may include administering to the subject up to 30 mg / m of fludarabine. 2 , 40 mg / m 2 , 50 mg / m 2 , 60 mg / m 2 , 80 mg / m 2 , 100 mg / m 2 , 120 mg / m 2 , 150 mg / m 2 or 180 mg / m 2 The method can include administering to the subject a dose of fludarabine.

[0415] A subject receiving one or more cellular components described herein may be administered one or more doses of fludarabine prior to cell transplantation. A subject receiving one or more cellular components described herein may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses of fludarabine prior to cell transplantation. In some cases, each dose of fludarabine has the same concentration. In some cases, the one or more doses of fludarabine have different concentrations. A subject may be administered a single dose of 20-60 mg / m 2 Subjects may receive a single dose of fludarabine of at least 30 mg / m 2 Subjects may receive at least 40 mg / m fludarabine in a single dose. 2 Subjects may receive at least 50 mg / m fludarabine in a single dose. 2of fludarabine may be administered.

[0416] The conditioning regimen of the present disclosure is based on the surface area of ​​the subject and is administered at a dose of 20 mg / m 2 ~180mg / m 2 The conditioning regimen of the present disclosure can include administering to the subject at least 20 mg / m of melphalan. 2 The conditioning regimen of the present disclosure can include administering to the subject up to 180 mg / m of melphalan. 2 The conditioning regimen of the present disclosure can include administering to the subject 20 mg / m melphalan. 2 ~30mg / m 2 , 20 mg / m 2 ~40mg / m 2 , 20 mg / m 2 ~50mg / m 2 , 20 mg / m 2 ~60mg / m 2 , 20 mg / m 2 ~80mg / m 2 , 20 mg / m 2 ~100mg / m 2 , 20 mg / m 2 ~120mg / m 2 , 20 mg / m 2 ~150mg / m 2 , 20 mg / m 2 ~180mg / m 2 , 30 mg / m 2 ~40mg / m 2 , 30 mg / m 2 ~50mg / m 2 , 30 mg / m 2 ~60mg / m 2 , 30 mg / m 2 ~80mg / m 2 , 30 mg / m 2 ~100mg / m 2 , 30 mg / m 2 ~120mg / m 2 , 30 mg / m 2 ~150mg / m 2 , 30 mg / m 2 ~180mg / m 2、40mg / m 2 ~50mg / m 2 、40mg / m 2 ~60mg / m 2 、40mg / m 2 ~80mg / m 2 、40mg / m 2 ~100mg / m 2 、40mg / m 2 ~120mg / m 2 、40mg / m 2 ~150mg / m 2 、40mg / m 2 ~180mg / m 2 、50mg / m 2 ~60mg / m 2 、50mg / m 2 ~80mg / m 2 、50mg / m 2 ~100mg / m 2 、50mg / m 2 ~120mg / m 2 、50mg / m 2 ~150mg / m 2 、50mg / m 2 ~180mg / m 2 、60mg / m 2 ~80mg / m 2 、60mg / m 2 ~100mg / m 2 、60mg / m 2 ~120mg / m 2 、60mg / m 2 ~150mg / m 2 、60mg / m 2 ~180mg / m 2 、80mg / m 2 ~100mg / m 2 、80mg / m 2 ~120mg / m 2 、80mg / m 2 ~150mg / m 2 、80mg / m 2 ~180mg / m 2 、100mg / m 2 ~120mg / m 2 、100mg / m 2 ~150mg / m 2 、100mg / m 2~180mg / m 2 , 120 mg / m 2 ~150mg / m 2 , 120 mg / m 2 ~180mg / m 2 or 150 mg / m 2 ~180mg / m 2 The conditioning regimen of the present disclosure can include administering to the subject 20 mg / m melphalan. 2 , 30 mg / m 2 , 40 mg / m 2 , 50 mg / m 2 , 60 mg / m 2 , 80 mg / m 2 , 100 mg / m 2 , 120 mg / m 2 , 150 mg / m 2 or 180 mg / m 2 The conditioning regimen of the present disclosure can include administering to the subject at least 20 mg / m of melphalan. 2 , 30 mg / m 2 , 40 mg / m 2 , 50 mg / m 2 , 60 mg / m 2 , 80 mg / m 2 , 100 mg / m 2 , 120 mg / m 2 or 150 mg / m 2 The conditioning regimen of the present disclosure can include administering to the subject up to 30 mg / m of melphalan. 2 , 40 mg / m 2 , 50 mg / m 2 , 60 mg / m 2 , 80 mg / m 2 , 100 mg / m 2 , 120 mg / m 2 , 1...

Claims

1. A multi-component pharmaceutical solution for use in a method of treating a human subject in need thereof, comprising: (a) a solution comprising a first population of CD45+ cells comprising hematopoietic stem progenitor cells (HSPCs) and granulocytes, wherein up to about 10% of said first population of CD45+ cells comprise granulocytes; (b) a solution comprising a population of cells enriched for regulatory T cells (Treg); (c) a solution comprising a second population of CD45+ cells, said second population of CD45+ cells comprising at least about 20% CD3+ conventional T cells (Tcon), at least about 10% monocytes, and at least about 10% granulocytes; and (d) a solution comprising one or more doses of a graft-versus-host disease (GVHD) prophylactic agent; 1. A multi-component pharmaceutical solution comprising:

2. the GVHD prophylactic agent is tacrolimus, Optionally, the tacrolimus is formulated for oral or intravenous administration; optionally, said tacrolimus is administered in an amount to maintain a target blood level of at least about 3 ng / ml for at least about 20 days following administration of said second population of CD45+ cells; optionally, said tacrolimus is administered for at least about 60 days following administration of said second population of CD45+ cells; - optionally, said tacrolimus is administered for up to about 150 days following administration of said second population of CD45+ cells; and Optionally, the tacrolimus is formulated for oral or intravenous delivery; A multi-component pharmaceutical solution for use according to claim 1.

3. - the first population of CD45+ cells comprises up to about 3% monocytes; and / or - said first population of CD45+ cells comprises up to about 0.5% lymphocytes; and / or - said second population of CD45+ cells comprises at least about 0.5% NK cells; and / or - said second population of CD45+ cells comprises at least about 0.1% CD34+ cells or about 0.2% to about 20% CD34+ cells; and / or - said second population of CD45+ cells comprises at least about 0.1% Tregs; A multi-component pharmaceutical solution for use according to claim 1 or claim 2.

4. The treatment further comprises a conditioning regimen, the conditioning regimen being administered prior to any of (a) to (d); - optionally, the conditioning regimen is administered about 2 days to about 10 days prior to any of (a)-(d); Optionally, the conditioning regimen is a myeloablative conditioning regimen. Optionally, the conditioning regimen comprises at least three conditioning agents, and at least one conditioning agent comprises thiotepa; Optionally, the myeloablative conditioning regimen comprises at least one dose of thiotepa; Optionally, said at least one dose of thiotepa comprises at least about 5 milligrams of thiotepa per kilogram of actual or ideal body weight of said human subject; Optionally, the conditioning regimen comprises one or more doses of busulfan, fludarabine and thiotepa; Optionally, said one or more doses of busulfan, fludarabine and thiotepa comprise from about 5 to about 12 mg of thiotepa per kg actual or ideal body weight of a human subject, from about 7 to about 11 mg of busulfan per kg actual or ideal body weight of a human subject, and from about 100 to about 200 mg of fludarabine per square meter of body surface area, respectively; A multi-component pharmaceutical solution for use according to any one of the preceding claims.

5. 10. The multi-component pharmaceutical solution for use according to any one of the preceding claims, wherein the first population of CD45+ cells comprises less than about 5 EU endotoxin per ml of the solution and / or the population of cells enriched for Tregs comprises less than about 5 EU endotoxin per ml of the solution; and / or the second population of CD45+ cells comprises less than about 5 EU endotoxin per ml of the solution.

6. the HSPCs are CD34+; and / or the Tregs are CD4+ CD25+ CD127dim, or the Tregs are CD4+ FOXP3+, and optionally, the population of cells enriched for Tregs comprises CD45+ cells, and greater than about 90% of the CD45+ cells are Tregs. A multi-component pharmaceutical solution for use according to any one of the preceding claims.

7. The method of claim 1, wherein the first population of CD45+ cells comprising HSPCs is about 5×10 per ideal body kilogram of the human subject. 5 ~Approx. 2×10 7 and / or - said population of cells enriched for Tregs comprises about 1 x 105 to about 1 x 107 Tregs per kilogram of actual or ideal body weight of said human subject; and / or - said second population of CD45+ cells comprises about 1 x 10 5 to about 1 x 10 7 Tcon per kilogram of actual or ideal body weight of said human subject; A multi-component pharmaceutical solution for use according to any one of the preceding claims.

8. 10. The multi-component pharmaceutical solution for use according to any one of the preceding claims, characterized in that a first dose of said one or more doses of GVHD prophylactic agent is administered after administration of said second population of CD45+ cells.

9. The method of treatment of a human subject diagnosed with a hematological malignancy, comprising: administering to the human subject a solution comprising the first population of CD45+ cells, a solution comprising the population of cells enriched for regulatory T cells (Tregs), a solution comprising the second population of CD45+ cells, and one or more doses of the GVHD prophylactic agent; The solution comprising the first population of CD45+ cells, the solution comprising the population of cells enriched for regulatory Tregs, the solution comprising the second population of CD45+ cells, and the solution comprising one or more doses of the GVHD prophylactic agent are as defined in any one of claims 1 to 8, Optionally, the hematological malignancy is selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, multiple myeloma, lymphoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. A multi-component pharmaceutical solution for use according to any one of claims 1 to 8.

10. wherein said second population of CD45+ cells is administered about 36 to about 60 hours after said first population of CD45+ cells; and / or wherein said second population of CD45+ cells is administered about 36 to about 60 hours after said population of cells enriched for Tregs; and / or 10. The multi-component pharmaceutical solution for use according to claim 9, wherein the human subject does not develop higher than stage 2 GVHD within about 100 days of the step of administering the second population of CD45+ cells.

11. the first population of CD45+ cells, the population of cells enriched for Tregs, and / or the second population of CD45+ cells are allogeneic to the human subject; Optionally, said first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are obtained from a donor that is HLA-matched to said human subject; or Optionally, said first population of CD45+ cells, said population of cells enriched for Tregs, and / or said second population of CD45+ cells are obtained from a donor that is HLA-mismatched to said human subject; or Optionally, the first population of CD45+ cells, the population of cells enriched for Tregs, and / or the second population of CD45+ cells are obtained from a donor that is haplotype-matched to the human subject. A multi-component pharmaceutical solution for use according to claim 9 or claim 10.

12. 12. The multi-component pharmaceutical solution for use according to any one of claims 9 to 11, wherein the risk and / or severity of an adverse event associated with said multi-component pharmaceutical solution is reduced compared to a similar pharmaceutical treatment in which a human subject receives Tcon but not Treg, and optionally said adverse event is acute GVHD (aGVHD), or said adverse event is chronic GVHD (cGVHD), or said adverse event is recurrence of a malignant tumor in said human subject.

13. The method of treatment, comprising transplanting a cell population into a human patient as part of a treatment regimen for a hematological malignancy, said method reducing the risk and / or severity of adverse events associated with said treatment regimen, said method comprising: providing a population of hematopoietic stem progenitor cells (HSPCs) to be administered to the patient, the population of HSPCs comprising HSPCs and a liquid suspending the HSPCs; providing a population of regulatory T cells (Tregs) to be administered to the patient, the population of Tregs comprising Tregs and a liquid in which the Tregs are suspended; providing a heterogeneous cell population for administration to said patient, said heterogeneous cell population comprising lymphocytes, granulocytes, monocytes and a liquid suspending said cells, wherein at least about 30% of said lymphocytes comprise conventional T cells (Tcon); Including, 9. The multi-component pharmaceutical solution for use according to any one of claims 1 to 8, wherein after administration of said cell population, said patient has a reduced risk and / or severity of said adverse events compared to a patient with a hematological malignancy who received a Tcon cell population but not a T-reg cell population.

14. The method of treatment, comprising transplanting a cell population into a human patient as part of a treatment regimen for a hematological malignancy, the method comprising: administering to the patient a population of hematopoietic stem progenitor cells (HSPCs), the population of HSPCs comprising HSPCs and a liquid in which the HSPCs are suspended; administering to the patient a population of regulatory T cells (Tregs) administered to the patient, the population of Tregs comprising Tregs and a liquid in which the Tregs are suspended; administering to said patient a heterogeneous cell population to be administered to said patient, said heterogeneous cell population comprising lymphocytes, granulocytes, monocytes and a liquid suspending said cells, wherein at least about 30% of said lymphocytes comprise conventional T cells (Tcon); administering to said patient a single graft-versus-host disease (GVHD) prophylaxis (GVHDPA) comprising tacrolimus (tacrolimus GHVDPA) for a period of up to about 180 days, said tacrolimus GHVDPA being administered to maintain a blood tacrolimus concentration in said patient above a threshold level during said period; Including, 9. The multicomponent pharmaceutical solution for use according to any one of claims 1 to 8, characterized in that the risk and / or severity of GHVD associated with said treatment regimen for said hematological malignancies is significantly reduced.

15. The method of treatment, comprising: transplanting a population of conventional T cells (Tcon) into a human subject without inducing a stage 2 or higher graft-versus-host disease (GVHD) response up to about 100 days after transplantation; wherein the method comprises: i. administering a heterogeneous cell population comprising lymphocytes, granulocytes and monocytes, wherein at least about 30% of the lymphocytes comprise conventional T cells (Tcon); ii. administering a population of regulatory T cells (Treg); Including, 9. The multi-component pharmaceutical solution for use according to any one of claims 1 to 8, wherein said population of heterologous cellular components and / or Tregs contains less than about 5 EU / ml endotoxin.